1
|
p4036+ p4361+ p4413+p4639+p4749+p5666+p28422 (PSA)
|
Protein
|
Humans
|
Upregulated in PCa: [p4036; p4361; p4413; p4639; p4749; p28422 (PSA)] Downregulated in PCa: [p5666]
|
Diagnostic
|
Prostate Cancer or Prostatic intraepithelial neoplasia Vs Benign Prostatic Hyperplasia or Normal Prostate
|
NA
|
Tissue
|
12171882
|
2
|
p4036
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
3
|
p4361
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
4
|
p4639
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
5
|
p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
6
|
p4036+p4361
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
7
|
p4036+p4639
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
8
|
p4361+p4639
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
9
|
p4036+p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
10
|
p4361+p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
11
|
p4639+p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
12
|
p4036+p4361+p4639
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
13
|
p4036+p4361+p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
14
|
MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2
|
mRNA
|
Humans
|
Differentially Expressed in Recurrent Cancer
|
Prognostic
|
Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
15067324
|
15
|
MGC5466+CHAF1A+CDS2+IER3
|
mRNA
|
Humans
|
Differentially Expressed in Recurrent Cancer
|
Prognostic
|
Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
15067324
|
16
|
PPFIA3+COPEB+FOS+JUNB+ZFP36
|
mRNA
|
Humans
|
Differentially Expressed in Recurrent Cancer
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.001
|
Tissue
|
15067324
|
17
|
MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2+CHAF1A+CDS2+IER3+PPFIA3+COPEB+FOS+JUNB+ZFP36
|
mRNA
|
Humans
|
Differentially Expressed in Recurrent Cancer
|
Prognostic
|
Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
15067324
|
19
|
XLKD1/LYVE1
|
mRNA
|
Humans
|
Downregulated in PCa(atleast 2 fold)
|
Diagnostic
|
Normal Prostate vs Prostate Cancer
|
p<0.05
|
Tissue
|
14654526
|
20
|
CGA
|
mRNA
|
Humans
|
Downregulated in PCa(atleast 2 fold)
|
Diagnostic
|
Normal Prostate vs Prostate Cancer
|
p<0.05
|
Tissue
|
14654526
|
21
|
F2R/PAR1
|
mRNA
|
Humans
|
Downregulated in PCa(atleast 2 fold)
|
Diagnostic
|
Normal Prostate vs Prostate Cancer
|
p<0.05
|
Tissue
|
14654526
|
22
|
BCL-G
|
mRNA
|
Humans
|
Downregulated in PCa(atleast 2 fold)
|
Diagnostic
|
Normal Prostate vs Prostate Cancer
|
p<0.05
|
Tissue
|
14654526
|
23
|
XLKD1/LYVE1+CGA+ F2R/PAR1+ BCL-G
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Patients with Relapse Vs Without Relapse
|
p<0.05
|
Tissue
|
14654526
|
24
|
Caveolin-1
|
Protein
|
Humans
|
Upregulated in African American Men (AA: 39% vs WA: 17%)
|
Prognostic
|
African Americans vs White American men with Prostate Cancer
|
p=0.0048
|
Tissue
|
10999725
|
27
|
BCL-2
|
Protein
|
Humans
|
Upregulated in High Gleason Score
|
Prognostic
|
High (8-10) vs Low (2-4) Gleason Score
|
p<0.001
|
Tissue
|
11500787
|
29
|
Alpha Methylacyl Coenzyme A Racemase (AMACR)
|
mRNA
|
Humans
|
Upregulated in Localised Prostate Cancer (3.1 fold)
|
Diagnostic
|
Benign Prostate vs Localised Prostate Cancer
|
p<0.001
|
Tissue
|
11926890
|
30
|
Alpha Methylacyl Coenzyme A Racemase (AMACR)
|
mRNA
|
Humans
|
Upregulated in Metastatic Prostate Cancer (1.67 fold)
|
Diagnostic
|
Benign Prostate vs Metastatic Prostate Cancer
|
p<0.004
|
Tissue
|
11926890
|
31
|
Alpha Methylacyl Coenzyme A Racemase (AMACR)
|
Protein
|
Humans
|
Upregulated in Localised Prostate Cancer [Mean expression Value: (Localised Prostate Cancer: 3.2 vs Normal Prostate: 1.3)]
|
Diagnostic
|
Benign Prostate vs Localised Prostate Cancer
|
p<0.001
|
Tissue
|
11926890
|
37
|
Lycopene
|
Protein
|
Humans
|
Downregulated (36% fold)
|
Diagnostic
|
Normal vs Cancerous
|
p<0.05
|
Tissue
|
12497123
|
38
|
Annexin 1
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (2.23 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p<0.001
|
Tissue
|
12507908
|
39
|
Annexin 2
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (1.51 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p=0.009
|
Tissue
|
12507908
|
40
|
Annexin 4
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (1.3 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p=0.001
|
Tissue
|
12507908
|
41
|
Annexin 7
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (1.42 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p<0.001
|
Tissue
|
12507908
|
42
|
Annexin 11
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (1.81 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p<0.001
|
Tissue
|
12507908
|
43
|
Fatty Acid Synthase (FAS)
|
mRNA
|
Humans
|
Upregulated in PCa (3 fold) [Mean Value: PCa:158 Vs Normal: 53]
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.00000029
|
Tissue
|
12939396
|
44
|
Fatty Acid Synthase (FAS)
|
mRNA
|
Humans
|
Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8]
|
Prognostic
|
Gleason Score 7 Vs Metastatic Tumor
|
p<0.00000029
|
Tissue
|
12939396
|
45
|
Fatty Acid Synthase (FAS) Intensity
|
Protein
|
Humans
|
Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8]
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.00000000857
|
Tissue
|
12939396
|
46
|
alpha-Methylacyl Coenzyme A Racemase (AMACR)
|
Protein
|
Humans
|
Upregulated in PCa (Prostate Cancer: 3.14 Vs Benign Prostate: 1.3)
|
Diagnostic
|
Benign Prostate Vs Localised Prostate Cancer
|
p<0.00001
|
Tissue
|
14982837
|
47
|
alpha-Methylacyl Coenzyme A Racemase (AMACR)
|
Protein
|
Humans
|
Upregulated in PCa (Prostate Cancer: 21.6 Vs Benign Prostate: 7.3)
|
Diagnostic
|
Benign Prostate Vs Localised Prostate Cancer
|
p<0.05
|
Tissue
|
14982837
|
48
|
phosphorylated Akt (pAkt)
|
Protein
|
Humans
|
Upregulated in PSA failures (PSA Failure: [222.18±33.9 vs PSA Non-Failure: 108.79±104.57)
|
Prognostic
|
PSA failure versus PSA non failure
|
p<0.001
|
Tissue
|
15289328
|
49
|
phosphorylated Akt (pAkt) + phosphorylated ERK (extracellular signal-regulated kinase) (pERK)
|
Protein
|
Humans
|
pAKT: Upregulated in PSA failures; pERK: Downregulated in PSA failures
|
Prognostic
|
PSA failure versus PSA non failure
|
NA
|
Tissue
|
15289328
|
50
|
GalNAc-T3+PSMA+Hepsin+DD3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
51
|
PSMA+Hepsin+DD3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
52
|
GalNAc-T3+Hepsin+DD3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
53
|
GalNAc-T3,+Hepsin+PSMA
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
54
|
GalNAc-T3+PSMA+DD3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
55
|
DDR/PCA3
|
mRNA
|
Humans
|
Upregulated (140 fold)
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
p=0.007
|
Tissue
|
15609297
|
56
|
HEPSIN
|
mRNA
|
Humans
|
Upregulated (21 fold)
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
p=0.049
|
Tissue
|
15609297
|
57
|
PSMA
|
mRNA
|
Humans
|
Upregulated (66 fold)
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
p=0.047
|
Tissue
|
15609297
|
58
|
GalNAc-T3
|
mRNA
|
Humans
|
Upregulated (4.6 fold)
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
p=0.005
|
Tissue
|
15609297
|
59
|
Kallikrein 4 (KLK4/hK4)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign prostatic hyperplasia Vs Prostate Cancer
|
p<0.05
|
Tissue
|
16172196
|
60
|
BCL-2
|
Protein
|
Humans
|
Upregulated in PCa Patients: PSA >10 ng/ml
|
Prognostic
|
PSA ≤10 ng/ml Vs PSA >10 ng/ml
|
p<0.01
|
Tissue
|
15655565
|
61
|
COX-2
|
Protein
|
Humans
|
Upregulated in PCa Patients: PSA >10 ng/ml
|
Prognostic
|
PSA ≤10 ng/ml Vs PSA >10 ng/ml
|
p<0.01
|
Tissue
|
15655565
|
62
|
BCL-2
|
Protein
|
Humans
|
Upregulated in Patients with relapse
|
Prognostic
|
PCa Relapse Vs No Relapse
|
p<0.01
|
Tissue
|
15655565
|
63
|
COX-2
|
Protein
|
Humans
|
Upregulated in Patients with relapse
|
Prognostic
|
PCa Relapse Vs No Relapse
|
p<0.01
|
Tissue
|
15655565
|
64
|
Heat Shock Protein (Hsp70)
|
Protein
|
Mice
|
Upregulated in PCa (2 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
65
|
Proliferating cell nuclear antigen (PCNA)
|
Protein
|
Mice
|
Upregulated in PCa (1.44 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
66
|
Apoliprotein A-1
|
Protein
|
Mice
|
Upregulated in PCa (1.65 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
67
|
Phospholipase C
|
Protein
|
Mice
|
Upregulated in PCa (1.95 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
68
|
Glucose regulated protein (GRP 58)
|
Protein
|
Mice
|
Upregulatd in PCa (2 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
69
|
Enolase 1, Non-Neuron
|
Protein
|
Mice
|
Upregulatd in PCa (1.8 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
70
|
AMACR (o-methylacyl-CoA racemaÌŠse)
|
mRNA
|
Humans
|
Upregulated in PCa (3.3 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
71
|
SIM2 (single-minded homolog 2)
|
mRNA
|
Humans
|
Upregulated in PCa (2.3 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
72
|
EST (similar to cDS4 retroviral related polyprotein)
|
mRNA
|
Humans
|
Upregulated in PCa (2.3 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
73
|
EST (weakly similar to protease)
|
mRNA
|
Humans
|
Upregulated in PCa (2.2 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
74
|
TRGV9 (Tcell receptory variable 9)
|
mRNA
|
Humans
|
Upregulated in PCa (2.1 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
75
|
EST (AGR2 anterior gradient 2 homolog)
|
mRNA
|
Humans
|
Upregulated in PCa (2.1 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
76
|
HPN (hepsin transmembrane protease, serine I)
|
mRNA
|
Humans
|
Upregulated in PCa (2.0 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
77
|
KCNA5 (potassium voltage-gated channel),
|
mRNA
|
Humans
|
Upregulated in PCa (2.0 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
78
|
TM4SF13 (transmembrane 4 superfamily member 13)
|
mRNA
|
Humans
|
Upregulated in PCa (2.0 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
79
|
SOX9 (SRY sex determining region Y-box 9)
|
mRNA
|
Humans
|
Upregulated in PCa (2.0 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
80
|
SOX4 (SRY sex determining region Y-box 4)
|
mRNA
|
Humans
|
Upregulated in PCa (1.9 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
81
|
SLC26A2 (solute carrier family 26 member 2)
|
mRNA
|
Humans
|
Upregulated in PCa (1.9 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
82
|
SYNP02 (synaptopodin)
|
mRNA
|
Humans
|
Downregulated in PCa (4.2 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
83
|
SLC18A2 (solute carrier family 18 member 2)
|
mRNA
|
Humans
|
Downregulated in PCa (3.0 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
84
|
CALD1 (caldesmon 1)
|
mRNA
|
Humans
|
Downregulated in PCa (2.8 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
85
|
MRE11A (meiotic recombination 11 homologue A)
|
mRNA
|
Humans
|
Downregulated in PCa (2.8 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
86
|
KRT15 (keratin 15)
|
mRNA
|
Humans
|
Downregulated in PCa (2.7 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
87
|
ACTG2 (actin gamma 2 smooth muscle, enteric)
|
mRNA
|
Humans
|
Downregulated in PCa (2.5 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
88
|
DSIPI (delta sleep inducing peptide, immunoreactor)
|
mRNA
|
Humans
|
Downregulated in PCa (2.5 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
89
|
SLC18A2 (solute carrier family 18 member 2)
|
mRNA
|
Humans
|
Downregulated in PCa (2.5 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
90
|
MME [membrane metallo-endopeptidase]
|
mRNA
|
Humans
|
Downregulated in PCa (2.4 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
91
|
KRT17 (similar to keratin 17)
|
mRNA
|
Humans
|
Downregulated in PCa (2.4 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
92
|
LY96 (lymphocyte antigen 96)
|
mRNA
|
Humans
|
Downregulated in PCa (2.4 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
93
|
SYNP02 (synaptopodin)
|
mRNA
|
Humans
|
Downregulated in PCa (2.4 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
99
|
Ghrelin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Prostatic Hypertrophy Vs Prostate Cancer
|
p<0.05
|
Tissue
|
16322288
|
100
|
Preproghrelin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Prostatic Hypertrophy Vs Prostate Cancer
|
p<0.05
|
Tissue
|
16322288
|
102
|
Methylation status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
p<0.03
|
Tissue
|
16322291
|
103
|
Methylation status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
P = 0.004
|
Tissue
|
16322291
|
104
|
Methylation status of APC
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
P = 0.004
|
Tissue
|
16322291
|
105
|
Methylation status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
P = 0.01
|
Tissue
|
16322291
|
106
|
Methylation status of Cyclin D2 + APC
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
0.01
|
Tissue
|
16322291
|
116
|
PP2A
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer (PCa)
|
p=0.0073
|
Tissue
|
17977648
|
123
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0001
|
Tissue
|
16614113
|
124
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
HGPIN vs PCa
|
p=0.0108
|
Tissue
|
16614113
|
125
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Upregulated in Gleason Pattern 4
|
Prognostic
|
Gleason Pattern 3 Vs Gleason Pattern 4
|
p=0.042
|
Tissue
|
16614113
|
126
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Upregulated in Gleason Pattern 5
|
Prognostic
|
Gleason Pattern 4 Vs Gleason Pattern 5
|
p=0.037
|
Tissue
|
16614113
|
127
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Increased expression with increase in relapse
|
Prognostic
|
Relapse Vs No Relapse after Radical Prosteactomy
|
p=0.037
|
Tissue
|
16614113
|
128
|
Macrophage Inhibitory Cytokine-1 (MIC-1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0001
|
Tissue
|
16614113
|
129
|
Macrophage Inhibitory Cytokine-1 (MIC-1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
HGPIN vs PCa
|
p<0.0001
|
Tissue
|
16614113
|
130
|
Macrophage Inhibitory Cytokine-1 (MIC-1)
|
Protein
|
Humans
|
Increased expression with increase in relapse
|
Prognostic
|
Relapse Vs No Relapse after Radical Prosteactomy
|
p=0.037
|
Tissue
|
16614113
|
138
|
CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1
|
mRNA
|
Humans
|
Upregulated GEX score in PCa Patients (PCa: 7.38 ± 0.35 Vs Non Cancer: 7.2±0.16)
|
Diagnostic
|
No Cancer Vs Prostate Cancer
|
p=0.0013
|
Tissue
|
17459658
|
139
|
CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1
|
mRNA
|
Humans
|
Increased GEX Score with relapse
|
Prognostic
|
Relapse Vs No Relapse
|
p=0.007
|
Tissue
|
17459658
|
140
|
PARP
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.02
|
Tissue
|
15491717
|
141
|
BCL-2
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
142
|
EGFR
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
143
|
BAD
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
144
|
H3
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
145
|
Lipoxygenase
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
146
|
p27
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
147
|
Racemase 3
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
148
|
Ki-67
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
149
|
PARP
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
150
|
BCL-2
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
151
|
EGFR
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
152
|
BAD
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
153
|
Lipoxygenase
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
154
|
p27
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
155
|
Racemase 3
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
156
|
Ki-67
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
157
|
Lipoxygenase
|
Protein
|
Humans
|
Downregulated (in JA compared to NJ)
|
Diagnostic
|
Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ)
|
p=0.01
|
Tissue
|
15491717
|
158
|
Caspase-3
|
Protein
|
Humans
|
Downregulated (in JA compared to NJ)
|
Diagnostic
|
Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ)
|
p=0.01
|
Tissue
|
15491717
|
159
|
AMACR (α-methylacyl-CoA racemåse) [AMACR 2094, 2097, 2098, 2095]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.12E-08
|
Tissue
|
16618727
|
160
|
PYCR1 (Pyroline 5 - Carboxylate reductase1)
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
8.58E-10
|
Tissue
|
16618727
|
161
|
MYO6 (Myosin VI) [MYO6-0041]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.15E-08
|
Tissue
|
16618727
|
162
|
SMPDL3B (Sphingomyelinase like phosphodiesterase 3B) [SMPDL3B 2030]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.32E-08
|
Tissue
|
16618727
|
163
|
NOX4 (NADPH oxidase 4) [NOX4 1355]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.57E-07
|
Tissue
|
16618727
|
164
|
FASN (Fatty Acid Synthase) [FASN 1432,1433, 1435]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
4.78E-05
|
Tissue
|
16618727
|
165
|
CACNA1D (Voltage-dep. L-type Calcium Channel Alpha 1D Subunit) [CACNA1D 2040, 2039]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
3.32E-06
|
Tissue
|
16618727
|
166
|
FBP1 (Fructose 1,6 Bisphosphatase 1) [FBP1 0807]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.46E-07
|
Tissue
|
16618727
|
167
|
IMPDH2 (Inosine-5′-monophosphate dehydrogenase 2) [IMPDH2 0144,0145]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.68E-05
|
Tissue
|
16618727
|
168
|
ABCC4 (Multidrug Resistance-Associated Protein 4) [ABCD4 2013]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.09E-05
|
Tissue
|
16618727
|
169
|
GART (Phosphoribosylglycinamide Formyltransferase) [GART 0310, 0307]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.57E-05
|
Tissue
|
16618727
|
170
|
CLN3 (ceroid lipofuscinosis, neuronal 3, juvenile) [CLN3 1132]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.50E-05
|
Tissue
|
16618727
|
171
|
DHPS (Deoxyhypusine Synthase) [DHPS 2028]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.68E-05
|
Tissue
|
16618727
|
172
|
BIRC5 (Baculoviral IAP Repeat Containing 5 (survivin)) [BIRC5 0847]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.73E-05
|
Tissue
|
16618727
|
173
|
REPS2 (RALBP1 Associated Eps Domain Containing 2) [REPS2 0732, 0733]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.18E-05
|
Tissue
|
16618727
|
174
|
RPS2 (40S Ribosomal Protein S2) [RPS2-0809]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.051607
|
Tissue
|
16618727
|
175
|
TMSNB (Thymosin, Beta, identified in neuroblastoma cells) [TMSNB 0227]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.34E-05
|
Tissue
|
16618727
|
176
|
EPB41 (Erythrocyte Membrane Protein Band 4.1) [EPB41 1096,1092]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.69E-05
|
Tissue
|
16618727
|
177
|
GCNT1 (Core 2 Beta1,6 N-Acetylglucosaminyltransferase-I) [GCNT1 0981, 0982,0985]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
8.15E-05
|
Tissue
|
16618727
|
178
|
LYPLA1 (Lysophospholipase 1) [LYPLA1 0862, 0860]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.006744
|
Tissue
|
16618727
|
179
|
RET1 (Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret) [RET1 0252 0250]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.008659
|
Tissue
|
16618727
|
180
|
HSPD1 (Heat Shock 60kDa Protein 1 (Chaperonin)) [HSPD1 0152, 0154]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.033554
|
Tissue
|
16618727
|
181
|
MAPT (Microtubule Associated Protein Tau) [MAPT 1060]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.000885
|
Tissue
|
16618727
|
182
|
C7ORF24 (Chromosome 7 Open Reading Frame 24) [C7ORF24 0.001028]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.001028
|
Tissue
|
16618727
|
183
|
ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3) [ERBB3 1431]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.001238
|
Tissue
|
16618727
|
184
|
PLA2G2A (Phospholipase A2 Group IIA) [PLA2G2A 1380]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.001569
|
Tissue
|
16618727
|
185
|
NME1 (Nucleoside Diphosphate Kinase A) [NME1 0827]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.001945
|
Tissue
|
16618727
|
186
|
CDK7 (Cyclin Dependent Kinase 7) [CDK7 0899]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.002319
|
Tissue
|
16618727
|
187
|
MMP9 (Matrix Metallopeptidase 9) [MMP9 1185]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.00262
|
Tissue
|
16618727
|
188
|
BGN (Biglycan) [BGN 1274]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.002956
|
Tissue
|
16618727
|
189
|
PPIB (Peptidylprolyl Isomerase B (Cyclophilin B)) [PPIB 0969]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.006963
|
Tissue
|
16618727
|
190
|
IQGAP2 (IQ Motif Containing GTPase Activating Protein 2) [IQGAP2 0234]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.010253
|
Tissue
|
16618727
|
191
|
DKFZP564B167 (DKFZP564B167 Protein) [DKFZP564B167 0717]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.015526
|
Tissue
|
16618727
|
192
|
TMEPAI (Transmembrane Prostate Androgen- Induced Protein) [TMEPAI 2074]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.023696
|
Tissue
|
16618727
|
193
|
STAC (SH3 And Cysteine Rich Domain) [STAC 1045, 1044, 1047]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
4.42E-07
|
Tissue
|
16618727
|
194
|
FGFR2 (Fibroblast Growth Factor Receptor 2) [FGFR2 0101,0095,0100,0106, 0107, 0097]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.42E-07
|
Tissue
|
16618727
|
195
|
CDC42BPA (CDC42 Binding Protein Kinase Alpha) [CDC42BPA 1051]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.56E-08
|
Tissue
|
16618727
|
196
|
KRT15 (keratin 15) [KRT15 1335, 1333, 1334,1341]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.60E-06
|
Tissue
|
16618727
|
197
|
TRIM29 (Tripartite Motif Containing 29) [TRIM29 1353, 1348, 1346]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
4.38E-06
|
Tissue
|
16618727
|
198
|
CES1 (Carboxylesterase ) [CES1 0942, 0937]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.43E-05
|
Tissue
|
16618727
|
199
|
CLU (Clusterin) [CLU 0196, 0192, 0191]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.000272
|
Tissue
|
16618727
|
200
|
ALDH1A2 (Aldehyde Dehydrogenase 1A2) [ALDH1A2 0004,0001, 0006]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.000266
|
Tissue
|
16618727
|
201
|
DRR1 (Collagen and Wnt5a regulated receptor tyrosin kinase) [DRR1 - 0753]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.88E-07
|
Tissue
|
16618727
|
202
|
ROBO1 (Roundabout, Axon Guidance Receptor, Homolog 1) [ROBO1 1419]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.26E-07
|
Tissue
|
16618727
|
203
|
LTBP4 (Latent TFG Beta Binding Protein 4) [LTBP4 0752, 0747, 0742, 1519, 1518, 0745, 0748, 0746]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.002361
|
Tissue
|
16618727
|
204
|
PGR (Progesterone Receptor) [PGR 1161, 1162]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
3.77E-06
|
Tissue
|
16618727
|
205
|
EDNRB (Endothelin Receptor Type B) [EDNRB 1187]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.88E-06
|
Tissue
|
16618727
|
206
|
ANGPT1 (Angiopoietin 1) [ANGPT1 1032, 1031]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
3.72E-05
|
Tissue
|
16618727
|
207
|
IGF1 (Insulin like Growth Factor 1 Somatomedin C) [IGF1 0025]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
3.77E-06
|
Tissue
|
16618727
|
208
|
COL6A2 (Collagen, Type VI, Alpha 2) [COL6A2 1489]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
8.16E-06
|
Tissue
|
16618727
|
209
|
PTGDS (Prostaglandin D2 Synthase 21kDa) [PTGDS 0787]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.09E-05
|
Tissue
|
16618727
|
210
|
ANGPTL2 (Angiopoietin-related Protein 2) [ANGPTL2 0950]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.20E-05
|
Tissue
|
16618727
|
211
|
VCL (Vinculin) [VCL 1534, 0933, 0936]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.011744
|
Tissue
|
16618727
|
212
|
GSTP1 (Glutathione S-transferase P) [GSTP1 0927, 0923]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.030854
|
Tissue
|
16618727
|
213
|
SAT (Spermidine/Spermine N1-acetyltransferase) [SAT 0840, 0842]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.052888
|
Tissue
|
16618727
|
214
|
TGFB2 (Transforming Growth Factor, Beta 2) [TGFB2 0085]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.095398
|
Tissue
|
16618727
|
229
|
ENC1 + GJB1
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
230
|
MYO6 + AMACR
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
231
|
TSPAN13 + PRKCBP1
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
232
|
C20ORF74 + DAPK1
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
233
|
IMAGE:396839 + ENC1
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
234
|
Metaclassifier: ENC1+GJB1+MYO6+AMACR+TSPAN13+PRKCBP+C20ORF74+DAPK1+IMAGE:396839 + ENC1
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
235
|
ARL6IP+MYH11
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Primary Vs Metastatic Prostate Cancer
|
NA
|
Tissue
|
17460773
|
248
|
PI3-K p85 α
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-10
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
249
|
ILK
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-11
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
250
|
PTEN
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-12
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
251
|
PHLPP
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-13
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
252
|
FOXO1A
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-14
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
253
|
AMACR (Alpha-methylacyl-coA racemase )
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
High Grade Prostatic Intraepithelial Neoplasia Vs Prostate Cancer
|
p=0.0044
|
Tissue
|
18343427
|
256
|
TOP2A
|
mRNA
|
Humans
|
Upregulated in PCa (≥2 fold)
|
Diagnostic
|
Prostate Cancer Vs Nonneoplastic Sample
|
p<0.05
|
Tissue
|
18347174
|
257
|
ERG
|
mRNA
|
Humans
|
Upregulated in PCa (≥2 fold)
|
Diagnostic
|
Prostate Cancer Vs Nonneoplastic Sample
|
p<0.05
|
Tissue
|
18347174
|
258
|
NRP1
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p=0.007
|
Tissue
|
18347174
|
259
|
TOP2A
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p<0.0001
|
Tissue
|
18347174
|
260
|
RRM2
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p<0.0001
|
Tissue
|
18347174
|
261
|
KHRDSB3
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p=0.015
|
Tissue
|
18347174
|
262
|
SSTR1
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p=0.006
|
Tissue
|
18347174
|
263
|
Methylation Status of NKX2-5
|
mRNA
|
Humans
|
Hypermethylated (2.7% normal vs 14% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
264
|
Methylation Status of CALSTN1
|
mRNA
|
Humans
|
Hypermethylated (2.5% normal vs 12.1% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
265
|
Methylation Status of SPOCK2
|
mRNA
|
Humans
|
Hypermethylated (7.5% normal vs 15.2% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
266
|
Methylation Status of NSE1
|
mRNA
|
Humans
|
Hypermethylated (10.3% normal vs 20.5% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
267
|
Methylation Status of SLC16A12
|
mRNA
|
Humans
|
Hypermethylated (9% normal vs 22% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
268
|
Methylation Status of FOXN4
|
mRNA
|
Humans
|
Hypermethylated (2.4% normal vs 4.3% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
269
|
Methylation Status of GALR2
|
mRNA
|
Humans
|
Hypermethylated (2% normal vs 4.3% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
270
|
Methylation Status of DPYS
|
mRNA
|
Humans
|
Hypermethylated (24.2% normal vs 42.71% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
271
|
Methylation Status of (DPYS or NKX2-5)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
272
|
Methylation Status of (CALSTN1 or DYPS)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
273
|
Methylation Status of (NSE1 or DPYS)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
274
|
Methylation Status of (NSE1 or SPOCK2)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
275
|
Methylation Status of (SLC16A12 or DPYS)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
276
|
Fusion Status of TMPRSS2:ERG
|
mRNA
|
Humans
|
Increased fusion in patients with biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence
|
p=0.0523
|
Tissue
|
18500259
|
277
|
Mutation of PTEN
|
mRNA
|
Humans
|
Deletion found in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence
|
p=0.0009
|
Tissue
|
18500259
|
278
|
Fusion Status of TMPRSS2:ERG + PTEN deletion
|
mRNA
|
Humans
|
Fusion + Deletion
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence
|
p=0.001
|
Tissue
|
18500259
|
279
|
Fusion Status of TMPRSS2:ERG + PTEN deletion
|
mRNA
|
Humans
|
Fusion + Deletion
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence
|
p=0.036
|
Tissue
|
18500259
|
280
|
Golgi phosphoprotein 2 (GOLPH2)
|
mRNA
|
Humans
|
Upregulated in Prostate Cancer(3.04 fold)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.001
|
Tissue
|
18543251
|
281
|
Golgi phosphoprotein 2 (GOLPH2)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.01
|
Tissue
|
18543251
|
282
|
Golgi phosphoprotein 2 (GOLPH2)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate epithelium
|
p<0.001
|
Tissue
|
18543251
|
283
|
Myosin VI (MYO6)
|
mRNA
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Tumor and adjacent normal prostate tissues
|
NA
|
Tissue
|
18543251
|
287
|
40S ribosomal protein S25
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.13 ±0.44)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
288
|
40S ribosomal protein S7
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 5.24 ±0.66)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
289
|
α-1-antitrypsin precursor (α-1protease inhibitor)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.19 ±0.97)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
290
|
Cellular nucleic acid-binding protein (CNBP) (Zinc finger protein 9)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.33 ±0.79)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
291
|
Chondroitin sulfate proteoglycan 2 (Versican) variant (Fragment)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.28 ±0.58)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
292
|
Chromobox protein homologue 1 (Heterochromatin protein 1 homologue β)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.36 ±0.50)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
293
|
Cofilin-1 (Cofilin, nonmuscle isoform) (18 kDa phosphoprotein) (p18)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.29 ± 1.2)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
294
|
Complement component 1 Q subcomponent-binding protein (p33)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 4.55 ± 1.70)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
295
|
Elongation factor 1-R 2 (Elongation factor 1 A-2) (Statin S1)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.68 ±0.73)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
296
|
Ezrin (p81) (Cytovillin) (Villin-2)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.26 ±0.0.49)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
297
|
FASN variant protein (Fragment)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.78 ±0.91)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
298
|
FK506-binding protein 4 (Peptidyl-prolyl cis-trans isomerase) (Rotamase)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.46 ±0.29)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
299
|
Glutamate carboxypeptidase 2 (Folate hydrolase 1) (Prostate- specific membrane antigen)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.82 ±0.95)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
300
|
Glutathione peroxidase 3 precursor
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.19 ±0.57)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
301
|
Glutathione S-transferase ω-1
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.36 ±0.58)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
302
|
Heat shock protein HSP90-β
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.2 ±0.61)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
303
|
Histone cluster 1, H1e
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.5 ±0.82)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
304
|
Histone H1.2 (Histone H1d)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.98 ±1.07)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
305
|
Lactoylglutathione lyase (Aldoketomutase) (Glyoxalase I)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.06 ±0.56)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
306
|
α-methylacyl-CoA racemase (AMAC)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.51 ±0.62)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
307
|
Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.6 ±1.01)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
308
|
Periostin, osteoblast specific factor
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.38 ± 1.59)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
309
|
Prostaglandin E synthase 3 (Telomerase-binding protein p23) (Hsp90 co-chaperone) (Progesterone receptor complex p23)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.14 ±0.56)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
310
|
Proteasome subunit alpha type 5 (Multicatalytic endopeptidase complex ?-chain)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.07 ±1.70)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
311
|
Protein mago nashi homologue 2
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.18 ±0.43)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
312
|
Protein-glutamine γ-glutamyltransferase 4 (Prostate transglutaminase) (Prostate-specific transglutaminase)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.45 ±1.00)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
313
|
Thioredoxin domain-containing protein 4 precursor
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.54 ±0.45)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
314
|
Ubiquinol-cytochrome c reductase complex 11 kDa protein
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.90 ±0.59)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
315
|
14-3-3 protein β/α
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.52 ±0.1)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
316
|
Androgen receptor-associated protein of 55 kDa (ARA 55)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.38 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
317
|
α-parvin (Calponin-like integrin-linked kinase-binding protein) (CH-ILKBP)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.53 ±0.08)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
318
|
Angiotensin-converting enzyme, somatic isoform (precursor) (CD143 antigen)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.32 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
319
|
Ankyrin repeat domain-containing protein 25 (SRC-1-interacting protein)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.46 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
320
|
BCL2-associated athanogene 3 variant (Fragment)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.32 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
321
|
CD44 antigen precursor (Phagocytic glycoprotein I) (Hyaluronate receptor) (Epican)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.23 ±0.07)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
322
|
Cell surface glycoprotein MUC18 precursor (Melanoma cell adhesion molecule) (CD146 antigen)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.49 ±0.08)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
323
|
Ciliary dynein heavy chain 10 (Axonemal beta dynein heavy chain 10) (Fragment)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.35 ±0.05)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
324
|
Collagen α-1(V) chain precursor
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.41 ±0.19)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
325
|
Collagen α-1(VI) chain precursor
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.43 ±0.15)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
326
|
Flotillin-1
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.33 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
327
|
G antigen family C member 1 (Prostate-associated gene 4 protein)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.25 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
328
|
γ-synuclein (Persyn) (Breast cancer-specific gene 1 protein) (Synoretin)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.18 ±0.07)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
329
|
Glutathione S-transferase μ-1
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.42 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
330
|
Glutathione S-transferase π-1
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.29 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
331
|
Hsc70-interacting protein (Hip) (Putative tumor suppressor ST13) (Progesterone receptor-associated p48 protein)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.33 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
332
|
Insulin-degrading enzyme (Insulysin) (Insulinase) (Insulin protease)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.38 ±0.12)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
333
|
Insulin-like growth factor-binding protein 7 precursor (IGFBP-7) (Prostacyclin-stimulating factor) (PGI2-stimulating factor)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.42 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
334
|
Kallikrein-11 precursor (Hippostasin)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.41 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
335
|
Keratin, type I cytoskeletal 17 (Cytokeratin-17)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.38 ±0.14)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
336
|
Leiomodin-1 (64 kDa autoantigen 1D)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.21 ±0.07)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
337
|
Microtubule-associated protein 1B (MAP 1B)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.46 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
338
|
Olfactomedin-like protein 1 precursor
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.33 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
339
|
Phosphoglucomutase-like protein 5 (Aciculin)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.47 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
340
|
Platelet-activating factor acetylhydrolase IB subunit α
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.42 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
341
|
Prostatic acid phosphatase [Precursor]
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.42 ±0.14)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
342
|
Ras-related protein R-Ras (p23)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.31 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
343
|
Retinol binding protein I, cellular
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.28 ±0.12)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
344
|
Selenium binding protein 1 (SELENBP1 protein)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.36 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
345
|
TFIIH basal transcription factor complex helicase XPB subunit (DNA-repair protein complementing XP-B)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.32 ±0.13)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
346
|
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Ubiquitin thioesterase L1
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.38 ±0.12)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
347
|
Vinculin (Metavinculin)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.46 ±0.12)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
348
|
Zinc-α-2-glycoprotein precursor
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.43 ±0.13)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
349
|
Zyxin
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.45 ±0.13)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
360
|
IL-8
|
Protein
|
Humans
|
Upregulated in Recurrent Group (Recurrent Group: 181.1 ± 89.3; Non Recurrent Group: 96.4 ± 85.6)
|
Prognostic
|
Reccurance Free Survival Vs Recurrance in 5 years
|
p<0.001
|
Tissue
|
18593988
|
361
|
Osteopontin
|
Protein
|
Humans
|
Upregulated in Recurrent Group (Recurrent Group: 203.2 ± 78.4; Non Recurrent Group: 127.76 ± 76.6)
|
Prognostic
|
Reccurance Free Survival Vs Recurrance in 5 years
|
p<0.001
|
Tissue
|
18593988
|
362
|
IL8 + Osteopontin
|
Protein
|
Humans
|
Upregulated in Recurrent Group
|
Prognostic
|
Reccurance Free Survival Vs Recurrance in 5 years
|
p<0.001
|
Tissue
|
18593988
|
363
|
Lactate
|
Metabolites
|
Humans
|
Upregulated (Benign: 0.61 ± 0.28 Vs Cancerous: 1.59 ± 0.61)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
18727052
|
364
|
Alanine
|
Metabolites
|
Humans
|
Upregulated (Benign: 0.14 ± 0.06 Vs Cancerous: 0.26 ± 0.07)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
18727052
|
365
|
CD31
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.009
|
Tissue
|
18767028
|
366
|
Ki67
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.003
|
Tissue
|
18767028
|
367
|
Her-2/neu
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.006
|
Tissue
|
18767028
|
368
|
CD31
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.001
|
Tissue
|
18767028
|
369
|
Ki67
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.03
|
Tissue
|
18767028
|
370
|
PCNA
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.03
|
Tissue
|
18767028
|
371
|
Her-2/neu
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.049
|
Tissue
|
18767028
|
372
|
CD31
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.028
|
Tissue
|
18767028
|
373
|
Her-2/neu
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.025
|
Tissue
|
18767028
|
374
|
Ki67
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.027
|
Tissue
|
18767028
|
375
|
Her-2/neu
|
Protein
|
Humans
|
Negative Staining in Patients with Progression Free Survival
|
Prognostic
|
Progression Free Survival Vs No Progression Survival
|
p=0.001
|
Tissue
|
18767043
|
376
|
Her-2/neu
|
Protein
|
Humans
|
Negative Staining in Patients with Metastatic Free Survival
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate cancer
|
p=0.002
|
Tissue
|
18767043
|
377
|
Her-2/neu
|
Protein
|
Humans
|
Negative Staining in Patients with PCa Death Free Survival
|
Prognostic
|
PCa Specific Death Vs No PCa Specific Death
|
p=0.021
|
Tissue
|
18767043
|
393
|
Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU)
|
mRNA
|
Humans
|
Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC)
|
Diagnostic
|
Benign Vs Prostate Cancer
|
Clusterin: p<0.01
|
Tissue
|
18974881
|
394
|
Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU)
|
mRNA
|
Humans
|
Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC)
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
NA
|
Tissue
|
18974881
|
395
|
CCL4
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical Recurrence Vs No Recurrence
|
p=0.011
|
Tissue
|
19047106
|
396
|
CX3CL1
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
19047106
|
397
|
CCL4
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.04
|
Tissue
|
19047106
|
398
|
CX3CL1
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p<0.0001
|
Tissue
|
19047106
|
399
|
PSA+Surgical Margins+ seminal vesicle invasion+ Gleason Score+CX3CL1+CCL4+IL-15
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical Recurrence Vs No Recurrence
|
NA
|
Tissue
|
19047106
|
400
|
Ki-67
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Localized prostate cancer Vs benign prostate
|
p<0.01
|
Tissue
|
19050681
|
401
|
p53
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Localized prostate cancer Vs benign prostate
|
p<0.01
|
Tissue
|
19050681
|
402
|
BCL-2
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Localized prostate cancer Vs benign prostate
|
p<0.01
|
Tissue
|
19050681
|
403
|
Ki-67
|
Protein
|
Humans
|
Downregulated with Flaxseed supplemented Diet [ Control Diet: 3.23 (95% CI: 2.42-3.92), Flaxseed Supplementation: 1.66 (95% CI: 1.13-2.64)]
|
Predictive
|
Controls Vs Flaxseed Supplementation in Patients with PCa
|
p=0.0013
|
Tissue
|
19064574
|
406
|
Androgen Receptor (AR)
|
mRNA
|
Humans
|
Upregulated in Hormone Refactory Prostate Cancer (11 fold)
|
Prognostic
|
Hormone Naive Vs Hormone Refractory Prostate Cancer
|
p<0.0001
|
Tissue
|
19117982
|
407
|
Androgen Receptor AR-V1
|
mRNA
|
Humans
|
Upregulated in Hormone Refactory Prostate Cancer (22 fold)
|
Prognostic
|
Hormone Naive Vs Hormone Refractory Prostate Cancer
|
p<0.0001
|
Tissue
|
19117982
|
408
|
Androgen Receptor AR-V7
|
mRNA
|
Humans
|
Upregulated in Hormone Refactory Prostate Cancer (20 fold)
|
Prognostic
|
Hormone Naive Vs Hormone Refractory Prostate Cancer
|
p<0.0001
|
Tissue
|
19117982
|
409
|
Androgen Receptor AR-V7
|
mRNA
|
Humans
|
Higher expression in patients with biochemical recurrence
|
Prognostic
|
PSA Recurrence Vs No PSA Recurrence
|
p=0.012
|
Tissue
|
19117982
|
426
|
p53
|
Protein
|
Humans
|
Increased Expression with PCa Specific Death
|
Prognostic
|
Prostate Cancer Specific Survival Vs No Survival
|
Univariate: p<0.001; Multivariate: p=0.03;
|
Tissue
|
19239456
|
427
|
p53
|
Protein
|
Humans
|
Increased Expression with Overall Death
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p<0.001; Multivariate: p=0.001;
|
Tissue
|
19239456
|
428
|
p53
|
Protein
|
Humans
|
Increased Expression with PCa Specific Death
|
Prognostic
|
Prostate Cancer Specific Survival Vs No Survival
|
Univariate: p=0.01; Multivariate: p=0.01;
|
Tissue
|
19239456
|
429
|
p53
|
Protein
|
Humans
|
Increased Expression with Overall Death
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p=0.001; Multivariate: p=0.004;
|
Tissue
|
19239456
|
430
|
TMPRSS2
|
mRNA
|
Humans
|
Upregulated in PCa: (Normal: 0.26 ± 0.04 vs PCa: 3.91 ± 0.78)
|
Diagnostic
|
prostate cancer Vs Adjacent Normal
|
p=0.001
|
Tissue
|
19242826
|
431
|
TMPRSS2
|
mRNA
|
Humans
|
Upregulated (Clinical Stage 1&2: 3.43 ± 0.62 ; Vs Clinical Stage 3: 5.45 ± 0.92)
|
Prognostic
|
Clincal Stage (1-2) Vs Clinical Stage 3
|
p=0.02
|
Tissue
|
19242826
|
432
|
TMPRSS2
|
mRNA
|
Humans
|
Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53)
|
Prognostic
|
Gleason Score ≤6, Vs Gleason Score>6
|
p=0.008
|
Tissue
|
19242826
|
433
|
TMPRSS2
|
mRNA
|
Humans
|
Upregulated (Tumor Grade 1-2: 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31)
|
Prognostic
|
Tumor Grade (1-2) Vs Tumor Grade 3
|
p=0.016
|
Tissue
|
19242826
|
434
|
KLK11
|
mRNA
|
Humans
|
Upregulated in PCa: (Normal: 0.49 ± 0.07 vs PCa: 3.63 ± 0.42)
|
Diagnostic
|
prostate cancer Vs Adjacent Normal
|
p=0.003
|
Tissue
|
19242826
|
435
|
KLK11
|
mRNA
|
Humans
|
Upregulated (CS: (1-2) 6.05 ± 1.34 vs CS 3: 3.93 ± 0.45)
|
Prognostic
|
Clincal Stage (1-2) Vs Clinical Stage 3
|
p=0.009
|
Tissue
|
19242826
|
436
|
KLK11
|
mRNA
|
Humans
|
Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53)
|
Prognostic
|
Gleason Score ≤6, Vs Gleason Score>6
|
p=0.01
|
Tissue
|
19242826
|
437
|
KLK11
|
mRNA
|
Humans
|
Upregulated (Tumor Grade 1-2 : 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31)
|
Prognostic
|
Tumor Grade (1-2) Vs Tumor Grade 3
|
p=0.006
|
Tissue
|
19242826
|
438
|
Methylation Status of: Chromosome 20 open reading frame 103 (C20orf103); Homeobox D9 (HOXD9); Nuclear receptor subfamily, group A, member 2 (NR5A2); Distal-less homeobox 5 (DLX5); Iroquois homeobox 1 (IRX1); Spastic paraplegia 20 (SPG20); Transcription factor AP-2 alpha (TFAP2A); Wilms tumor 1 (WT1); SIX homeobox 6 (SIX6); Homeobox D4 (HOXD4) ; Transcription factor 7-like 1 (TCF7L1); Sonic hedgehog homolog (SHH); Protocadherin, gamma subfamily C,5 (PCDHG5); Methionine aminopeptidase 1D (MAP1D); Runt-related transcription factor 1 (RUNX1)
|
Methylation
|
Humans
|
Hypermethylated in PCa: [Chromosome 20 open reading frame 103 (C20orf103) (3.7 fold); Homeobox D9 (HOXD9) (3.2 fold); Nuclear receptor subfamily, group A, member 2 (NR5A2) (3.1 fold); Distal-less homeobox 5 (DLX5) (3.7 fold); Iroquois homeobox 1 (IRX1) (3.0 fold); Spastic paraplegia 20 (SPG20) (3.0 fold); Transcription factor AP-2 alpha (TFAP2A) (2.9 fold); Wilms tumor 1 (WT1) (2.9 fold); SIX homeobox 6 (SIX6) (2.8 fold); Homeobox D4 (HOXD4) (2.7 fold) ; Transcription factor 7-like 1 (TCF7L1) (2.6 fold); Sonic hedgehog homolog (SHH) (2.5 fold) ; Protocadherin , gamma subfamily C,5 (PCDHG5) (2.4 fold); Methionine aminopeptidase 1D (MAP1D) (2.3 fold); Runt-related transcription factor 1 (RUNX1) (2.3 fold);]
|
Diagnostic
|
Cancer Vs Non Cancer
|
p<0.05
|
Tissue
|
19283074
|
439
|
Methylation Status of: Ventral anterior homeobox 1 (VAX1); Homeobox D3 (HOXD3); CAP-GLY domain containing linker protein family (CLIP4); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) ; Glycoprotein V (GP5); Somatostatin receptor 1 (SSTR1); Methylthioadenosine phosporylase (MTAP); NK2 homeobox 2 (NKX2-2); Homeobox C11 (HOXC11); Ladybird homeobox 1 (LBX1); Motor neuron and pancreas homeobox 1 (MNX1); Glutamate receptor, metabotropic 1 (GRM1); LIM homeobox 9 (LHX9); Microtubule-associated protein tau (MAPT); Galactosidase, beta 1-like (GLB1L)
|
Methylation
|
Humans
|
Hypermethylated in Progression (PP4): [Ventral anterior homeobox 1 (VAX1) (2.7 fold); Homeobox D3 (HOXD3) (2.3 fold); CAP-GLY domain containing linker protein family (CLIP4) (2.1 fold); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) (2.0 fold); Glycoprotein V (GP5) (1.9 fold); Somatostatin receptor 1 (SSTR1) (1.8 fold); Methylthioadenosine phosporylase (MTAP) (1.8 fold); NK2 homeobox 2 (NKX2-2) (1.7 fold); Homeobox C11 (HOXC11) (1.6 fold); Ladybird homeobox 1 (LBX1) (1.6 fold); Motor neuron and pancreas homeobox 1 (MNX1) (1.6 fold); Glutamate receptor, metabotropic 1 (GRM1) (1.6 fold); LIM homeobox 9 (LHX9) (1.6 fold); Microtubule-associated protein tau (MAPT) (1.5 fold); Galactosidase, beta 1-like (GLB1L) (1.5 fold)]
|
Prognostic
|
Gleason Score 6 (Pure pattern 3) vs Gleason Score 8 (Pure Pattern 4)
|
p<0.05
|
Tissue
|
19283074
|
440
|
Ki-67
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Cause Specific Survival Vs No Survival
|
p<0.001
|
Tissue
|
19293807
|
441
|
Ki-67
|
Protein
|
Humans
|
Differentially Expressed [Cause Specific Survial (Δχ2 = 24.6) and overall survival (Δχ2 = 20.5)]
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Tissue
|
19293807
|
468
|
DNA Ploidy - Diploid
|
Mutation
|
Humans
|
DIPLOID: 5 year disease free survival - (80.5% ); 10 year disease free survival - (72.9%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival
|
p<0.001
|
Tissue
|
19633362
|
469
|
DNA Ploidy - Tetraploid
|
Mutation
|
Humans
|
TETRAPLOID: 5 year disease free survival - (67.8% ); 10 year disease free survival - (61.6%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival
|
p<0.001
|
Tissue
|
19633362
|
470
|
DNA Ploidy - Aneploid
|
Mutation
|
Humans
|
ANUEPLOID: 5 year disease free survival - (49.5% ); 10 year disease free survival - (31.8%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival
|
p<0.001
|
Tissue
|
19633362
|
471
|
DNA Ploidy - Diploid
|
Mutation
|
Humans
|
DIPLOID: 5 year disease free survival - (88.7% ); 10 year disease free survival - (84.8%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival for Gleason Score=7
|
p<0.001
|
Tissue
|
19633362
|
472
|
DNA Ploidy - Tetraploid
|
Mutation
|
Humans
|
TETRAPLOID: 5 year disease free survival - (74.3% ); 10 year disease free survival - (64.7%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival for Gleason Score=7
|
p<0.001
|
Tissue
|
19633362
|
473
|
DNA Ploidy - Anueploid
|
Mutation
|
Humans
|
ANUEPLOID: 5 year disease free survival - (25.0% ); 10 year disease free survival - (0%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival for Gleason Score=7
|
p<0.001
|
Tissue
|
19633362
|
474
|
CCNB1 (cyclin B1); CENPF (centromere protein F, 350/400 ka (mitosin)); BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)); CLDN4 (claudin 4); KIAA0101 (KIAA0101); LOC400879 (Hypothetical gene supported by AK096951); SLC39A6 (solute carrier family 39 (zinc transporter), member 6); SOX4 (SRY (sex determining region Y)-box 4); TOP2A (topoisomerase (DNA) II alpha 170 kDa)
|
mRNA
|
Humans
|
Upregulated: CCNB1 (cyclin B1) [1.8 fold]; CENPF (centromere protein F, 350/400 ka (mitosin)) [1.4 fold]; BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)) [1.4 fold]; CLDN4 (claudin 4) [2.4 fold]; KIAA0101 (KIAA0101) [1.6 fold]; LOC400879 (Hypothetical gene supported by AK096951) [1.7 fold]; SLC39A6 (solute carrier family 39 (zinc transporter), member 6) [1.6 fold]; SOX4 (SRY (sex determining region Y)-box 4) [1.8 fold]; TOP2A (topoisomerase (DNA) II alpha 170 kDa) [1.7 fold]
|
Diagnostic
|
Tumor Vs Adjacent To Tumor
|
p=0.05
|
Tissue
|
19652763
|
475
|
ABLIM3 (actin binding LIM protein family, member 3); AOX1 (aldehyde oxidase 1); CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)); DSCR1 (Down syndrome critical region gene 1); GLRX (glutaredoxin (thioltransferase)); IGFBP4 (insulin-like growth factor binding protein 4); MT1B (metallothionein 1B); MT1E (metallothionein 1E); MT1F (metallothionein 1F); MT1H (metallothionein 1H); C1QB (complement component 1, q subcomponent, B chain); CYB5R3 (cytochrome b5 reductase 3); DARC (Duffy blood group, chemokine receptor); DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)); F13A1 (coagulation factor XIII, A1 polypeptide); FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)); G0S2 (G0/G1switch 2); GAS6 (growth arrest-specifi c 6); IFITM2 (interferon induced transmembrane protein 2 (1–8D)); ITGA1 (integrin, alpha 1); MAP4 (microtubule-associated protein 4); MT1A (metallothionein 1A); MT2A (metallothionein 2A); PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase); PROS1 (protein S (alpha)); RBPMS (RNA binding protein with multiple splicing); RDX (Radixin); RNF11 (ring finger protein 11); S100A8 (S100 calcium binding protein A8); SERINC1 (serine incorporator 1); SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)); STOM (stomatin); TGFBR3 (transforming growth factor, beta receptor III); TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)); WDR47 (WD repeat domain 47)
|
mRNA
|
Humans
|
Downregulated: ABLIM3 (actin binding LIM protein family, member 3) [1.6 fold]; AOX1 (aldehyde oxidase 1) [2.6 fold]; CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)) [1.7 fold]; DSCR1 (Down syndrome critical region gene 1) [1.6 fold]; GLRX (glutaredoxin (thioltransferase)) [1.7 fold]; IGFBP4 (insulin-like growth factor binding protein 4) [2.5 fold]; MT1B (metallothionein 1B) [2.3 fold]; MT1E (metallothionein 1E) [1.9 fold]; MT1F (metallothionein 1F) [2.3 fold]; MT1H (metallothionein 1H) [2.4 fold]; C1QB (complement component 1, q subcomponent, B chain) [1.4 fold]; CYB5R3 (cytochrome b5 reductase 3) [1.4 fold]; DARC (Duffy blood group, chemokine receptor) [2.9 fold]; DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)) [1.4 fold]; F13A1 (coagulation factor XIII, A1 polypeptide) [2.1 fold]; FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)) [1.6 fold]; G0S2 (G0/G1switch 2) [2.2 fold]; GAS6 (growth arrest-specifi c 6) [2 fold]; IFITM2 (interferon induced transmembrane protein 2 (1–8D)) [2 fold]; ITGA1 (integrin, alpha 1) [1.4 fold]; MAP4 (microtubule-associated protein 4) [1.6 fold]; MT1A (metallothionein 1A) [2.6 fold]; MT2A (metallothionein 2A) [2.5 fold]; PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase) [1.3 fold]; PROS1 (protein S (alpha)) [1.7 fold]; RBPMS (RNA binding protein with multiple splicing) [2.4 fold]; RDX (Radixin) [1.4 fold]; RNF11 (ring finger protein 11) [1.4 fold]; S100A8 (S100 calcium binding protein A8) [2.3 fold]; SERINC1 (serine incorporator 1) [1.5 fold]; SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)) [2.2 fold]; STOM (stomatin) [1.8 fold]; TGFBR3 (transforming growth factor, beta receptor III) [1.7 fold]; TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)) [1.8 fold]; WDR47 (WD repeat domain 47) [1.5 fold]
|
Diagnostic
|
Tumor Vs Adjacent To Tumor
|
p=0.05
|
Tissue
|
19652763
|
476
|
GLUT1
|
Protein
|
Humans
|
Increased expression in Biochemical Recurrence
|
Prognostic
|
PSA recurrence Vs No PSA recurrence
|
p=0.005
|
Tissue
|
19854473
|
492
|
ezrin; lamin B1; succinate dehydrogenase complex, subunit A, flavoprotein precursor; succinate dehydrogenase complex, subunit A, flavoprotein precursor; acute morphine dependence related protein 2; methylcrotonoyl Coenzyme A carboxylase 2 (beta); 3-oxoacid CoA transferase 1 precursor; CCT2; CCT2; CCT2; keratin 8; lamin A/C transcript variant 1; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex; Stomatin (EPB72)-like 2; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP; Heterogeneous nuclear ribonucleoprotein C (C1/C2); SEC13 homologue (S. cerevisiae); HSPC124; Enoyl Coenzyme A hydratase 1, peroxisomal; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy; cathepsin D preproprotein; chloride intracellular channel 4; endoplasmic reticulum protein 29 isoform 1 precursor; heat shock 27 kDa protein 1; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B; thioredoxin peroxidase, peroxiredoxin 4; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; hypothetical protein LOC79017; ATP synthase, H+ transporting, mitochondrial F0; Ferritin, light polypeptide; nonmetastatic cells 1, protein (NM23A) expressed in isoform a; keratin-10; ubiquitin-conjugating enzyme E2N; fatty acid binding protein 5 (psoriasis-associated);
|
Protein
|
Humans
|
Upregulated ratio in LNMPCA: ezrin [2.4]; lamin B1 [2.76]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [2.22]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [1.86]; acute morphine dependence related protein 2 [1.94]; methylcrotonoyl Coenzyme A carboxylase 2 (beta) [5.27]; 3-oxoacid CoA transferase 1 precursor [1.90]; CCT2 [2.74]; CCT2 [2.22]; CCT2 [1.82]; keratin 8 [4.19]; lamin A/C transcript variant 1 [3.66]; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex [2.95]; Stomatin (EPB72)-like 2 [2.10]; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP [2.25]; Heterogeneous nuclear ribonucleoprotein C (C1/C2) [2.01]; SEC13 homologue (S. cerevisiae) [2.62]; HSPC124 [4.70]; Enoyl Coenzyme A hydratase 1, peroxisomal [3.79]; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy [2.39]; cathepsin D preproprotein [2.49]; chloride intracellular channel 4 [2.16]; endoplasmic reticulum protein 29 isoform 1 precursor [2.54]; heat shock 27 kDa protein 1 [3.47]; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B [4.62]; thioredoxin peroxidase, peroxiredoxin 4 [2.12]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.19]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.56]; hypothetical protein LOC79017 [3.15]; ATP synthase, H+ transporting, mitochondrial F0 [2.46]; Ferritin, light polypeptide [2.49]; nonmetastatic cells 1, protein (NM23A) expressed in isoform a [2.99]; keratin-10 [3.84]; ubiquitin-conjugating enzyme E2N [2.23]; fatty acid binding protein 5 (psoriasis-associated) [20.86];
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.05
|
Tissue
|
19894759
|
493
|
collagen, type VI, alpha 1 precursor; vinculin isoform meta-VCL; FLNA protein; gelsolin isoform b; transferrin; transferrin; lamin A/C transcript variant 1; archain; Dihydropyrimidinase-like 3; mutant desmin; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox; splicing factor, arginine/ serine-rich 1 isoform 1; Unknown (protein for IMAGE:3906970); ubiquitin carboxy-terminal hydrolase L1; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9; regulatory myosin light chain long version; smooth muscle protein (SM22); haptoglobin-related protein precursor; smooth muscle protein (SM22); smooth muscle protein (SM22); Chain A, X-ray Crystal Structure Of Human Galectin-1;
|
Protein
|
Humans
|
Downregulated ratio in LNMPCA: collagen, type VI, alpha 1 precursor [2.15]; vinculin isoform meta-VCL [3.47]; FLNA protein [1.99]; gelsolin isoform b [2.15]; transferrin [2.04]; transferrin [2.15]; lamin A/C transcript variant 1 [2.06]; archain [1.63]; Dihydropyrimidinase-like 3 [1.86]; mutant desmin [2.38]; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2 [2.89]; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox [2.68]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.6]; Unknown (protein for IMAGE:3906970) [2.04]; ubiquitin carboxy-terminal hydrolase L1 [2.78]; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2 [3.32]; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9 [2.85]; regulatory myosin light chain long version [4.25]; smooth muscle protein (SM22) [13.98]; haptoglobin-related protein precursor [6.16]; smooth muscle protein (SM22) [5.08]; smooth muscle protein (SM22) [3.30]; Chain A, X-ray Crystal Structure Of Human Galectin-1 [2.46];
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.05
|
Tissue
|
19894759
|
494
|
transglutaminase 2 isoform a; TPM1 protein; FTH1 protein; S100 calcium binding protein A9; splicing factor, arginine/ serine-rich 1 isoform 1; chromatin modifying protein 4B;
|
Protein
|
Humans
|
Upregulated ratio in Localised PCA: transglutaminase 2 isoform a [2.03]; TPM1 protein [4.18]; FTH1 protein [2.28]; S100 calcium binding protein A9 [3.81]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.07]; chromatin modifying protein 4B [2.16];
|
Diagnostic
|
Localized PCa and BPH
|
p<0.05
|
Tissue
|
19894759
|
495
|
keratin 5; mutant desmin; histone cluster 2, H2bf;
|
Protein
|
Humans
|
Downregulated ratio in Localised PCA: keratin 5 [2.08]; mutant desmin [2.03]; histone cluster 2, H2bf [2.02];
|
Diagnostic
|
Localized PCa and BPH
|
p<0.05
|
Tissue
|
19894759
|
498
|
e-FABP5, MCCC2, PPA2, Ezrin, and SLP2
|
Protein
|
Humans
|
Upregulated in LNM PCa
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.01
|
Tissue
|
19894759
|
499
|
SM22
|
Protein
|
Humans
|
Downregulated in LNM PCa
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.01
|
Tissue
|
19894759
|
500
|
Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP)[Fixed
|
DNA (Gene)
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical recurrence (within 1 year ) Vs No recurrence (24 months)
|
NA
|
Tissue
|
20028763
|
501
|
Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Floating]
|
DNA (Gene)
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical recurrence (within 1 year ) Vs No recurrence (24 months)
|
NA
|
Tissue
|
20028763
|
502
|
Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Integrated]
|
DNA (Gene)
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical recurrence (within 1 year ) Vs No recurrence (24 months)
|
NA
|
Tissue
|
20028763
|
503
|
ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1;
|
mRNA
|
Humans
|
Differentially Expressed: ANXA5 [1.47 fold]; APLP2 [1.22 fold]; COL1A2 [1.18 fold]; CRIM1 [1.20 fold]; ECHS1 [1.18 fold]; HMGB1 [1.40 fold]; MAP3K5 [1.35 fold]; NGFRAP1 [1.32 fold]; NPM1 [1.30 fold]; NUB1 [1.12 fold]; PDIA3 [1.43 fold]; PLA2G2A [1.75 fold]; ROCK1 [1.17 fold]; TEGT [1.32 fold]; TMEM16G [0.66 fold]; TMEM69 [1.08 fold]; TRAF4 [1.26 fold]; VCAN [1.31 fold]; VCP [1.18 fold]; VDAC1 [1.51 fold];
|
Prognostic
|
Gleason Score 6 Vs Gleason Score (8-10)
|
p<0.05
|
Tissue
|
20035634
|
504
|
ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1;
|
mRNA
|
Humans
|
Differentially Expressed: ANXA5 [4.28 fold]; APLP2 [2.83 fold]; COL1A2 [2.02 fold]; CRIM1 [3.23 fold]; ECHS1 [1.89 fold]; HMGB1 [4.68 fold]; MAP3K5 [2.98 fold]; NGFRAP1 [3.95 fold]; NPM1 [3.07 fold]; NUB1 [1.62 fold]; PDIA3 [2.40 fold]; PLA2G2A [3.00 fold]; ROCK1 [9.76 fold]; TEGT [2.77 fold]; TMEM16G [0.35 fold]; TMEM69 [2.77 fold]; TRAF4 [2.59 fold]; VCAN [2.92 fold]; VCP [2.75 fold]; VDAC1 [5.41 fold];
|
Prognostic
|
Gleason Score 6 Vs Gleason Score (8-10)
|
p<0.05
|
Tissue
|
20035634
|
505
|
MAP3K5
|
mRNA
|
Humans
|
Upregulated in Gleason Score 8-10
|
Prognostic
|
Gleason Score 6 Vs Gleason Score (8-10)
|
qRT-PCR: p=0.0129
|
Tissue
|
20035634
|
506
|
PDIA3
|
mRNA
|
Humans
|
Upregulated in Gleason Score 8-10
|
Prognostic
|
Gleason Score 6 Vs Gleason Score (8-10)
|
qRT-PCR: p=0.00167
|
Tissue
|
20035634
|
507
|
TRPM8 (transient receptor potential member 8)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Tumors Vs patient matched non-tumor
|
NA
|
Tissue
|
20043080
|
508
|
TRPM8 (transient receptor potential member 8)
|
mRNA
|
Humans
|
Upregulated in PCa (ratio = 1.94±0.256)
|
Diagnostic
|
Tumors Vs patient matched non-tumor
|
p<0.01
|
Tissue
|
20043080
|
511
|
TMPRSS2–ERG
|
mRNA
|
Humans
|
Fusion Positive in Recurrence
|
Prognostic
|
Biochemical recurrence Vs No recurrence
|
p=0.0000000354
|
Tissue
|
20068566
|
512
|
ERG expression in TMPRSS2–ERG
|
mRNA
|
Humans
|
Upregulated in Fusion (3.07-fold)
|
Prognostic
|
ERG Fusion Vs No Fusion
|
p=3.48E-11
|
Tissue
|
20068566
|
513
|
CSPG2+ WNT10B+E2F3+CDKN2A+TYMS+TGFB3+ALOX12+CD44+LAF4
|
mRNA
|
Humans
|
Upregulated with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No recurrence
|
Univariate: p=0.0000002; Multivariate: p=0.0270
|
Tissue
|
20068566
|
519
|
EGFR [SNP rs884419]
|
Mutation
|
Humans
|
AG And GG Phenotypes associated with decreased risk of recurrence
|
Prognostic
|
Biochemical recurrence Vs No recurrence
|
A/G Phenotype: p= 0.0018; G/G Phenotype: p = 0.0016
|
Tissue
|
20303520
|
520
|
CB:SA ratio: (cathepsin B/stefin A)
|
Protein
|
Humans
|
Upregulated in Cancer: (BPH Geometric Mean : 1.448 Vs Cancer Geometric Mean : 2.990)
|
Diagnostic
|
benign prostatic hyperplasia Vs Prostate Cancer
|
p=0.0001
|
Tissue
|
20392989
|
521
|
CB:SA ratio: (cathepsin B/stefin A)
|
Protein
|
Humans
|
Upregulated in Cancer (Gleason Score 6): (BPH Geometric Mean : 1.448 Vs GS6 Geometric Mean : 3.452)
|
Diagnostic
|
benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 6)
|
p=0.0003
|
Tissue
|
20392989
|
522
|
CB:SA ratio: (cathepsin B/stefin A)
|
Protein
|
Humans
|
Upregulated in Cancer (Gleason Score 7): (BPH Geometric Mean : 1.448 Vs GS7: Geometric Mean : 2.756)
|
Diagnostic
|
benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 7)
|
p=0.0052
|
Tissue
|
20392989
|
529
|
miRNA-375
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Tumor Vs Normal
|
p<0.001
|
Tissue
|
20473869
|
530
|
miRNA-141
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Tumor Vs Normal
|
p<0.001
|
Tissue
|
20473869
|
531
|
KLK15 (kallikrein-related peptidase)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p = 0.045
|
Tissue
|
20473923
|
532
|
KLK15 (kallikrein-related peptidase)
|
Protein
|
Humans
|
High levels associated with shorter progression-free survival.
|
Prognostic
|
PSA recurrence Vs No PSA recurrence
|
Univariate: p = 0.002; Multivariate: p=0.037; StepWise Inclusion: p=0.032
|
Tissue
|
20473923
|
538
|
SPATA19
|
mRNA
|
Humans
|
Upregulated in PCa (Increased Prostate cancer risk with High expression)
|
Diagnostic
|
Benign Prostatic Hyperplasia Vs Prostate Cancer
|
p<0.0001
|
Tissue
|
20682177
|
539
|
LEMD1
|
mRNA
|
Humans
|
Upregulated in PCa (Increased Prostate cancer risk with High expression)
|
Diagnostic
|
Benign Prostatic Hyperplasia Vs Prostate Cancer
|
p=0.012
|
Tissue
|
20682177
|
540
|
MMP-9 %
|
Protein
|
Humans
|
Increased expression in Recurrence free survival
|
Prognostic
|
Biochemical Recurrence Vs No Recurrence
|
p=0.03
|
Tissue
|
20889560
|
541
|
MMP-9 intensity
|
Protein
|
Humans
|
Increased expression in Disease Specific Mortality
|
Prognostic
|
Disease Specific Mortality Vs No Mortality
|
p<0.001
|
Tissue
|
20889560
|
542
|
MMP-9 intensity
|
Protein
|
Humans
|
Increased expression in Overall Mortality
|
Prognostic
|
Overall Mortality Vs No Mortality
|
p<0.001
|
Tissue
|
20889560
|
555
|
Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Flotillin 1; 26S protease regulatory subunit 8; Annexin A2;
|
Protein
|
Humans
|
Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.15]; Isocitrate dehydrogenase [1.09]; Citrate synthase [1.18]; L-Lactate dehydrogenase A [1.40]; ATP synthase gamma chain [1.28]; Alpha-enolase [1.48]; Phosphoglycerate mutase 1 [1.56]; Malate dehydrogenase [1.64]; Core protein II [1.19]; Transketolase [1.31]; 60 kDa heat shock protein [1.83]; Flotillin 1 [1.07]; 26S protease regulatory subunit 8 [1.14]; Annexin A2 [1.29];
|
Diagnostic
|
Gleason 6 Vs Benign Prostate
|
p<0.05
|
Tissue
|
20977276
|
556
|
Lamin A; Cytokeratin-1; Mimecan; Prostatic acid phosphatase; Prostate-specific antigen;
|
Protein
|
Humans
|
Downregulated (with Regulation Coefficient): Lamin A [-1.52]; Cytokeratin-1 [-1.09]; Mimecan [-1.08]; Prostatic acid phosphatase [-2.85]; Prostate-specific antigen [-1.15];
|
Diagnostic
|
Gleason 6 Vs Benign Prostate
|
p<0.05
|
Tissue
|
20977276
|
557
|
Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Lamin A; Flotillin 1; Cytokeratin-1; Mimecan; 26S protease regulatory subunit 8; Annexin A2;
|
Protein
|
Humans
|
Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.85]; Isocitrate dehydrogenase [1.79]; Citrate synthase [1.76]; L-Lactate dehydrogenase A [1.75]; ATP synthase gamma chain [1.7]; Alpha-enolase [1.67]; Phosphoglycerate mutase 1 [1.65]; Malate dehydrogenase [1.64]; Core protein II [1.61]; Transketolase [1.59]; 60 kDa heat shock protein [2.13]; Lamin A [2.08]; Flotillin 1 [1.85]; Cytokeratin-1 [1.65]; Mimecan [1.58]; 26S protease regulatory subunit 8 [1.47]; Annexin A2 [1.46];
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 8 and above
|
p<0.05
|
Tissue
|
20977276
|
558
|
Prostatic acid phosphatase; Prostate-specific antigen;
|
Protein
|
Humans
|
Downregulated (with Regulation Coefficient): Prostatic acid phosphatase [-1.84]; Prostate-specific antigen [-3.04];
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 8 and above
|
p<0.05
|
Tissue
|
20977276
|
559
|
HSP60
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Gleason 6 Vs Benign Prostate
|
p<0.05
|
Tissue
|
20977276
|
560
|
Lamin A
|
Protein
|
Humans
|
Upregulated in GS 8 and above
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 8 and above
|
p<0.05
|
Tissue
|
20977276
|
561
|
C8orf4; TMC5; PDLIM5; JAG1; HOXA9; C4A; STEAP4; HLA-DMB; COL12A1; DHRS8; C10orf137; SLC7A1; PDZRN3; F3; ACER3; POLB; PXDN; PROM2; GUCY1A3; SOX4;
|
mRNA
|
Humans
|
Upregulated (Fold Change): [C8orf4 (5.14 fold); TMC5 (4.83 fold) ; PDLIM5 (4.51 fold); JAG1 (4.36 fold); HOXA9 (4.25 fold) ; C4A (3.98 fold); STEAP4 (3.92 fold); HLA-DMB (3.85fold); COL12A1 (3.81 fold); DHRS8 (3.81 fold); C10orf137 (3.62 fold); SLC7A1 (3.44 fold); PDZRN3 (3.30 fold); F3 (3.26 fold) ; ACER3 (3.17fold); POLB (3.16 fold); PXDN (3.12 fold); PROM2 (3.11 fold); GUCY1A3 (3.10 fold); SOX4 (3.02 fold);]
|
Diagnostic
|
High BMI Tumor Vs High BMI Normal
|
p<0.05
|
Tissue
|
21060327
|
562
|
ACADL; PHLDA2; GPD1; L; NTAN1; LOC389048; SFN; HSRG1; PAK1IP1; EBP; ANPEP; ANTXR2; COL4A6; LOC400880; RHOU; GREB1; FLJ30428; C3orf14; ZNF532; SCD; PTN; SC4MOL; MAF; NPAL3; CYP3A5; NOV; ALOX15B; LOC399959; VGL-3; INSIG1; Rcan3; Poteg; P704P; EFS;
|
mRNA
|
Humans
|
Downregulated (Fold Change): [ACADL (0.33 fold); PHLDA2 (0.33 fold); GPD1L (0.33 fold); NTAN1 (0.33 fold); LOC389048 (0.32 fold); SFN (0.32 fold); HSRG1 (0.32 fold); PAK1IP1 (0.32 fold); EBP (0.31 fold); ANPEP (0.31 fold); ANTXR2 (0.29 fold); COL4A6 (0.29 fold); LOC400880 (0.29 fold); RHOU (0.29 fold); GREB1 (0.28 fold); FLJ30428 (0.27 fold); C3orf14 (0.27 fold); ZNF532 (0.26 fold); SCD (0.25 fold); PTN (0.24 fold); SC4MOL (0.24 fold); MAF (0.22 fold); NPAL3 (0.22 fold); CYP3A5 (0.21 fold); NOV (0.20 fold); ALOX15B (0.17 fold); LOC399959 (0.17 fold); VGL-3 (0.16 fold); INSIG1 (0.16 fold); Rcan3 (0.15 fold); Poteg (0.14 fold); P704P (0.13 fold); EFS (0.13 fold)]
|
Diagnostic
|
High BMI Tumor Vs High BMI Normal
|
p<0.05
|
Tissue
|
21060327
|
580
|
Methylation Status of [A4GALT; ADAM8; ALOX15B; BIK; CCK; CRCP; CTSC; CXCL2; CXCL3; CYBA; EIF4B; GSTM1 ; GSTM2; IGF2; LTF; MCAM; PDCD1; PDPN; PKMYT1; PPP1R3C; RAB32; RFTN1; SERPINB1; SLC16A5; SOCS1; TIMP3; TNF]
|
Methylation
|
Humans
|
HyperMethylated in PCa ( Positive Fold change): [A4GALT(2.0 fold) ; ADAM8(3.9 fold); ALOX15B(5.1fold, 2.7 fold); BIK(2.6 fold); CCK(9.3 fold); CRCP(2.1fold); CTSC(3.7 fold); CXCL2(3.2 fold); CXCL3(3.0fold); CYBA(3.8 fold); EIF4B(3.5 fold); GSTM1 (20.5 fold); GSTM2(4.1 fold); IGF2(4.2 fold); LTF(2.1 fold); MCAM(2.7 fold); PDCD1(3.2 fold); PDPN(4.5 fold); PKMYT1(2.9 fold); PPP1R3C(8.2 fold) ; RAB32(3.3 fold); RFTN1(5.5 fold); SERPINB1(2.4 fold); SLC16A5(17.2fold, 4.2 fold); SOCS1(2.6 fold); TIMP3(2.2 fold); TNF(2.0 fold)]
|
Diagnostic
|
Tumor Vs Tumor Adjacent
|
p=0.013
|
Tissue
|
21237555
|
581
|
Methylation Status of [ALDH1A3; NR4A2; PF4; RELB; SOCS1; TNFRSF1B; ZBTB11; ZNF365]
|
Methylation
|
Humans
|
HypoMethylated in PCa: ( Negative Fold change): [ALDH1A3(2.6 fold); NR4A2(2.5 fold); PF4(3.4 fold); RELB(2.1 fold); SOCS1(8.2 fold); TNFRSF1B(3.0 fold); ZBTB11(2.9 fold); ZNF365(5.0 fold)]
|
Diagnostic
|
Tumor Vs Tumor Adjacent
|
p=0.013
|
Tissue
|
21237555
|
582
|
GSTP1, BCL2, ADCY4, CACNA1G, LOC63928, and D4S234E
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Tumor Vs Tumor Adjacent
|
p<0.05
|
Tissue
|
21237555
|
583
|
β-microseminoprotein (MSMB)
|
Protein
|
Humans
|
increased expression with decreased biochemical recurrence-free survival
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.001
|
Tissue
|
21240253
|
584
|
SLCO1B1; SLCO1B3; SLCO2A1; SLCO3A1;
|
mRNA
|
Humans
|
Upregulated in CRPC metastases: SLCO1B1 (5.5 fold); SLCO1B3( 3.6 fold); SLCO2A1 (3.2 fold); SLCO3A1 (5.4 fold);
|
Prognostic
|
CRPC metastases versus untreated prostate cancer
|
p<0.053
|
Tissue
|
21266523
|
587
|
Tropomyosin β chain fibroblast and epithelia, Keratin type II cytoskeletal 8 Cytokeratin 8 K, 14-3-3 protein γ protein kinase C inhibitor p, Protein disulfide isomerase precursor PDI EC 5, Keratin type I cytoskeletal 19 Cytokeratin 19, Actin muscle type A2, Desmin, α1 antitrypsin precursor, Tubulin β2 chain, 78 kDa glucose regulated protein prec GRP 78, Rho GDP dissociation inhibitor 1, Creatine kinase B chain EC 2 7 3 2 B CK, Fibrinogen γ chain precursor, Heat shock cognate 71 kDa protein, Stress 70 protein mitochondrial precursor 75 kD, Heat shock 70 kDa protein 1 HSP70 1a, Enoyl CoA hydratase mitochprecursor EC 4, Prohibitin, Apolipoprotein A I precursor Apo AI, ATP synthase β chain mitochondrial precursor, Small nuclear ribonucleoprotein 200 kDa helicas, Glycerol 3 phosphate acyltransferase EC 2 3 1 15, Keratin type I cytoskeletal 18 Cytokeratin 18, Serum albumin precursor, Annexin A4 Lipocortin IV Endonexin, Serum albumin precursor, 60 kDa heat shock protein mitochondrial precursor.
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
BPH Vs Prostate Cancer
|
p<0.05
|
Tissue
|
21305254
|
588
|
Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Creatine kinase, brain (CKB); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Fibrinogen γ chain (FGG); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Heat shock 60 kDa protein 1 (chaperonin) (HSPD1); Prolyl 4-hydroxylase, β polypeptide (P4HB); Prohibitin (PHB); Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1);
|
Protein
|
Humans
|
Upregulated in Gleason Score 7(Fold Change) : Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [7.440]; Creatine kinase, brain (CKB) [1.000]; Desmin (DES) [2.059]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [2.335]; Fibrinogen γ chain (FGG) [7.634]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [2.339]; Heat shock 60 kDa protein 1 (chaperonin) (HSPD1) [1.000]; Prolyl 4-hydroxylase, β polypeptide (P4HB) [11.540]; Prohibitin (PHB) [1.000]; Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1) [2.992];
|
Prognostic
|
Gleason Score 5 Vs Gleason Score 7
|
p<0.05
|
Tissue
|
21305254
|
589
|
Albumin (ALB); Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8);
|
Protein
|
Humans
|
Downregulated in Gleason Score 7(Fold Change) : Albumin (ALB) [2.155]; Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.571]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950];
|
Prognostic
|
Gleason Score 5 Vs Gleason Score 7
|
p<0.05
|
Tissue
|
21305254
|
590
|
Albumin (ALB); Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Fibrinogen γ chain (FGG);
|
Protein
|
Humans
|
Upregulated in Stage T3 (Fold Change) : Albumin (ALB) [2.684]; Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [1.000]; Fibrinogen γ chain (FGG) [1.000];
|
Prognostic
|
Stage T2 Vs Stage T3
|
p<0.05
|
Tissue
|
21305254
|
591
|
Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8);
|
Protein
|
Humans
|
Downregulated in Stage T3(Fold Change) : Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.165]; Desmin (DES) [8.929]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [7.407]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [1.613]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950];
|
Prognostic
|
Stage T2 Vs Stage T3
|
p<0.05
|
Tissue
|
21305254
|
596
|
Engrailed-2 (EN2)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Biopsy Positive Vs Biopsy Negative
|
p<0.05
|
Tissue
|
21364037
|
599
|
vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
BPH Vs Prostate Cancer
|
p<0.001
|
Tissue
|
21367627
|
600
|
matrix metalloproteinase-9 (MMP-9)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
BPH Vs Prostate Cancer
|
p=0.004
|
Tissue
|
21367627
|
601
|
vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Upregulated in Lymph Node Metastatis
|
Prognostic
|
Lymph Node Metastatis Posititve Lymph Node Metastatis Negative
|
p<0.001
|
Tissue
|
21367627
|
602
|
matrix metalloproteinase-9 (MMP-9)
|
Protein
|
Humans
|
Upregulated in Lymph Node Metastatis
|
Prognostic
|
Lymph Node Metastatis Posititve Lymph Node Metastatis Negative
|
p<0.001
|
Tissue
|
21367627
|
603
|
Stromal cell-derived factor-1 (SDF-1)
|
Protein
|
Humans
|
Upregulated in Lymph Node Metastatis
|
Prognostic
|
Lymph Node Metastatis Posititve Lymph Node Metastatis Negative
|
p<0.001
|
Tissue
|
21367627
|
604
|
Stromal cell-derived factor-1 (SDF-1)
|
Protein
|
Humans
|
Patients with low levels survived longer than those with high levels
|
Prognostic
|
Prostate Cancer Specific Survival VS No Survival
|
Univariate: p<0.001; Multivariate: p=0.017
|
Tissue
|
21367627
|
605
|
vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Patients with low levels survived longer than those with high levels
|
Prognostic
|
Prostate Cancer Specific Survival VS No Survival
|
Univariate: p<0.001; Multivariate: p<0.001
|
Tissue
|
21367627
|
606
|
matrix metalloproteinase-9 (MMP-9)
|
Protein
|
Humans
|
Patients with low levels survived longer than those with high levels
|
Prognostic
|
Prostate Cancer Specific Survival VS No Survival
|
p<0.001
|
Tissue
|
21367627
|
607
|
let-7a; miR-101; miR-106a; miR-106b; miR-1274; miR-141; miR-17; miR-182; miR-1826; miR-200b; miR-200c; miR-20a; miR-20b; miR-21; miR-375; miR-720; miR-768-3p; miR-93
|
miRNA
|
Humans
|
Upregulated in PCa(Fold Change): let-7a(1.53 fold) ; miR-101(1.13 fold) ; miR-106a(2.41 fold); miR-106b(1.70 fold); miR-1274(1.87 fold); miR-141(1.44 fold); miR-17(2.69 fold); miR-182(2.39 fold) ; miR-1826(1.73 fold) ; miR-200b( 1.54 fold) ; miR-200c( 2.92 fold); miR-20a(2.67 fold); miR-20b(2.81 fold); miR-21( 1.40 fold); miR-375(3.90 fold) ; miR-720(1.41 fold); miR-768-3p(1.67 fold); miR-93(2.52 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.001
|
Tissue
|
21400514
|
608
|
miR-136-star; miR-145; miR-214; miR-221; miR-222; miR-302d-star; miR-378-star
|
miRNA
|
Humans
|
Downregulated in PCa (Fold Change): miR-136-star(1.18 fold) ; miR-145(1.44 fold); miR-214(1.74 fold); miR-221(2.16 fold) ; miR-222(2.91 fold) ; miR-302d-star(1.13 fold); miR-378-star(1.30 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.001
|
Tissue
|
21400514
|
609
|
miRNA- 375; miRNA-143; miRNA-145 (Individual assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 145
|
Diagnostic
|
Prostate Cancer Vs Normal
|
miRNA- 375 (p=0.002) ; miRNA-143 (p=0.001); miRNA-145 (p<0.0001);
|
Tissue
|
21400514
|
610
|
miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 146
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.0001
|
Tissue
|
21400514
|
611
|
miRNA- 375; miRNA-143; miRNA-145 (Individual assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 147
|
Diagnostic
|
Prostate Cancer Vs Normal
|
miRNA- 375 (p=0.005) ; miRNA-143 (p=0.005); miRNA-145 (p<0.0001);
|
Tissue
|
21400514
|
612
|
miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 148
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.0001
|
Tissue
|
21400514
|
613
|
miRNA- 375; miRNA-143; miRNA-145 (Individual assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 149
|
Diagnostic
|
Prostate Cancer Vs Normal
|
miRNA- 375 (p<0.0001) ; miRNA-143 (p<0.0001); miRNA-145 (p<0.0001);
|
Tissue
|
21400514
|
614
|
miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 150
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.0001
|
Tissue
|
21400514
|
636
|
40S ribosomal protein S8; Heterogeneous nuclear ribonucleoprotein H; 78 kDa glucose-regulated protein; Cytochrome c oxidase polypeptide VIc; Cytochrome c oxidase subunit 5B, mitochondrial ATP synthase subunit beta, mitochondrial Stress-70 protein, mitochondrial Biglycan; Elongation factor Tu mitochondrial; Ubiquitin-like modifier-activating enzyme 1; Protein disulfide-isomerase A4; Heterochromatin protein 1-binding protein 3; Tumor protein D52 Prohibitin-2; Protein disulfide-isomerase; EH domain-containing protein 2; 60 kDa heat shock protein mitochondrial; Nucleophosmin Periostin; Sorbitol dehydrogenase
|
Protein
|
Humans
|
Upregulated in PCA(Fold Change) :
|
Diagnostic
|
Prostate Cancer Vs BPH
|
p<0.05
|
Tissue
|
21504578
|
637
|
Desmin; Serum deprivation-response protein 3; Sorbin and SH3 domain-containing protein 1; Vimentin; Calponin-1; Heat shock protein beta-1; Actin, gamma-enteric smooth muscle; Protein kinase C delta-binding protein; Collagen alpha-1(VI) chain Laminin subunit gamma-1; Sorbin and SH3 domain-containing protein 2; Tenascin; Zyxin; Talin-1; Collagen alpha-1(I) chain; Vinculin; Mimecan; Lipoma-preferred partner; Neuroblast differentiation-associated protein AHNAK; Decorin; Basement membrane-specific heparan sulfate proteoglycan core protein; Phosphatidylethanolamine-binding protein 1
|
Protein
|
Humans
|
Downregulated in PCA(Fold Change):
|
Diagnostic
|
Prostate Cancer Vs BPH
|
p<0.05
|
Tissue
|
21504578
|
638
|
Neuroblast differentiation-associated protein AHNAK; Glutamate dehydrogenase 1, mitochondrial; Protein disulfide-isomerase A4; Cytochrome c oxidase subunit 5B, mitochondrial; Collagen alpha-3(VI) chain; Heterogeneous nuclear ribonucleoprotein H; 10 kDa heat shock protein, mitochondrial; Elongation factor Tu, mitochondrial; 78 kDa glucose-regulated protein; Myosin-9; Protein disulfide-isomerase; Biglycan; Nucleoside diphosphate kinase B; 60 kDa heat shock protein, mitochondrial; Periostin; 60S ribosomal protein L10a Nucleophosmin; Asporin; Sorbitol dehydrogenase;
|
Protein
|
Humans
|
Upregulated in PCA(Fold Change) :
|
Diagnostic
|
Prostate Cancer Vs BPH with Local PIN
|
p<0.05
|
Tissue
|
21504578
|
639
|
Desmin; Myosin regulatory light polypeptide 9; Serum deprivation-response protein 3; Sorbin and SH3 domain- containing protein 1; Tropomyosin alpha-1 chain; Protein kinase C delta-binding protein; Calponin-1; Vinculin; Prostatic acid phosphatase; Zyxin; Fibrinogen alpha chain; Histone H1.0; Talin-1; Protein disulfide-isomerase A3;
|
Protein
|
Humans
|
Downregulated in PCA(Fold Change):
|
Diagnostic
|
Prostate Cancer Vs BPH with Local PIN
|
p<0.05
|
Tissue
|
21504578
|
640
|
Periostin
|
Protein
|
Humans
|
Upregulated in PCA
|
Diagnostic
|
Prostate Cancer Vs BPH with Local PIN
|
p<0.01
|
Tissue
|
21504578
|
641
|
Ki-67
|
Protein
|
Humans
|
Upregulated in Black men
|
Prognostic
|
Prostate Cancer in Black Men Vs Prostate Cancer in White Men
|
Univariate: p=0.02; Multivariate: =0.002
|
Tissue
|
21519348
|
642
|
Norm AR (Androgen Receptor)
|
Protein
|
Humans
|
Upregulated in Black men
|
Prognostic
|
Prostate Cancer in Black Men Vs Prostate Cancer in White Men
|
Univariate: p=0.006; Multivariate: p=0.001
|
Tissue
|
21519348
|
643
|
Ki-67/lum
|
Protein
|
Humans
|
Upregulated in Black men
|
Prognostic
|
Prostate Cancer in Black Men Vs Prostate Cancer in White Men
|
p=0.022
|
Tissue
|
21519348
|
655
|
enhancer of zeste homologue 2 (EZH2)
|
Protein
|
Humans
|
Progression Vs No Progression
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.004
|
Tissue
|
21592298
|
656
|
minichromosome maintenance protein 7 (MCM7)
|
Protein
|
Humans
|
Progression Vs No Progression
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p<0.001
|
Tissue
|
21592298
|
657
|
Ki-67
|
Protein
|
Humans
|
Increased expression in patients with Progression
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p<0.001
|
Tissue
|
21592298
|
665
|
MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1)
|
Genes
|
Humans
|
TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence,
|
Prognostic
|
PSA Reccurence Vs No Recurrence for 8 years
|
p=0.001
|
Tissue
|
21629784
|
666
|
PSA+ Grade + Stage +MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1)
|
Genes
|
Humans
|
TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence,
|
Prognostic
|
PSA Reccurence Vs No Recurrence for 8 years
|
p=0.005
|
Tissue
|
21629784
|
667
|
NA
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis:
|
Prognostic
|
Primary vs Bone Metastatis
|
p<0.05
|
Tissue
|
21647377
|
668
|
NA
|
miRNA
|
Humans
|
Upregulated in Bone Metastatis:
|
Prognostic
|
Primary vs Bone Metastatis
|
p<0.05
|
Tissue
|
21647377
|
669
|
miR-143
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis: 12.9 fold
|
Prognostic
|
Primary vs Bone Metastatis
|
p=0.012
|
Tissue
|
21647377
|
670
|
miR-145
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis: 17.3 fold
|
Prognostic
|
Primary vs Bone Metastatis
|
p=0.014
|
Tissue
|
21647377
|
671
|
miR-143
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis
|
Prognostic
|
Bone Metastatis Vs No Bone Metastasis
|
p=0.039
|
Tissue
|
21647377
|
672
|
miR-145
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis
|
Prognostic
|
Bone Metastatis Vs No Bone Metastasis
|
p=0.041
|
Tissue
|
21647377
|
673
|
Androgen Receptor
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p=0.018
|
Tissue
|
21667031
|
685
|
miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-940
|
miRNA
|
Humans
|
Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)]
|
Diagnostic
|
Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP)
|
p= 0.0046
|
Tissue
|
21765474
|
686
|
miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-941
|
miRNA
|
Humans
|
Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)]
|
Diagnostic
|
Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP)
|
p= 0.0046
|
Tissue
|
21765474
|
687
|
miR-139-5p; miR-1; miR-133b; miR-133a; miR-143*; miR-145*; miR-143; miR-145; miR-27b, miR-221; miR-222; miR-378; miR-204; miR-141*; miR-32; let-7b; miR-183*, miR-301b; miR-106b; miR-93; miR-25; miR-183; miR-96; miR-425; miR-663
|
miRNA
|
Humans
|
NA
|
Prognostic
|
group I (good prognosis) from group II (poor prognosis)
|
p=0.0005
|
Tissue
|
21765474
|
698
|
PCAT-1
|
ncRNA
|
Humans
|
Upregulated in a subset of metastatic and high-grade localized (Gleason score ≥7) cancers
|
Prognostic
|
High grade tumor vs. low grade tumor/non-tumor
|
NA
|
Tissue
|
21804560
|
703
|
Methylation Status of RARB
|
Methylation
|
Humans
|
Hypermethylated in Cancer
|
Prognostic
|
Methylation in Patients with PCa
|
NA
|
Tissue
|
21822036
|
720
|
Katanin p60
|
Protein
|
Humans
|
Upregulated in PCa
|
Prognostic
|
bone metastasis (Met) Vs No bone metastasis (controls)
|
p<0.05
|
Bone Marrow (Tissue)
|
21681775
|
721
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
negative histology followed by a positive biopsy less than 24 months later
|
NA
|
Tissue
|
19755651
|
722
|
Methylation Status of RAR-2β
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
negative histology followed by a positive biopsy less than 24 months later
|
NA
|
Tissue
|
19755651
|
723
|
Methylation Status of GST-Pi
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
negative histology followed by a positive biopsy less than 24 months later
|
NA
|
Tissue
|
19755651
|
752
|
CEP55
|
Protein
|
Humans
|
Upregulated in Patients with Recurrence
|
Prognostic
|
PSA Reccurence Vs No Recurrence
|
p<0.0001
|
Tissue
|
21917134
|
753
|
NUF2
|
Protein
|
Humans
|
Upregulated in Patients with Recurrence
|
Prognostic
|
PSA Reccurence Vs No Recurrence
|
p<0.0001
|
Tissue
|
21917134
|
754
|
PAGE4
|
Protein
|
Humans
|
Downregulated in Patients with Recurrence
|
Prognostic
|
PSA Reccurence Vs No Recurrence
|
p=0.0045
|
Tissue
|
21917134
|
755
|
CEP55
|
Protein
|
Humans
|
Upregulated with high Gleason Score
|
Prognostic
|
Gleason Score (≤6, (3+4), (4+3), 8-10)
|
For Hazrard Ratio: (p = 0.003)
|
Tissue
|
21917134
|
756
|
NUF2
|
Protein
|
Humans
|
Upregulated with high Gleason Score
|
Prognostic
|
Gleason Score (≤6, (3+4), (4+3), 8-10)
|
For Hazrard Ratio: (p = 0.002)
|
Tissue
|
21917134
|
757
|
PBK
|
Protein
|
Humans
|
Upregulated with high Gleason Score
|
Prognostic
|
Gleason Score (≤6, (3+4), (4+3), 8-10)
|
For Hazrard Ratio: (p = 0.001)
|
Tissue
|
21917134
|
758
|
TTK
|
Protein
|
Humans
|
Upregulated with high Gleason Score
|
Prognostic
|
f
|
For Hazrard Ratio: (p = 0.002)
|
Tissue
|
21917134
|
759
|
PAGE4
|
Protein
|
Humans
|
Downregulated with high Gleason Score
|
Prognostic
|
Gleason Score (≤6, (3+4), (4+3), 8-10)
|
For Hazrard Ratio: (p = 0.002)
|
Tissue
|
21917134
|
760
|
OPNa (osteopontin -a )
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (PCA: Median: 62.43; BPH: Median: 0.20)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
761
|
OPNb (osteopontin -b )
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (PCA: Median: 43.47; BPH: Median: 0.50)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
762
|
OPNc (osteopontin -c )
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (PCA: Median: 200.36; BPH: Median: 0.0)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
764
|
OPNa+OPNb+OPNc
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
765
|
OPNa+OPNb+OPNc+PSA
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
766
|
OPNc+PSA
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
767
|
OPNa (osteopontin -a )
|
mRNA
|
Humans
|
Upregulated with high Gleason Score (Median for GS< 7: 0.35, Median for GS ≥ 7: 84.54)
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
p= 0.006
|
Tissue
|
21963599
|
768
|
OPNb (osteopontin -b )
|
mRNA
|
Humans
|
Upregulated with high Gleason Score (Median for GS< 7: 3.54, Median for GS ≥ 7: 61.19)
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
p = 0.003
|
Tissue
|
21963599
|
769
|
OPNa (osteopontin -a )
|
mRNA
|
Humans
|
Upregulated with high Gleason Score (Median for GS< 7: 112.06, Median for GS ≥ 7: 526.39)
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
p= 0.001
|
Tissue
|
21963599
|
770
|
miR-7; miR-126; miR-144; miR-144*; miR-335*; miR-374a;miR-374a*; miR-28-3p; miR-542-3p
|
miRNA
|
Humans
|
Upregulated: [miR-7: (3.22 fold); miR-126: (14.45 fold); miR-144 (6.78 fold);miR-144* (12.98 fold); miR-335* (1.39 fold) ; miR-374a (2.43 fold) ; miR-374a (1.16 fold) ; miR-28-3p (1.69 fold); miR-542-3p (3.72 fold)]
|
Prognostic
|
Metastatic Vs Non Metastatic
|
p<0.001
|
Tissue
|
21980368
|
771
|
miR-7-1*; miR-126*; miR-335; miR-28-5p; miR-339-3p; miR-339-5p; miR-542-5p
|
miRNA
|
Humans
|
Downregulated: [miR-7-1* (8.88 fold); miR-126* (3.46b fold); miR-335 (2,42 fold); miR-28-5p (6.84 fold); miR-339-3p (-1.57 fold); miR-339-5p (5.26 fold); miR-542-5p (13.31 fold)]
|
Prognostic
|
Metastatic Vs Non Metastatic
|
p<0.001
|
Tissue
|
21980368
|
786
|
AMACR+CSTA+HPN+MYO6+LAMB3+ABCC4
|
mRNA
|
Humans
|
Upregulated: [ABCC4, AMACR, HPN and MYO6]; Downregulated: [CSTA and LAMB3]
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p<0.001
|
Tissue
|
22009027
|
804
|
Methylation of GSTP1
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
negative histology followed by a positive biopsy more than 24 months later
|
NA
|
Tissue
|
22077694
|
805
|
Methylation of APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
negative histology followed by a positive biopsy more than 24 months later
|
P=0.012
|
Tissue
|
22077694
|
806
|
Methylation of GSTP1 + APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
negative histology followed by a positive biopsy more than 24 months later
|
NA
|
Tissue
|
22077694
|
813
|
TGFβ1 (transforming growth factor beta 1)
|
mRNA
|
Humans
|
Associated with Prostate cancer specific Survival
|
Prognostic
|
disease specific survival Vs no survival
|
p=0.0
|
Tissue
|
22113713
|
814
|
(IL-7) Interleukin-7
|
mRNA
|
Humans
|
Associated with Prostate cancer specific Survival
|
Prognostic
|
disease specific survival Vs no survival
|
p=0.03
|
Tissue
|
22113713
|
815
|
miRNA - 221 and miRNA-222
|
miRNA
|
Humans
|
Upregulated in aggressive Prostate Cancer (Aggressive: 20.1 ± 2.4; Non Aggressive: 3.4 ± 0.2)
|
Prognostic
|
Agressive Vs Non - Agressive Prostate Cancer
|
p=0.001
|
Tissue
|
22117988
|
816
|
ARHI
|
mRNA
|
Humans
|
Downregulated in aggressive Prostate Cancer (Aggressive:9.6 ± 1.2; Non Agressive: 8.3 ± 2.3 )
|
Prognostic
|
Agressive Vs Non - Agressive Prostate Cancer
|
p=0.001
|
Tissue
|
22117988
|
821
|
Methylation Status of AIM1
|
Methylation
|
Humans
|
Decreased hypermethylation in progression
|
Prognostic
|
Time To Progression
|
Univariate: p = 0.02 ; Multivariate: p = 0.05
|
Tissue
|
22127895
|
822
|
TDRD1
|
mRNA
|
Humans
|
Upregulated in Prostate cancer
|
Diagnostic
|
Benign Vs Tumor
|
p<0.05
|
Tissue
|
22142399
|
823
|
TDRD1
|
mRNA
|
Humans
|
Upregulated in TMPRSS2-ERG gene fusion (36 fold) compared to benign samples and TMPRSS2-ERG gene fusion compared to non fusion (23 fold).
|
Prognostic
|
Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion
|
TMPRSS2-ERG positive tumors compared to normal (p = 1.77*10^-9) and fusion-negative samples (p = 1.51*10^-9)
|
Tissue
|
22142399
|
824
|
CRISP3
|
mRNA
|
Humans
|
Upregulated in Prostate cancer
|
Diagnostic
|
Benign Vs Tumor
|
p<0.05
|
Tissue
|
22142399
|
825
|
CRISP3
|
mRNA
|
Humans
|
Upregulated in TMPRSS2-ERG gene fusion (37 fold) compared to benign samples, normal and fusion-negative tumor samples (FC = 1.2)
|
Diagnostic
|
Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion
|
TMPRSS2-ERG positive tumors compared to normal tissue (p = 2.2*10-12), normal and fusion-negative tumor samples (p = 0.03)
|
Tissue
|
22142399
|
826
|
CRISP3, AMACR , OR51E2, SPRR2F , TDRD1, F5, ACSM1, C20orf74, GOLM1 , MYC, CACNA1D, SFRP4, TRIB1, GDF15, LRRN1, FOLH1 , PRR16, LUZP2, RRM2, ERG, COL1A1, DNAH5, ZNF417 , SPON2, RICS, HIPK2 , ACACA , TUG1, COQ6 , LARP1, NETO2, FLJ20184, FASN, NEDD4L, LOC286161, MAOA, XPO6, ABCC4, RAB3B, TMEM45B, IMPDH2, DAPK1, LOC100131821 , C19orf48, KIAA1244 , GPI , HIVEP1, NAALADL2, C11orf92, THBS4, MYO6, BAMBI, ZNF462, SPOCK1, REPS2, SGEF, TBC1D16, TRIM36, LBH, AGPAT3, CAMKK2, GCNT1, F2R, BAT2L , LRIG1, GLYATL1 , DDX21, PLA1A, TMEFF2, SLC7A1, KIAA0368, PCDHB13 , UGT2B10 , EEF2 , C10orf137 , MICAL2, BGN, BICC1 , EIF4A1 , STX19, CHD6, ASPN, PTPN13, RAB3IP, ZNF146, BCOR, SH3RF1, TMTC4, ZDHHC9, MS4A8B, UTRN, DIP2B, UAP1, C4A , HDLBP, KIF5C, PMEPA1, GRPR , ZNF217, HUWE1, ZNF417 , AAK1 , CCDC6, BRD2, CRKRS, TP53INP1, ABCA1 , H2BFS , LIG3, PHF12, FAM117B, MED13L, TMEM2, PLA2G7, DICER1, SRRM2, BAGE2 , USP54, MYH10, SLC36A1, SLC7A11, LOC651907 , CREB3L1, ATP13A5 , ATP2B1, ANKRD34B, BAZ2A, C10orf12, POSTN, CALR3 , ZNF828, CS, ERGIC1, BXDC1, EIF4G1, PRKCSH, ABHD2, SIM2, NUFIP2, SPP1, RPL9P11 , HSN2 , JAG1, TPX2, MOSC1, TMEM161B , C4orf18 , BAT2L, DDAH1, NOLC1, ANKRD17, LOC100130958 , CMTM4, APOF, GALNT7, SETD5, HIST1H3B, TSPAN13, EPCAM, MLL, ADAR, EGR1, DNAJC10, MLEC, SEL1L, HYOU1, COL1A2, PSD3, MYO10 , ENC1 , BAT2D1, DDI2 , KDM2A , ENO1, C20orf191 , EP300, ALDH1A3, FAM119A , SLC27A2, C9orf91, TKT, NCL , ABHD2, STK33, ACTG2, IGJ, SLC26A4, SLC39A2, ZNF701 , COCH , BZW1 , CCDC68, PTPLA, VSNL1, GCNT2 , RND3, SCN7A, CYP27A1, CYP3A5 , GJA1, GSTM3, CFL2, C2 , HBB, SPATA6, KRT23, GPR87, MPPED2, HIST1H4C, OGN, LRCH2, C12orf75, NTN4, LOC100188947 , NEFH, SRD5A2, ADAM32, DPT, AZGP1, ACSS3, SLC15A2, PROM1, CACNA2D1, CXCL13, MME, ZNF483, L3MBTL4, APLF , CHRDL1, HIST1H1A, LEPREL1, ARMCX1, ANGPT1, MT1M , DSC3, B3GALT2, SLC22A3, ANO5, MT1G, PCP4, ANXA1 , PLN, EAF2 , ANPEP, TCEAL2 , LTF, PRDM5, LOC100134430 , ATRNL1, KRT15, SPOCK3, PI15, CD177, GDEP, CD38, FLRT3, SLC18A2, AOX1, MSMB, TGM4, OLFM4, SLC14A1, AMY1A
|
mRNA
|
Humans
|
Differentially expressed (Log fold change) [CRISP3 ( 2.93 fold); , AMACR ( 2.85 fold); , OR51E2 ( 2.46 fold); , SPRR2F ( 2.36 fold); , TDRD1 ( 2.31 fold); , F5 ( 2.23 fold); , ACSM1 ( 2.23 fold); , C20orf74 ( 2.05 fold); , GOLM1 ( 2.01 fold); , MYC ( 1.83 fold); , CACNA1D ( 1.73 fold); , SFRP4 ( 1.68 fold); , TRIB1 ( 1.68 fold); , GDF15 ( 1.67 fold); , LRRN1 ( 1.67 fold); , FOLH1 ( 1.66 fold); , PRR16 ( 1.59 fold); , LUZP2 ( 1.58 fold); , RRM2 ( 1.57 fold); , ERG ( 1.57 fold); , COL1A1 ( 1.57 fold); , DNAH5 ( 1.57 fold); , ZNF417 ( 1.56 fold); , SPON2 ( 1.56 fold); , RICS ( 1.55 fold); , HIPK2 ( 1.54 fold); , ACACA ( 1.54 fold); , TUG1 ( 1.51 fold); , COQ6 ( 1.5 fold); , LARP1 ( 1.49 fold); , NETO2 ( 1.49 fold); , FLJ20184 ( 1.48 fold); , FASN ( 1.48 fold); , NEDD4L ( 1.47 fold); , LOC286161 ( 1.46 fold); , MAOA ( 1.45 fold); , XPO6 ( 1.43 fold); , ABCC4 ( 1.43 fold); , RAB3B ( 1.42 fold); , TMEM45B ( 1.42 fold); , IMPDH2 ( 1.39 fold); , DAPK1 ( 1.38 fold); , LOC100131821 ( 1.38 fold); , C19orf48 ( 1.37 fold); , KIAA1244 ( 1.36 fold); , GPI ( 1.35 fold); , HIVEP1 ( 1.34 fold); , NAALADL2 ( 1.34 fold); , C11orf92 ( 1.34 fold); , THBS4 ( 1.33 fold); , MYO6 ( 1.31 fold); , BAMBI ( 1.31 fold); , ZNF462 ( 1.3 fold); , SPOCK1 ( 1.3 fold); , REPS2 ( 1.28 fold); , SGEF ( 1.28 fold); , TBC1D16 ( 1.27 fold); , TRIM36 ( 1.27 fold); , LBH ( 1.26 fold); , AGPAT3 ( 1.26 fold); , CAMKK2 ( 1.25 fold); , GCNT1 ( 1.24 fold); , F2R ( 1.24 fold); , BAT2L ( 1.24 fold); , LRIG1 ( 1.23 fold); , GLYATL1 ( 1.23 fold); , DDX21 ( 1.23 fold); , PLA1A ( 1.22 fold); , TMEFF2 ( 1.22 fold); , SLC7A1 ( 1.22 fold); , KIAA0368 ( 1.22 fold); , PCDHB13 ( 1.21 fold); , UGT2B10 ( 1.21 fold); , EEF2 ( 1.2 fold); , C10orf137 ( 1.2 fold); , MICAL2 ( 1.2 fold); , BGN ( 1.19 fold); , BICC1 ( 1.19 fold); , EIF4A1 ( 1.19 fold); , STX19 ( 1.18 fold); , CHD6 ( 1.18 fold); , ASPN ( 1.18 fold); , PTPN13 ( 1.18 fold); , RAB3IP ( 1.18 fold); , ZNF146 ( 1.18 fold); , BCOR ( 1.17 fold); , SH3RF1 ( 1.17 fold); , TMTC4 ( 1.16 fold); , ZDHHC9 ( 1.16 fold); , MS4A8B ( 1.16 fold); , UTRN ( 1.16 fold); , DIP2B ( 1.15 fold); , UAP1 ( 1.15 fold); , C4A ( 1.15 fold); , HDLBP ( 1.15 fold); , KIF5C ( 1.14 fold); , PMEPA1 ( 1.14 fold); , GRPR ( 1.14 fold); , ZNF217 ( 1.13 fold); , HUWE1 ( 1.13 fold); , ZNF417 ( 1.13 fold); , AAK1 ( 1.13 fold); , CCDC6 ( 1.12 fold); , BRD2 ( 1.12 fold); , CRKRS ( 1.12 fold); , TP53INP1 ( 1.12 fold); , ABCA1 ( 1.12 fold); , H2BFS ( 1.12 fold); , LIG3 ( 1.11 fold); , PHF12 ( 1.11 fold); , FAM117B ( 1.11 fold); , MED13L ( 1.11 fold); , TMEM2 ( 1.11 fold); , PLA2G7 ( 1.11 fold); , DICER1 ( 1.11 fold); , SRRM2 ( 1.1 fold); , BAGE2 ( 1.1 fold); , USP54 ( 1.1 fold); , MYH10 ( 1.1 fold); , SLC36A1 ( 1.1 fold); , SLC7A11 ( 1.1 fold); , LOC651907 ( 1.1 fold); , CREB3L1 ( 1.1 fold); , ATP13A5 ( 1.09 fold); , ATP2B1 ( 1.09 fold); , ANKRD34B ( 1.09 fold); , BAZ2A ( 1.08 fold); , C10orf12 ( 1.08 fold); , POSTN ( 1.08 fold); , CALR3 ( 1.07 fold); , ZNF828 ( 1.07 fold); , CS ( 1.07 fold); , ERGIC1 ( 1.07 fold); , BXDC1 ( 1.07 fold); , EIF4G1 ( 1.06 fold); , PRKCSH ( 1.06 fold); , ABHD2 ( 1.06 fold); , SIM2 ( 1.06 fold); , NUFIP2 ( 1.06 fold); , SPP1 ( 1.06 fold); , RPL9P11 ( 1.06 fold); , HSN2 ( 1.05 fold); , JAG1 ( 1.05 fold); , TPX2 ( 1.05 fold); , MOSC1 ( 1.04 fold); , TMEM161B ( 1.04 fold); , C4orf18 ( 1.04 fold); , BAT2L ( 1.04 fold); , DDAH1 ( 1.04 fold); , NOLC1 ( 1.03 fold); , ANKRD17 ( 1.03 fold); , LOC100130958 ( 1.03 fold); , CMTM4 ( 1.03 fold); , APOF ( 1.03 fold); , GALNT7 ( 1.02 fold); , SETD5 ( 1.02 fold); , HIST1H3B ( 1.02 fold); , TSPAN13 ( 1.02 fold); , EPCAM ( 1.02 fold); , MLL ( 1.02 fold); , ADAR ( 1.02 fold); , EGR1 ( 1.02 fold); , DNAJC10 ( 1.02 fold); , MLEC ( 1.02 fold); , SEL1L ( 1.01 fold); , HYOU1 ( 1.01 fold); , COL1A2 ( 1.01 fold); , PSD3 ( 1.01 fold); , MYO10 ( 1.01 fold); , ENC1 ( 1.01 fold); , BAT2D1 ( 1.01 fold); , DDI2 ( 1.01 fold); , KDM2A ( 1.01 fold); , ENO1 ( 1.01 fold); , C20orf191 ( 1.01 fold); , EP300 ( 1.01 fold); , ALDH1A3 ( 1.01 fold); , FAM119A ( 1.01 fold); , SLC27A2 ( 1.0 fold); , C9orf91 ( 1.0 fold); , TKT ( 1.0 fold); , NCL ( 1.0 fold); , ABHD2 ( 1.0 fold); , STK33 ( -1.0 fold); , ACTG2 ( -1.01 fold); , IGJ ( -1.01 fold); , SLC26A4 ( -1.01 fold); , SLC39A2 ( -1.01 fold); , ZNF701 ( -1.01 fold); , COCH ( -1.02 fold); , BZW1 ( -1.03 fold); , CCDC68 ( -1.03 fold); , PTPLA ( -1.04 fold); , VSNL1 ( -1.04 fold); , GCNT2 ( -1.05 fold); , RND3 ( -1.05 fold); , SCN7A ( -1.05 fold); , CYP27A1 ( -1.05 fold); , CYP3A5 ( -1.05 fold); , GJA1 ( -1.06 fold); , GSTM3 ( -1.07 fold); , CFL2 ( -1.09 fold); , C2 ( -1.09 fold); , HBB ( -1.1 fold); , SPATA6 ( -1.1 fold); , KRT23 ( -1.11 fold); , GPR87 ( -1.11 fold); , MPPED2 ( -1.11 fold); , HIST1H4C ( -1.11 fold); , OGN ( -1.12 fold); , LRCH2 ( -1.12 fold); , C12orf75 ( -1.12 fold); , NTN4 ( -1.12 fold); , LOC100188947 ( -1.12 fold); , NEFH ( -1.13 fold); , SRD5A2 ( -1.15 fold); , ADAM32 ( -1.16 fold); , DPT ( -1.16 fold); , AZGP1 ( -1.16 fold); , ACSS3 ( -1.17 fold); , SLC15A2 ( -1.17 fold); , PROM1 ( -1.18 fold); , CACNA2D1 ( -1.18 fold); , CXCL13 ( -1.18 fold); , MME ( -1.18 fold); , ZNF483 ( -1.19 fold); , L3MBTL4 ( -1.19 fold); , APLF ( -1.21 fold); , CHRDL1 ( -1.21 fold); , HIST1H1A ( -1.23 fold); , LEPREL1 ( -1.25 fold); , ARMCX1 ( -1.25 fold); , ANGPT1 ( -1.26 fold); , MT1M ( -1.27 fold); , DSC3 ( -1.29 fold); , B3GALT2 ( -1.29 fold); , SLC22A3 ( -1.3 fold); , ANO5 ( -1.31 fold); , MT1G ( -1.31 fold); , PCP4 ( -1.32 fold); , ANXA1 ( -1.32 fold); , PLN ( -1.32 fold); , EAF2 ( -1.33 fold); , ANPEP ( -1.35 fold); , TCEAL2 ( -1.39 fold); , LTF ( -1.4 fold); , PRDM5 ( -1.42 fold); , LOC100134430 ( -1.42 fold); , ATRNL1 ( -1.42 fold); , KRT15 ( -1.43 fold); , SPOCK3 ( -1.44 fold); , PI15 ( -1.44 fold); , CD177 ( -1.46 fold); , GDEP ( -1.47 fold); , CD38 ( -1.53 fold); , FLRT3 ( -1.58 fold); , SLC18A2 ( -1.69 fold); , AOX1 ( -1.72 fold); , MSMB ( -1.74 fold); , TGM4 ( -1.76 fold); , OLFM4 ( -1.85 fold); , SLC14A1 ( -1.95 fold); , AMY1A ( -2.11 fold)]
|
Diagnostic
|
Benign Vs Tumor
|
p<0.006857824
|
Tissue
|
22142399
|
829
|
Secreted frizzled-related protein (SFRP)-2
|
Protein
|
Humans
|
Downregulated in Prostate cancer (PCa: 2.28 ± 0.33 Vs Controls: 1.11 ± 0.09)
|
Diagnostic
|
Benign Vs malignant prostate glands
|
p<0.0001
|
Tissue
|
22175903
|
830
|
Secreted frizzled-related protein (SFRP)-2
|
Protein
|
Humans
|
Upregulated in Gleason Grade 5 (PCa: 3.16 ± 0.99; Control: 0.77±0.15)
|
Prognostic
|
Gleason Grade 3,4 Vs Gleason Grade 5
|
p<0.0001
|
Tissue
|
22175903
|
834
|
Mutation Status of StAR
|
Mutation
|
Humans
|
Allelic Loss in StAR in Recurrence
|
Prognostic
|
Biochemical Recurrenece (5 years)
|
p=0.00269
|
Tissue
|
22213075
|
835
|
Mutation Status of HSD17B2
|
Mutation
|
Humans
|
Allelic Loss in HSD17B2 in Recurrence
|
Prognostic
|
Biochemical Recurrenece (5 years)
|
p=0.031
|
Tissue
|
22213075
|
836
|
Mutation Status of StAR or HSD17B2
|
Mutation
|
Humans
|
Allelic Loss in atleast one (HSD17B2 or StaR) in Recurrence
|
Prognostic
|
Biochemical Recurrenece (5 years)
|
p=0.0028
|
Tissue
|
22213075
|
842
|
breast cancer antiestrogen resistance 1 (BCAR1)
|
Protein
|
Humans
|
Significantly associated with Biochemical Relapse
|
Prognostic
|
Biochemical Recurrence
|
p=0.02
|
Tissue
|
22241677
|
882
|
ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1
|
LncRNA
|
Humans
|
Differentially expressed (Median Fold Change): [ANRIL (MFD: −1.17 fold); H19 (MFD: 1.32 fold); PCA3 (MFD: 14.3 fold); MALAT1 (MFD: −1.64 fold); PCGEM1 (MFD: 1.75 fold); PTENP1 (MFD: −1.34 fold);]
|
Diagnostic
|
Primary Vs Normal
|
p<0.01
|
Tissue
|
22371711
|
883
|
ANRIL; H19; PCA3; MALAT1
|
LncRNA
|
Humans
|
Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.49 fold); H19 (MFD: 1.43 fold); PCA3 (MFD: 4.46 fold); MALAT1 (MFD: -3.33 fold)]
|
Diagnostic
|
Metastatic Vs Normal
|
p<0.01
|
Tissue
|
22371711
|
884
|
ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1
|
LncRNA
|
Humans
|
Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.33 fold); H19 (MFD: -1.12 fold); PCA3 (MFD: -3.44 fold); MALAT1 (MFD: -2.63 fold); PCGEM1 (MFD: -4 fold); PTENP1 (MFD: 1.50 fold);]
|
Diagnostic
|
Metastatic Vs Primary
|
p<0.04
|
Tissue
|
22371711
|
885
|
miR145; miR221;
|
miRNA
|
Humans
|
Differentially expressed (Median Fold Change): [miR145 (MFD: -7.98 fold); miR221 (MFD: -2.11 fold);]
|
Diagnostic
|
Metastatic Vs Normal
|
p<0.01
|
Tissue
|
22371711
|
886
|
miR143; miR145; miR221;
|
miRNA
|
Humans
|
Differentially expressed (Median Fold Change): [miR143 (MFD: -1.78 fold); miR145 (MFD: -4.77 fold); miR221 (MFD: -1.52 fold);]
|
Diagnostic
|
Metastatic Vs Primary
|
p<0.04
|
Tissue
|
22371711
|
887
|
kallikrein-related peptide 4 (KLK4)
|
mRNA
|
Humans
|
Downregulated in genistein treated patients compared to placebo treated
|
Predictive
|
Treated with Placebo Vs Treated with Genistein (30mg capsule)
|
p=0.033
|
Tissue
|
22397815
|
888
|
NK3 homeobox 1 (NKX3-1)
|
Protein
|
Humans
|
Downregulated in Gleason Grade 3
|
Diagnostic
|
Normal Prostate Vs Gleason Grade 3
|
p=0.012
|
Tissue
|
22397815
|
889
|
Methylation Status of TBX15
|
Methylation
|
Humans
|
Highly methylated in ERG positive fusion compared to ERG negative fusion
|
Prognostic
|
ERG positive fusion compared to ERG negative fusion in Prostate cancer
|
p<0.01
|
Tissue
|
22452941
|
890
|
Methylation Status of HOXD3
|
Methylation
|
Humans
|
Highly methylated in ERG positive fusion compared to ERG negative fusion
|
Prognostic
|
ERG positive fusion compared to ERG negative fusion in Prostate cancer
|
p<0.01
|
Tissue
|
22452941
|
891
|
Methylation Status of CYP26A1
|
Methylation
|
Humans
|
Highly methylated in ERG positive fusion compared to ERG negative fusion
|
Prognostic
|
ERG positive fusion compared to ERG negative fusion in Prostate cancer
|
p≤0.041
|
Tissue
|
22452941
|
892
|
Methylation Status of HOXD3
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Pathological Stage (pT2 Vs pT3/pT4)
|
p=0.026
|
Tissue
|
22452941
|
893
|
Methylation Status of TBX15
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Pathological Stage (pT2 Vs pT3/pT4)
|
p=0.010
|
Tissue
|
22452941
|
894
|
Methylation Status of HOXD3
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Gleason score as ≤ 7 Vs 8 and above
|
p<0.001
|
Tissue
|
22452941
|
895
|
Methylation Status of TBX15 or HOXD3
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Disease specific survival Vs no survival
|
p=0.044
|
Tissue
|
22452941
|
900
|
Transthyretin (TTR)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Normal Tissue Vs BPH Vs PCa
|
p<0.01
|
Tissue
|
22496929
|
901
|
Clusterin (CLU)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Normal Tissue Vs BPH Vs PCa
|
p<0.01
|
Tissue
|
22496929
|
903
|
ERG
|
mRNA
|
Humans
|
Upregulated in TMPRSS2-ERG positive fusion cases
|
Prognostic
|
TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer
|
p<0.0001
|
Tissue
|
22505341
|
904
|
SPINK1
|
mRNA
|
Humans
|
Upregulated in TMPRSS2-ERG negative fusion cases
|
Prognostic
|
TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer
|
p=0.03
|
Tissue
|
22505341
|
905
|
ERG
|
mRNA
|
Humans
|
Upregulated in TERT positive cases
|
Prognostic
|
TERT positive compared to TERT negative in Prostate cancer
|
p=0.016
|
Tissue
|
22505341
|
911
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product scores
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p<0.001
|
Tissue
|
22554381
|
912
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product scores
|
Protein
|
Humans
|
Upregulated with Increasing Gleason Score
|
Prognostic
|
Gleason Score ≤6 Vs 7 Vs ≥8
|
p=0.002
|
Tissue
|
22554381
|
913
|
Ki-67
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p<0.001
|
Tissue
|
22554381
|
914
|
Ki-67
|
Protein
|
Humans
|
Upregulated with Increasing Gleason Score
|
Prognostic
|
Gleason Score ≤ 6 Vs 7 Vs ≥ 8
|
p=0.008
|
Tissue
|
22554381
|
915
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product scores
|
Protein
|
Humans
|
High in Patients with BCR
|
Prognostic
|
Biochemical Recurrence (Group 1)
|
p=0.001
|
Tissue
|
22554381
|
916
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product score OR ki-67 Product Score
|
Protein
|
Humans
|
High in Patients with BCR
|
Prognostic
|
Biochemical Recurrence (Group 1)
|
p=0.02
|
Tissue
|
22554381
|
917
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product score AND ki-67 Product Score
|
Protein
|
Humans
|
High in Patients with BCR
|
Prognostic
|
Biochemical Recurrence (Group 1)
|
p=0.002
|
Tissue
|
22554381
|
921
|
Methylation Status Of A0X1; CYBA; EDG3; ELF4; EPB41L3; FLJ12056; FLJ90650; FLT4; GAS6; GRASP; GSTP1; HAAO; HIF3A; HOXC11; LEP; MGC39606; MOBKL2B; RAB34; RARb; RHCG; RND2; SLC34A2; SPATA6; TPM4; ZNF154
|
Methylation
|
Humans
|
Methylated in PCA:
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p<0.0001
|
Tissue
|
22589488
|
922
|
Methylation Status Of ACTL6B; AEBP1; AMID; CD8A; CRIP1; FLJ30934; FLNC; FMOD; FOXE3; GAS7; GDPD5; HS3ST2; LOC349136; NEUROG1; PLTP; PTGER2; RASGRF2; RUNX3; SIX6; SLC9A3; SPSB4; SRD5A2; SUSD3; SYT10; TMEM74
|
Methylation
|
Humans
|
Hypermethlated in recurrent prostate cancer :
|
Prognostic
|
recurrent prostate cancer Vs nonrecurrent cancer
|
NA
|
Tissue
|
22589488
|
923
|
Methylation Status Of CHST7; LMX1B; RAFTLIN; RASGRF2; TNFRSF10D; ZNF135
|
Methylation
|
Humans
|
Methylated with Clinical Recurrence
|
Prognostic
|
clinical recurrence Vs biochemical recurrence
|
NA
|
Tissue
|
22589488
|
924
|
Methylation Status Of ALPL; AMPH; BCDIN3; BCL11B; BRD4; C18orf34; DCAMKL1; FGF5; FLJ42486; JAM2; LHX9; LOC283537; LRAT; PDE4B; POU3F3; PTGS2; RASGRF2; SLC27A6; SLC03A1; SPSB4; STAT3; SYN2; TACR3; TIRAP; WNT11
|
Methylation
|
Humans
|
Methylated with Systemic Recurrence
|
Prognostic
|
systemic recurrence Vs local recurrence
|
NA
|
Tissue
|
22589488
|
925
|
Methylation Status Of HIF3A; HAAO; RARb; GSTP1
|
Methylation
|
Humans
|
Methylated with Systemic Recurrence
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p<0.0182
|
Tissue
|
22589488
|
926
|
Methylation Status Of CRIP1; RUNX3; HS3ST2; FLNC; RASGRF2
|
Methylation
|
Humans
|
Methylated in PCA:
|
Prognostic
|
recurrent prostate cancer Vs nonrecurrent cancer
|
NA
|
Tissue
|
22589488
|
927
|
Methylation Status Of PHLDA3; RASGRF2; TNFRSF10D; ZNF135
|
Methylation
|
Humans
|
Hypermethlated in recurrent prostate cancer :
|
Prognostic
|
clinical recurrence Vs biochemical recurrence
|
NA
|
Tissue
|
22589488
|
928
|
Methylation Status Of BCL11B; POU3F3; RASGRF2
|
Methylation
|
Humans
|
Methylated with Clinical Recurrence
|
Prognostic
|
systemic recurrence Vs local recurrence
|
NA
|
Tissue
|
22589488
|
931
|
Spondin-2 (SPON2)
|
Protein
|
Humans
|
Upregulated with Gleason Score >=7 and 8
|
Diagnostic
|
Gleason Score (2-6), (7-8) and (9-10)
|
p=0.001
|
Tissue
|
22615945
|
934
|
NACA + CCNB1
|
mRNA
|
Humans
|
CCNB1 upregulated in Prostate cancer; NACA Downregulated in Prostate Cancer
|
Diagnostic
|
BPC VS BP
|
p<0.05
|
Tissue
|
22640805
|
935
|
GPR37; SOX4; CCNB1; TOP2A; DLG5; NACA; NR2C2; PDCD5; IDSP1
|
mRNA
|
Humans
|
Upregulated: [GPR37; SOX4; CCNB1; TOP2A;] Downregulated: [DLG5; NACA; NR2C2; PDCD5; IDSP1]
|
Diagnostic
|
BPC (benign prostates containing PCa) VS BP
|
GPR37 (training: 0.018, testing: 0.003); SOX4 (training: 0.03, testing: 0.03); CCNB1 (training: 0.002, testing: 0.007); TOP2A (training: 0.018); DLG5 (training: p< 0.001, testing: 0.004); NACA (p<0.001, testing: 0.003) ; NR2C2 (training: p<0.001, testing: 0.02); PDCD5 (training: p<0.001); IDSP1 (training: p<0.001)
|
Tissue
|
22640805
|
936
|
PCA3
|
mRNA
|
Humans
|
Upregulated (RQ = NP: 7.4 Vs LG = 202)
|
Diagnostic
|
Normal adjacent to Prostate (NP) Vs Low Grade PCa
|
<0.005
|
Tissue
|
22674214
|
937
|
TMPRSS2:ERG Fusion
|
mRNA
|
Humans
|
Upregulated (RQ = NP: 0.6 Vs LG = 11)
|
Diagnostic
|
Normal adjacent to Prostate (NP) Vs Low Grade PCa
|
<0.005
|
Tissue
|
22674214
|
938
|
PCA3 + TMPRSS2:ERG gene fusion
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Normal adjacent to Prostate (NP) Vs Low Grade PCa
|
NA
|
Tissue
|
22674214
|
939
|
TMPRSS2:ERG gene fusion (given that PCA3 test is negative)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Normal adjacent to Prostate (NP) Vs Low Grade PCa
|
NA
|
Tissue
|
22674214
|
968
|
GADD45B; CDKN1A; NLRP1; ERBB3; FMO5; SERINC2; AMFR; DPP4; PGC; YWHAE; EHF; TF; TNFSF10; EIF5A; TGM4;
|
mRNA
|
Humans
|
Upregulated in Relapse: [GADD45B (4.86 fold); CDKN1A (2.65 fold); NLRP1 (1.57 fold)]; Downregulated in Relapse: [ERBB3 (0.55 fold); FMO5 (0.55 fold); SERINC2 (0.43 fold); AMFR (0.41 fold); DPP4 (0.40 fold); PGC (0.38 fold); YWHAE (0.34 fold); EHF(0.33 fold); TF (0.33 fold); TNFSF10 (0.31 fold); EIF5A (0.15 fold); TGM4 (0.03 fold);]
|
Prognostic
|
Relpase Vs No Relapse
|
p<0.05
|
Tissue
|
22870216
|
970
|
miR-375; miR-141; miR-378*;
|
miRNA
|
Humans
|
Upregulated in Primary Tumors: [miR-375 and miR-141]; Downregulated in Primary Tumors: [miR-378*]
|
Prognostic
|
Normal Vs Primary Tumor
|
p<0.0001
|
Tissue
|
22887127
|
971
|
miR-375; miR-141; miR-378*; miR-409-3p
|
miRNA
|
Humans
|
Upregulated in Low Risk PCa: [miR-375 ; miR-141]; Downregulated in Low Risk PCa: [miR-378*, miR-409-3p]
|
Prognostic
|
Normal Vs Low Risk Prostate Cancer
|
miR-375; miR-141; miR-378*[p<0.0001]; miR-409-3p [p=0.004]
|
Tissue
|
22887127
|
976
|
RhoC score
|
Protein
|
Humans
|
10-point increase in the RhoC score reduced the subsequent risk of PSA failure by about 6%
|
Prognostic
|
Time to PSA Failure
|
p=0.009
|
Tissue
|
22935975
|
977
|
RhoC score
|
Protein
|
Humans
|
Decreased in Cases
|
Prognostic
|
Time to PSA Failure
|
p=0.009
|
Tissue
|
22935975
|
978
|
ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004;
|
genes or ncRNA
|
Humans
|
Upregulated: AOX1-001, RSRC2-017, ABCC4-004, ALK-001, ATP1A1-002, NAMPT-006, RP11-627G23.1-004 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.0
|
Diagnostic
|
Primary Vs Normal
|
p<0.05
|
Tissue
|
22956952
|
979
|
ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004;
|
genes or ncRNA
|
Humans
|
Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1
|
Prognostic
|
Metastatic Vs Primary
|
p<0.05
|
Tissue
|
22956952
|
980
|
ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001;
|
genes or ncRNA
|
Humans
|
Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1
|
Diagnostic
|
Metastatic Vs Normal
|
p<0.05
|
Tissue
|
22956952
|
981
|
ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004;
|
genes or ncRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence
|
p<0.005
|
Tissue
|
22956952
|
982
|
EGFR
|
Protein
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
p= 0.01
|
Tissue
|
22977195
|
983
|
EGFR
|
mRNA
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
p= 0.005
|
Tissue
|
22977195
|
984
|
PTEN
|
Protein
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
p= 0.02
|
Tissue
|
22977195
|
985
|
PTEN
|
mRNA
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
p= 0.0003
|
Tissue
|
22977195
|
986
|
PTEN
|
mRNA
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Overall Survival
|
p= 0.02
|
Tissue
|
22977195
|
987
|
EGFR + PTEN
|
mRNA
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
NA
|
Tissue
|
22977195
|
990
|
FLIP
|
Protein
|
Humans
|
NA
|
Prognostic
|
PSA Failure Vs Non Failure
|
p<0.05
|
Tissue
|
23028678
|
991
|
Sp1
|
Protein
|
Humans
|
NA
|
Prognostic
|
PSA Failure Vs Non Failure
|
p<0.05
|
Tissue
|
23028678
|
992
|
Sp3
|
Protein
|
Humans
|
NA
|
Prognostic
|
PSA Failure Vs Non Failure
|
p<0.05
|
Tissue
|
23028678
|
993
|
FLIP + Sp1 + Sp3 + Gleason Score
|
Protein
|
Humans
|
NA
|
Prognostic
|
PSA Failure Vs Non Failure
|
p<0.05
|
Tissue
|
23028678
|
994
|
Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8)
|
mRNA
|
Humans
|
Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)]
|
Prognostic
|
Biochemical relapse Vs No biochemical Relpase
|
p<0.002
|
Tissue
|
23028830
|
995
|
Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) + Cell Type Hetrogenity + Gleason Score
|
mRNA
|
Humans
|
Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)]
|
Prognostic
|
Biochemical relapse Vs No biochemical Relpase
|
p<0.002
|
Tissue
|
23028830
|
1014
|
Chromatin Assembly Factor 1 (CAF-1 p60)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Normal Vs prostate cancer
|
NA
|
Tissue
|
23109837
|
1015
|
NA
|
Methylation
|
Humans
|
Hypermethylation in PCa (Δ Log Intensity): []; Hypomethylated in PCa: (Δ Log intensity): []
|
Diagnostic
|
Pca Tumor Vs Tumor Adjacent
|
NA
|
Tissue
|
23119026
|
1016
|
Aldehyde Oxidase 1 (AOX1)
|
Methylation
|
Humans
|
Hypermethylation in PCa
|
Diagnostic
|
Pca Tumor Vs Tumor Adjacent
|
p = 7.46 x10^-8
|
Tissue
|
23119026
|
1017
|
Spondin 2 (SPON2)
|
Methylation
|
Humans
|
Hypermethylation in PCa
|
Diagnostic
|
Pca Tumor Vs Tumor Adjacent
|
p = 2.1 x10^-14
|
Tissue
|
23119026
|
1030
|
miR-30d
|
miRNA
|
Humans
|
Upregulated in PCa [Normal (6.23 ± 6.06) Vs Cancer (7.95 ± 7.03)]
|
Diagnostic
|
Cancerous Vs Cancer Adjacent from Same patient
|
p = 0.03
|
Tissue
|
23231923
|
1031
|
miR-30d
|
miRNA
|
Humans
|
Shorter Survival Time in High miRNA-30d group
|
Prognostic
|
Biochemical Recurrence
|
p = 0.026 (BCR); p =0.04 (Univariate); 0.003 (multivariate)
|
Tissue
|
23231923
|
1036
|
BMI1
|
Protein
|
Humans
|
Upregulated in PCa: (Normal: 0.81 ± 0.07; PCa stage 2: 1.8 ± 0.08)
|
Diagnostic
|
Normal Vs PCa
|
p< 0.05
|
Tissue
|
23308129
|
1037
|
Aminopeptidase N (APN)
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant Tissue
|
p=0.034
|
Tissue
|
23322201
|
1038
|
Alanyl membrane aminopeptidase (ANPEP)
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant Tissue
|
p=0.0023
|
Tissue
|
23322201
|
1039
|
Alanyl membrane aminopeptidase (ANPEP)
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant Tissue
|
p=0.0025
|
Tissue
|
23322201
|
1040
|
Aminopeptidase N (APN)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Recurrence Free Survival
|
Univariate: p=0.002; Mutlivariate: p=0.017
|
Tissue
|
23322201
|
1041
|
Aminopeptidase N (APN)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Cancer Specific Survival
|
Univariate: p=0.017; Mutlivariate: p=0.049
|
Tissue
|
23322201
|
1042
|
Early Growth Response 3 (Egr3)
|
mRNA
|
Humans
|
Upregulated in PCa (5.35 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p = 2 x 10^-15
|
Tissue
|
23342084
|
1043
|
Early Growth Response 3 (Egr3)
|
Protein
|
Humans
|
Upregulated in PCa (NSR (number of strong positive pixels ratio):normal prostate: 0.039 ; NSR: prostate cancer: 0.13)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p = 0.00047
|
Tissue
|
23342084
|
1044
|
Prostate Specific Membrane Antigen (PSMA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p = 0.001
|
Tissue
|
23342084
|
1045
|
Early Growth Response 1 (Egr1)
|
mRNA
|
Humans
|
Downregulated in Relapse (0.784 fold)
|
Prognostic
|
Relpase Vs No Relapse
|
p = 0.017
|
Tissue
|
23342084
|
1049
|
Prostate biopsy clinical decision rule (PBCDR): (HGB+ Age+ PSA+ RBC+Hematuria+ Creatinine+ Black (Ethnicity) + Albumin+ MCV)
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Tissue
|
23356551
|
1050
|
Prostate biopsy clinical decision rule (PBCDR): (HGB+ RBC+ Creatinine+ PSA+ Age+ MCV+ Black (ethnicity))
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.05
|
Tissue
|
23356551
|
1065
|
PCA3
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (Cancerous: 7.69 Vs Non Cancerous: 7.00)
|
Diagnostic
|
Cancerous Vs Non Cancerous
|
p<0.0005
|
Tissue
|
23391636
|
1066
|
PCA3
|
mRNA
|
Humans
|
Upregulated in Stage pT3/4 (1.9 Median fold difference)
|
Diagnostic
|
Stage pT2 Vs Stage pT3/4
|
p=0.015
|
Tissue
|
23391636
|
1067
|
KLK15
|
mRNA
|
Humans
|
Upregulated in Stage pT3/4 (2.71 Median fold difference)
|
Diagnostic
|
Stage pT2 Vs Stage pT3/4
|
p=0.032
|
Tissue
|
23391636
|
1073
|
Methylation Status of RASSF1A
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23431474
|
1074
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23431474
|
1075
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in early stages of PCa
|
Prognostic
|
Stage 1 & 2 Vs Stage 3 & 4
|
p<0.049
|
Tissue
|
23431474
|
1078
|
ACAT1
|
Protein
|
Humans
|
Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold)
|
Diagnostic
|
Normal Prostate Vs Bone Metastatis
|
p = 0.0001
|
Tissue
|
23443136
|
1086
|
miR-183
|
miRNA
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
prostate tumour Vs adjacent normal tissues
|
p<0.05
|
Tissue
|
23538390
|
1087
|
miR-183
|
miRNA
|
Humans
|
Upregulated in Prostate Cancer
|
Prognostic
|
Tumor Stage pT2 Vs pT3
|
p<0.05
|
Tissue
|
23538390
|
1088
|
miR-183
|
miRNA
|
Humans
|
Upregulated in Prostate Cancer
|
Prognostic
|
Overall Survival
|
p<0.05
|
Tissue
|
23538390
|
1115
|
Spermine; Putrescine; Cho; PCho; GPC; PE; Lactate; Alanine; Glucose; Citrate; Succinate; Glutamate; Glutamine; Glycine; Isoleucine; Leucine; Valine;
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer [Cho; PCho; GPC; PE; Lactate; Alanine; Glutamate; Glutamine; Glycine; Isoleucine; Leucine; Valine;]; Downregulated in Prostate Cancer: [Spermine; Putrescine; Citrate; Creatine;]
|
Diagnostic
|
Normal adjacent samples Vs Cancer samples
|
p<0.05
|
Tissue
|
23626811
|
1116
|
Spermine
|
Metabolites
|
Humans
|
Downregulated in High Grade Prostate Cancer
|
Diagnostic
|
High Grade (GS >=7) Vs Low Grade (GS =6)
|
p = 0.0044
|
Tissue
|
23626811
|
1117
|
Citrate
|
Metabolites
|
Humans
|
Downregulated in High Grade Prostate Cancer
|
Diagnostic
|
High Grade (GS >=7) Vs Low Grade (GS =6)
|
p = 0.000773
|
Tissue
|
23626811
|
1118
|
Citrate
|
Metabolites
|
Humans
|
Downregulated in Gleason Score 7
|
Diagnostic
|
Gleason Score 6 Vs Gleason Score 7
|
p = 0.014
|
Tissue
|
23626811
|
1119
|
Citrate
|
Metabolites
|
Humans
|
Downregulated in Gleason Score 7
|
Diagnostic
|
Gleason Score 6 Vs Gleason Score (8 & 9)
|
p = 0.005
|
Tissue
|
23626811
|
1120
|
Spermine
|
Metabolites
|
Humans
|
Downregulated in Gleason Score 7
|
Diagnostic
|
Gleason Score 6 Vs Gleason Score (8 & 9)
|
p = 0.022
|
Tissue
|
23626811
|
1121
|
Asporin; Cartilage oligomeric matrix Protein (COMP); Versican; EMILIN 3;
|
Protein
|
Humans
|
Upregulated in Agressive Prostate Cancer (Fold Change); [Asporin (2.14 fold); Cartilage oligomeric matrix Protein (COMP) (100 fold) ; Versican (100 fold) ; EMILIN 3 ( 6 fold);
|
Prognostic
|
Agressive Vs Non Agressive Prostate Cancer
|
Asporin (p=0.00016) ; Cartilage oligomeric matrix Protein (COMP) (p = 0.00228) ; Versican ( 0.03367) ; EMILIN 3 (0.04983);
|
Tissue
|
23716368
|
1122
|
Acid ceramidase
|
Protein
|
Humans
|
Downregulated in Agressive Prostate Cancer 0.18 Fold
|
Prognostic
|
Agressive Vs Non Agressive Prostate Cancer
|
p = 0.04983
|
Tissue
|
23716368
|
1126
|
PCA3; GAS5; PVT1; DANCR; PCAT1; MEG3; PRINS; HOTTIP; EGOT;
|
LncRNA
|
Humans
|
Upregulated in PCa: [PCA3; GAS5; PVT1; DANCR; PCAT1;]lDownregulated in PCa: [MEG3; PRINS; HOTTIP; EGOT;]
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p< 0.05
|
Tissue
|
23728290
|
1127
|
Aminoadipic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1128
|
Cerebronic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1129
|
Gluconic acid
|
Metabolites
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1130
|
Glycerophosphoethanol-amine
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1131
|
2-Hydroxybehenic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1132
|
Isopentenyl pyrophosphate
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1133
|
Maltotriose
|
Metabolites
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1134
|
7-Methylguanine
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1135
|
Tricosanoic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1136
|
Aminoadipic acid
|
Metabolites
|
Humans
|
Increased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.031
|
Tissue
|
23737455
|
1137
|
Gluconic acid
|
Metabolites
|
Humans
|
Decreased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.036
|
Tissue
|
23737455
|
1138
|
Maltotriose
|
Metabolites
|
Humans
|
Decreased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.006
|
Tissue
|
23737455
|
1139
|
Aminoadipic acid
|
Metabolites
|
Humans
|
Increased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.048
|
Tissue
|
23737455
|
1140
|
hsa-miR-10b; hsa-miR-15a; hsa-miR-15b; hsa-miR-16; hsa-miR-18a; hsa-miR-18b; hsa-miR-25; hsa-miR-30c; hsa-miR-32; hsa-miR-34a; hsa-miR-34c-5p; hsa-miR-92a; hsa-miR-181a; hsa-miR-181b; hsa-miR-181c; hsa-miR-184; hsa-miR-122; hsa-miR-124; hsa-miR-125a-5p; hsa-miR-125b; hsa-miR-128a; hsa-miR-133b; hsa-miR-134; hsa-miR-135b; hsa-miR-146b-5p; hsa-miR-148b; hsa-miR-193a-5p; hsa-miR-193b hsa-miR-206; hsa-miR-20b; hsa-miR-214; hsa-miR-215; hsa-miR-301a; hsa-miR-372
|
miRNA
|
Humans
|
Upregulated with fold change > 2
|
Diagnostic
|
prostate tumor Vs normal epithelium
|
p<0.05
|
Tissue
|
23781281
|
1141
|
let-7a; let-7b; let-7c, miR-515-3p; miR515-5p; miR-181b; miR-146b; miR-361
|
miRNA
|
Humans
|
Upregulated: [let-7a - 1.7 fold; let-7b 3.7 fold; let-7c 3.0 fold, miR-515-3p 3.2 fold; miR515-5p 3.2 fold;] Downregulated: [miR-181b 1.8 fold; miR-146b 1.7 fold; miR-361 1.7 fold]
|
Prognostic
|
Clinical progression free survival (CPFS) Vs. clinical failure (CF)
|
p<0.05
|
Tissue
|
23798998
|
1142
|
let-7a; let-7b; let-7c
|
miRNA
|
Humans
|
Downregulated in PCa: [let-7a; let-7b; let-7c]
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.01
|
Tissue
|
23798998
|
1144
|
HPN; CLDN3; AMACR; GOLPH2; TRIB1; LOC729677; GDF15; TARP; MYC; LOC731404; ZFP36; SIM2; CTGF; GJB1; CENPN; EGR2; FBP1; KLF4; LUZP2; C8orf4; PDLIM3; CREB3L1; GCNT1; CTPS; PTP4A3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23813660
|
1145
|
SLC14A1; LOC642587; TRIM29; CYP3A5; TP73L; SNAI2; PIK3R1; KRT5; NPAL3; FGFR2; CSTA; CAPG; ITGA2; FER1L3; MEIS2; LGALS3BP; GPRC5B; NEFH; GSTM2; S100A16; MME; EVA1; KRT23; ADD3; GSTP1;
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23813660
|
1146
|
Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;]
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Tissue
|
23813660
|
1147
|
Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;]
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Agressive Vs Non Agressive Prostate Cancer
|
NA
|
Tissue
|
23813660
|
1150
|
1,5-anhydroglucitol; 10-heptaadecenoate (17:1n7); 10-nonadecenoate (19:1n9); ; 15-HETE; 1-arachidonoylglycerophosphoethanolamine; 1- arachidonoylglycerophosphoinositol; 1-arachidoylglycerophosphocholine; 1-eicosadienoylglycerophosphocholine; 1-heptadecanoylglycerophosphocholine; 1-heptadecanoylglycerophosphoethanolamine; 1-linoleoylglycerophosphocholine; 1-linoleoylglycerophosphoethanolamine; 1-myristoylglycerophosphocholine; 1-oleoylglycerol; 1-oleoylglycerophosphocholine; 1-oleoylglycerophosphoethanolamine; 1-oleoylglycerophosphoinositol; 1-oleoylglycerophosphoserine; 1-palmitoleoylglycerophosphocholine; 1-palmitoleoylglycerophosphoethanolamine; 1-palmitoylglycerol; 1-palmitoylglycerophosphocholine; 1-palmitoylglycerophosphoethanolamine 1-palmitoylglycerophosphoinositol; 1-palmitoylplasmenylethanolamine; 1-stearoylglycerol; 1-stearoylglycerophosphocholine; 1-stearoylglycerophosphoethanolamine; 1-stearoylglycerophosphoglycerol; 1-stearoylglycerophosphoinositol; 2-aminoadipate; 2-aminobutyrate; 2-arachidonoylglycerophosphocholine; 2-arachidonoylglycerophosphoethanolamine; 2-docosahexaenoylglycerophosphoethanolamine; 2-hydroxybutyrate; 2-hydroxyglutarate; 2-hydroxypalmitate; 2-hydroxystearate; 2-linoleoylglycerophosphocholine; 2-linoleoylglycerophosphoethanolamine; 2-methylbutyrylcarnitine; 2-oleoylglycerophosphocholine; 2-oleoylglycerophosphoethanolamine; 2-oleoylglycerophosphoserine; 2-palmitoylglycerophosphocholine; 2-palmitoylglycerophosphoethanolamine; 2-stearoylglycerophosphocholine; 3-(4-hydroxyphenyl)lactate; 3-aminoisobutyrate; 3-carboxy-4-methyl-5-propyl-2-furanpropanoate; 3-dehydrocarnitine; 3-dephosphocoenzyme-A; 3-hydroxybutyrate; 3-hydroxyhippurate; 3-indoxyl-sulfate; 3-phosphoglycerate; 4-acetamidobutanoate; 4-androsten-3beta_17beta-diol-disulfate-1; 4-hydroxybutyrate; 4-hydroxyhippurate; 4-methyl-2-oxopentanoate; 5,6-dihydrouracil; 5-alpha-androstan-3beta_17beta-diol-disulfate 5-methylthioadenosine; 5-oxoproline; 6-sialyllactose; 6-sialyl-N-acetyllactosamine; 7-alpha-hydroxy-3-oxo-4-cholestenoate; acetylcarnitine; acetylcholine; Ac-Ser-Asp-Lys-Pro; adenine; adenosine; adenosine 5'-diphosphate; adenosine 5'-monophosphate; adenosine 5'-diphosphoribose; adenosine 5-triphosphate; adenylosuccinate; adrenate (22:4n6); agmatine; alanine; alanylleucine; alanylphenylalanine; alanyltyrosine; alpha-glutamylvaline; alpha-hydroxyisovalerate; alpha-tocopherol; androsterone sulfate; arabitol; arabonate; arachidonate (20:4n6); arginine; ascorbate; asparagine; aspartate; aspartylleucine; aspartylphenylalanine; beta-alanine; beta-hydroxyisovalerate; betaine; butyrylcarnitine; caffeine; caproate (6:0); caprylate (8:0); carnitine; catechol-sulfate; C-glycosyltryptophan; chiro-inositol; cholesterol; choline; choline phosphate; cis-aconitate; cis-vaccenate (18:1n7); citrate; citrulline; coenzyme-A; creatine; creatinine; cysteine; cysteine-glutathione-disulfide; cysteinylglycine; cystine; cytidine; cytidine 5'-diphosphocholine; cytidine 5'-monophosphate; dehydroisoandrosterone sulfate; deoxycarnitine; dihomo-linoleate (20:2n6); docosadienoate (22:2n6); docosahexaenoate (22:6n3); docosapentaenoate (22:5n3); docosapentaenoate (22:5n6); docosatrienoate (22:3n3); eicosapentaenoate (20:5n3); ergothioneine; erythritol; erythronate; ethanolamine; flavin adenine dinucleotide; fructose; fucose; fumarate; galactose; gamma-aminobutyrate; gamma-glutamylalanine; gamma-glutamylglutamate; gamma-glutamylglutamine; gamma-glutamylleucine; gamma-tocopherol; gluconate; glucose; glucose 6-phosphate; glucose 1-phosphate; glutamate; glutamate, gamma-methyl ester; glutamine; glutarate; glutarylcarnitine; glutathione, oxidized; glutathione, reduced; glycerate; glycerol; glycerol 2-phosphate; glycerol 3-phosphate; glycerophosphoethanolamine; glycerophosphorylcholine; glycine; glycochenodeoxycholate; glycylisoleucine; glycylleucine; glycylproline; glycyltyrosine; glycylvaline; guanine; guanosine; guanosine-5-monophosphate; hexanoylcarnitine; hippurate; histamine; histidine; hydroxyisovaleroyl-carnitine; hypotaurine; hypoxanthine; inosine; inositol-1-phosphate; Isobar: 15-methylpalmitate, 2-methylpalmitate; Isobar: alpha-linolenate, gamma-linolenate (18:3n3 18:3n6); Isobar: dihomo-linolenate (20:3n3, 20:3n6); Isobar: dimethylarginine (ADMA, SDMA); Isobar: eicosenoate (20:1n9, 20:1n11); Isobar: fructose-1,6-diphosphate, glucose-1,6-diphosphate, myo-inositol-1,4-diphosphate, myo-inositol-1,3-diphosphate; Isobar: 13-HODE, 9-HODE; isobutyrylcarnitine; isocitrate; isoleucine; isoleucylisoleucine; isoleucylserine; isovalerylcarnitine; kynurenine; lactate; laurate (12:0); leucine; leucylglutamate; leucylleucine; leucylphenylalanine; leucylserine; linoleate (18:2n6); lysine; malate; maltose; maltotetraose; maltotriose; mannitol; mannose; margarate (17:0); mead acid (20:3n9); methionine; methyl-alpha-glucopyranoside; methylphosphate; myo-inositol; myristate (14:0); myristoleate (14:1n5); myristoylcarnitine; N1-methylguanosine; N2-methylguanosine; N-acetylalanine; N-acetylaspartate; N-acetyl-aspartylglutamate; N-acetylgalactosamine; N-acetylglucosamine; N-acetylglutamate; N-acetylmethionine; N-acetylneuraminate; N-acetylputrescine; N-acetyltryptophan; nicotinamide; nicotinamide adenine dinucleotide, reduced; nicotinamide adenine dinucleotide; nicotinamide ribonucleotide; nicotinamide riboside; nonadecanoate (19:0); octanoylcarnitine; oleate (18:1n9); oleoylcarnitine; ophthalmate; ornithine; palmitate (16:0); palmitoleate (16:1n7); palmitoylcarnitine; palmitoyl sphingomyelin; pantothenate; p-cresol sulfate; phenol sulfate; phenylacetylglutamine; phenylalanine; phenylalanylalanine; phenylalanylaspartate; phenylalanylglutamate; phenylalanylleucine; phenyllactate; phosphate; phosphoethanolamine; pipecolate; piperine; pregnen-diol-disulfate; pro-hydroxy-pro-proline; propionylcarnitine; prostaglandin I2; pseudouridine; putrescine; pyridoxate; pyroglutamine; pyroglutamylvaline; pyruvate; quinate; ribitol; riboflavin; ribose; ribulose; S-adenosylhomocysteine; sarcosine; scyllo-inositoll; serine; serotonin; serylleucine; serylphenylalanine; S-methylcysteine; sorbitol; spermidine; spermine; sphingosine ; stearate (18:0); stearoylcarnitine; stearoyl sphingomyelin; succinate; succinylcarnitine; taurine; theobromine; threonine; threonylisoleucine; threonylleucine; threonylphenylalanine; thymol sulfate; tiglyl carnitine; trans-4-hydroxyproline; tryptophan; tryptophan betaine; tyrosine; tyrsoylleucine; uracil; urate; urea; uridine; uridine 5'-monophosphate; valerylcarnitine; valine; valylmethionine; valyltyrosine; VGAHAGEYGAEALER; xanthine; xanthosine; xylitol; xylonate; xylulose;
|
Metabolites
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Tissue
|
23824564
|
1151
|
Histidine; Glycine; Alanine; Kynurenine; Glutamate; Glycerol 3-phosphate (G3P); Betaine; Pipecolate 2-methylbutyrylcarnitin; Isobar: 15-methylpalmitate; 2-methylpalmitate; Threonine; Cytidine 50-diphosphocholine; Valine; Myristoleate (14:1n5); S-adenosylhomocysteine (SAH); Phosphate; Choline; 2-aminobutyrate 2-hydroxypalmitate; Glycerol; Adenine; 2-hydroxystearate; Deoxycarnitine; Fumarate; Docosadienoate (22:2n6);
|
Metabolites
|
Humans
|
Increased with Upgraded Gleason Score
|
Prognostic
|
Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8]
|
p<0.05
|
Tissue
|
23824564
|
1152
|
Adenosine 50 -diphosphate (ADP); Citrate; Palmitoyl-sphingomyelin;
|
Metabolites
|
Humans
|
Decreased with Upgraded Gleason Score
|
Prognostic
|
Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8]
|
p<0.05
|
Tissue
|
23824564
|
1153
|
5,6-dihydrouracil +choline phosphate+ glycerol + methylpalmitate
|
Metabolites
|
Humans
|
Differentially Expressed
|
Prognostic
|
Organ Confined Vs Non Orgnan Confined
|
p<0.05
|
Tissue
|
23824564
|
1154
|
7-HOCA+ pregnen-diol disulfate +mannosyl tryptophan
|
Metabolites
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Free Survival (5 years) Vs No Progression Free Survival (5 years)
|
p<0.05
|
Tissue
|
23824564
|
1155
|
LASP1 + IQGAP3+ NFIB+ S1PR4+ THBS2+ANO7+ PCDH7 + MYBPC1+ EPPK1+ TSBP+ PBX1+ NUSAP1+ ZWILCH+ UBE2C+ CAMK2N1+ RABGAP1+ PCAT-32 + GLYATL1P4/PCAT-80 + TNFRSF19
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Metastasis Vs No Metastasis
|
p<0.01
|
Tissue
|
23826159
|
1160
|
Crystallin, alpha B (CRYAB)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1161
|
Distal-less homeobox 1 (DLX1)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1162
|
Serum deprivation response (SDPR)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1163
|
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA1)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1164
|
Prostate Cancer Antigen 3 (PCA3)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1165
|
Aldo-keto reductase family 1, member C1/2 (AKR1C1/2)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1166
|
Cyclin-dependent kinase 5, regulatory subunit 1 (CDK5R1)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1167
|
Claudin 7 (CLDN7)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1168
|
Activated leukocyte cell adhesion molecule (ALCAM)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1169
|
RAS, dexamethasone-induced 1 (RASD1)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1179
|
Methylation Status of BNC1
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.0476
|
Tissue
|
23896626
|
1180
|
Methylation Status of FZD1
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.0363
|
Tissue
|
23896626
|
1181
|
Methylation Status of SYN2
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.049
|
Tissue
|
23896626
|
1182
|
Methylation Status of ZNF783
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.011
|
Tissue
|
23896626
|
1183
|
Methylation Status of CYB5R2
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.0003
|
Tissue
|
23896626
|
1184
|
Bone Sialoprotein
|
Protein
|
Humans
|
Upregulated in Bone Metastatis (BM: 38.7 ±19.3; NBM: 9.1 ± 5.8)
|
Prognostic
|
Bone Metastatis Vs No Bone Metastatis
|
p<0.05
|
Tissue
|
23904377
|
1185
|
Methylation Status of AOX1 (High vs. Low)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1186
|
Methylation Status of AOX1 (as continous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1187
|
Methylation Status of C1orf114 (as continous variable)
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1188
|
Methylation Status of C1orf114 (High vs. Low)
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1189
|
Methylation Status of GAS6 (as continous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1190
|
Methylation Status of GSTP1
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1191
|
Methylation Status of HAPLN3 (as continous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1192
|
Methylation Status of HAPLN3 (High vs. Low)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1193
|
Methylation Status of KLF8 (High vs. Low)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1194
|
Methylation Status of KLF8 (as continuous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1195
|
Methylation Status of MOB3B
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1196
|
Methylation Status of AOX1/C1orf114/HAPLN3
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
NA
|
Tissue
|
23918943
|
1197
|
Methylation Status of AOX1/C1orf114/HAPLN3
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
NA
|
Tissue
|
23918943
|
1204
|
hsa-mir-31; hsa-mir-145; hsa-mir-455; hsa-mir-221; hsa-mir-222; hsa-mir-143; hsa-mir-221; hsa-mir-133b; hsa-mir-376c; hsa-mir-187; hsa-mir-139; hsa-mir-455; hsa-mir-224; hsa-mir-204; hsa-mir-505; hsa-mir-149; hsa-mir-222; hsa-mir-34a; hsa-mir-152; hsa-mir-30e; hsa-mir-377; hsa-mir-181c;
|
miRNA
|
Humans
|
Upregulated in PCa (log Fold Change): []
|
Diagnostic
|
Cancer Vs Benign
|
p < 0.0401
|
Tissue
|
23984644
|
1205
|
hsa-mir-33a; hsa-mir-25; hsa-mir-18b; hsa-mir-130b; hsa-mir-769; hsa-mir-182; hsa-mir-148a; hsa-mir-96;
|
miRNA
|
Humans
|
Downregulated in PCa (log Fold Change): []
|
Diagnostic
|
Cancer Vs Benign
|
p < 0.0401
|
Tissue
|
23984644
|
1211
|
PSMA/PSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 4.95 ± 0.83; BPH: 0.47 ± 0.02)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Tissue
|
24063616
|
1212
|
PSMA/PSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 4.95 ± 0.83; NP: 1.22 ± 0.15)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p= 0.0001
|
Tissue
|
24063616
|
1216
|
Cytochrome P450 family 24 subfamily A member 1 (CYP24A1)
|
mRNA
|
Humans
|
Upregulated in PCa (4 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p = 0.03
|
Tissue
|
24081904
|
1217
|
Cytochrome P450 family 24 subfamily A member 1 (CYP24A1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p = 0.03
|
Tissue
|
24081904
|
1218
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.02
|
Tissue
|
24086370
|
1220
|
Semaphorin 4F (SF4)
|
mRNA
|
Humans
|
Upregulated (high levels) had increased risk of biochemical recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.0002
|
Tissue
|
24097862
|
1223
|
Prostate Specific Membrane Antigen (PSMA)
|
Protein
|
Humans
|
Upregulted in Lethal PCa
|
Prognostic
|
Lethal Vs Non Lethal Prostate Cancer
|
p< 0.01
|
Tissue
|
24130224
|
1224
|
hsa-miR-367; hsa-miR-758; hsa-miR-190 hsa-miR-221; hsa-miR-205; hsa-miR-212; hsa-miR-99b; hsa-miR-214; hsa-miR-203; hsa-miR-127-3p; hsa-miR-130a; hsa-miR-335; hsa-miR-376; hsa-miR-10a; hsa-miR-589; hsa-miR-422a; hsa-miR-10b; hsa-miR-25; hsa-miR-210; hsa-miR-99a; hsa-miR-429; hsa-miR-92a; hsa-miR-100; hsa-miR-222; hsa-miR-484; hsa-miR-125b; hsa-miR-574-3p; hsa-miR-328; hsa-miR-483-5p; hsa-miR-331-3p; hsa-let-7c; hsa-miR-135a;
|
miRNA
|
Humans
|
miR-367, miR-758 and miR-190 were found to be upregulated in PCa; while, rest were Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p ≤ 0.046
|
Tissue
|
24167554
|
1225
|
miR-205
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.0001
|
Tissue
|
24167554
|
1226
|
miR-214
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.0001
|
Tissue
|
24167554
|
1227
|
miR-221
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.001
|
Tissue
|
24167554
|
1228
|
miR-99b
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.0001
|
Tissue
|
24167554
|
1233
|
Prostate Stem Cell Antigen (PSCA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
24183365
|
1234
|
Prostate Stem Cell Antigen (PSCA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer VS HGPIN
|
p<0.05
|
Tissue
|
24183365
|
1235
|
Prostate Stem Cell Antigen (PSCA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Gleason Score 6 Vs Gleason Score 8
|
p<0.05
|
Tissue
|
24183365
|
1236
|
Prostate Stem Cell Antigen (PSCA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Gleason Score 7 Vs Gleason Score 8
|
p<0.05
|
Tissue
|
24183365
|
1237
|
Peroxisome proliferator activated receptors (PPAR) [PPARβ/δ]
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
24189640
|
1238
|
cutaneous fatty acid-binding protein (C-FABP)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
24189640
|
1239
|
cutaneous fatty acid-binding protein (C-FABP)
|
Protein
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Low Vs Moderate Vs High Gleason Score
|
p<0.05
|
Tissue
|
24189640
|
1243
|
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 )
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Tissue
|
p<0.0001
|
Tissue
|
24240687
|
1244
|
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 )
|
Protein
|
Humans
|
Upregulated with High Tumor Stage
|
Prognostic
|
Tumor Stage pT2 Vs pT3 Vs pT4
|
p= 0.004
|
Tissue
|
24240687
|
1245
|
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 )
|
Protein
|
Humans
|
Upregulated with High Gleason Score
|
Prognostic
|
Gleason Score 3 Vs 4 Vs 5
|
p=0.028
|
Tissue
|
24240687
|
1246
|
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 )
|
Protein
|
Humans
|
Increased in Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p = 0.0038; Multivariate: p =0.036
|
Tissue
|
24240687
|
1254
|
Forkhead Box A1 [FOXA1]
|
mRNA
|
Humans
|
Increased in shorter time to Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.028
|
Tissue
|
24292680
|
1255
|
ACACA; CDCA3; CEP55; CCNB1; CKS2; DLGAP5; SLC7A1;HMMR; HIG2; LOX; MMP10; MCOLN2; NLN; PDLIM5; PSD3; C20orf74; FAM80A; SDK1; STC2; SOX4; TMEM200A; TFF3; UBE2C; UBE2E3;
|
mRNA
|
Humans
|
Upregulated in PCa (log 2 PCa/Normal): []
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
24349376
|
1256
|
Discs Large Homolog 7 [DLG7]
|
mRNA
|
Humans
|
Upregulated in PCa (log 2 PCa/Normal): []
|
Prognostic
|
Progression Vs No Progression
|
NA
|
Tissue
|
24349376
|
1274
|
BTF3
|
Protein
|
Humans
|
Upregulated in PCa (2.5 fold)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1275
|
HINT1
|
Protein
|
Humans
|
Upregulated in PCa (2.3 fold)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1276
|
NDRG1
|
Protein
|
Humans
|
Upregulated in PCa (2.6 fold)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1277
|
ODC1
|
Protein
|
Humans
|
Upregulated in PCa (1.8 fold)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1278
|
BTF3 + HINT1
|
Protein
|
Humans
|
Upregulated in PCa [BTF3: 2.5 fold; HINT1: 2.3 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1279
|
BTF3 + NDRG1
|
Protein
|
Humans
|
Upregulated in PCa [BTF3: 2.5 fold; NDRG1: 2.6 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1280
|
BTF3 + ODC1
|
Protein
|
Humans
|
Upregulated in PCa [BTF3: 2.5 fold; ODC1: 1.8 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1281
|
HINT1 + NDRG1
|
Protein
|
Humans
|
Upregulated in PCa [NDRG1: 2.6 fold; HINT1: 2.3 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1282
|
HINT1 + ODC1
|
Protein
|
Humans
|
Upregulated in PCa [ODC1: 1.8 fold; HINT1: 2.3 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1283
|
NDRG1 + ODC1
|
Protein
|
Humans
|
Upregulated in PCa [ODC1: 1.8 fold; NDRG1: 2.6 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1288
|
F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.001
|
Tissue
|
24394557
|
1289
|
WNT5B
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.004
|
Tissue
|
24394557
|
1290
|
VGLL3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.0001
|
Tissue
|
24394557
|
1291
|
c-MAF-a
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.008
|
Tissue
|
24394557
|
1292
|
CTGF
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.008
|
Tissue
|
24394557
|
1293
|
AMACR
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.009
|
Tissue
|
24394557
|
1294
|
MUC1
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.025
|
Tissue
|
24394557
|
1295
|
F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p<0.0001
|
Tissue
|
24394557
|
1296
|
WNT5B
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p<0.0001
|
Tissue
|
24394557
|
1297
|
VGLL3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.014
|
Tissue
|
24394557
|
1298
|
c-MAF-a
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.036
|
Tissue
|
24394557
|
1299
|
CTGF
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.023
|
Tissue
|
24394557
|
1300
|
IGFBP3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.013
|
Tissue
|
24394557
|
1301
|
c-MAF-b
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.019
|
Tissue
|
24394557
|
1302
|
EZH2
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.018
|
Tissue
|
24394557
|
1303
|
AMACR
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.049
|
Tissue
|
24394557
|
1304
|
VGLL3 + IGFBP3 + F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: [p<0.0001;] Multivariate:[Group2: p=0.013 Group 1: p<0.0001]
|
Tissue
|
24394557
|
1305
|
Clinical Parameters + VGLL3 + IGFBP3 + F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
NA
|
Tissue
|
24394557
|
1306
|
VGLL3 + IGFBP3 + F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
Group2: [Univariate: p= 0.002; Multivariate: 0.030]; Group 1: p<0.0001
|
Tissue
|
24394557
|
1307
|
Clinical Parameters + VGLL3 + IGFBP3 + F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
NA
|
Tissue
|
24394557
|
1325
|
Monoclonal Antibody MIB-1 [Ki-67]
|
Protein
|
Humans
|
Increased with increased risk of death
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p<0.001
|
Tissue
|
24486077
|
1326
|
Monoclonal Antibody MIB-1 [Ki-67]
|
Protein
|
Humans
|
Increased with increased risk of death
|
Prognostic
|
Progression Vs No Progression
|
p<0.001
|
Tissue
|
24486077
|
1333
|
U78_x; SNORD78; U78_s; miR-182; U17b; miR-22; miR-34a*; miR-221*; miR-187; miR-221; miR-34c-3p;
|
miRNA
|
Humans
|
Upregulated in PCa: U78_x (3.8 fold); SNORD78 (3.6-fold); U78_s (3.7-fold); miR-182 (4.7-fold); U17b (2.7- fold)Downregulated in PCa: miR-224 (4.05-fold); miR-34a* (3-fold); miR-221* (3.3-fold); miR-187 (12-fold); miR-221 (2.2-fold); miR-34c-3p (1.7-fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
24518785
|
1334
|
miR-182
|
miRNA
|
Humans
|
Upregulated in PCa (4.7 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
0.717
|
Tissue
|
24518785
|
1335
|
miR-187
|
miRNA
|
Humans
|
Downregulated in PCa (12 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
0.052
|
Tissue
|
24518785
|
1336
|
PSA+PCA3+miR-187
|
miRNA
|
Humans
|
Downregulated in PCa (12 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
24518785
|
1337
|
PCAT18
|
LncRNA
|
Humans
|
Upregulated in PCa (8.8-11.1 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.001
|
Tissue
|
24519926
|
1338
|
PCAT18
|
LncRNA
|
Humans
|
Upregulated in metastatic Prostatic Cancer
|
Prognostic
|
Localised Vs Metastatic Prostate Cancer
|
p<0.001
|
Tissue
|
24519926
|
1351
|
miR-221
|
miRNA
|
Humans
|
Downregulation in high-risk prostate cancer
|
Prognostic
|
Cancer Related Death Vs No Cancer Related Death
|
p<0.0001
|
Tissue
|
24607843
|
1352
|
ERG
|
Protein
|
Humans
|
NA
|
Prognostic
|
Histopathological Progression For ERG Positive Vs ERG Negative samples
|
p<0.0001
|
Tissue
|
24630684
|
1353
|
ERG
|
Protein
|
Humans
|
NA
|
Prognostic
|
Active Survillence (AS) Progression For ERG Positive Vs ERG Negative samples
|
p<0.0001
|
Tissue
|
24630684
|
1369
|
Hyaluronan-Mediated Motility Receptor (HMMR)
|
Metabolites
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
Univariate: p=0.028; Multivariate: p=0.04
|
Tissue
|
24668563
|
1371
|
CCND1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.042
|
Tissue
|
24708576
|
1372
|
HMMR
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
Univariate: p=0.005 Multivariate; p=0.008
|
Tissue
|
24708576
|
1373
|
HOXC6
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.05
|
Tissue
|
24708576
|
1374
|
IGF1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
Univariate: p=0.039 Multivariate; p=0.015
|
Tissue
|
24708576
|
1375
|
MAP4K4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.024
|
Tissue
|
24708576
|
1376
|
MKI67
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.026
|
Tissue
|
24708576
|
1377
|
SIAH2
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.016
|
Tissue
|
24708576
|
1378
|
SMAD4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
Univariate: p=0.01 Multivariate; p=0.016
|
Tissue
|
24708576
|
1379
|
HMMR+ SIAH2+ SMAD4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure (3 years)
|
p=0.052
|
Tissue
|
24708576
|
1380
|
HMMR+ SIAH2+ SMAD4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure (5 years)
|
p=0.024
|
Tissue
|
24708576
|
1381
|
BTG2; CDC37L1; COL15A1; COL3A1; EIF2D; FDPS; HIST1H1C; HIST1H2BG; IFT57; IGFBP3; ITPR1; LBH; LOC284801; MARCH5; MED4; MEMO1; MXI1; PTN; RPL23AP53; SACM1L; SIRT1; SNORA20; SRSF3; SYNM;
|
mRNA
|
Humans
|
Poor score with decreased BCR Survival
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 1.45E-21; Validation: p=2.85e-3
|
Tissue
|
24713434
|
1395
|
GABRE
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant
|
p=0.001
|
Tissue
|
24737792
|
1396
|
miR-224
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant
|
p=0.000628
|
Tissue
|
24737792
|
1397
|
miR-452
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant
|
p=0.000494
|
Tissue
|
24737792
|
1398
|
Methylation status of GABRE + miR-224 +miR-452
|
miRNA + Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant
|
p=0.001
|
Tissue
|
24737792
|
1399
|
Methylation status of GABRE + miR-224 +miR-452 (as continous value )
|
miRNA + Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008
|
Tissue
|
24737792
|
1400
|
Methylation status of GABRE + miR-224 +miR-452 (High vs. Low )
|
miRNA + Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008
|
Tissue
|
24737792
|
1401
|
GABRE + miR-224 +miR-452
|
mRNA + miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1402
|
GABRE
|
RNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1403
|
miR-224
|
miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1404
|
miR-452
|
miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1405
|
OAZ2
|
mRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1406
|
GABRE + miR-224 +miR-452+OAZ2
|
mRNA + miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1414
|
POSTN; ASPN; LAMB2; SERPH; CSPG2; ENTP1; SE1L1; ITAV; FOLH1; STIM1; PTK7; ICOSL; SPP2A; CD276; KLK3; ZA2G; FBN1; CD38; CNTP2; AMPN; FAM3B; RNT2; NAAA; PPAP; GSLG1; TSN1; DPP4; ST14;
|
Protein
|
Humans
|
Upregulated in Agressive PCa; Downregulated in Agressive PCa: []
|
Prognostic
|
Agressive Vs Non Agressive PCa
|
NA
|
Tissue
|
24741114
|
1415
|
TIMP1; CLUS; MFAP4; AOC3; CADM1; HYOU1; FSTL1; KLK11; NBL1; GOLM1; VTNC; CERU; A1AG2; LYVE1; A1AG1;
|
Protein
|
Humans
|
Upregulated in Metastatic PCa;Downregulated in Non Metastatic PCa: []
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate Cancer
|
NA
|
Tissue
|
24741114
|
1416
|
ATRN; CATD; BTD; MTA1; NCAM1; PECA1;
|
Protein
|
Humans
|
Upregulated in PCa: [];Downregulated in PCa: []
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
24741114
|
1417
|
NAAA
|
Protein
|
Humans
|
Downregulated in GS >7
|
Prognostic
|
Gleason Score ≤ 7 and Gleason Score >7
|
p <0.05
|
Tissue
|
24741114
|
1418
|
PTK7
|
Protein
|
Humans
|
Upregulated in GS >7
|
Prognostic
|
Gleason Score ≤ 7 and Gleason Score >7
|
p <0.01
|
Tissue
|
24741114
|
1419
|
NAAA+ PTK7
|
Protein
|
Humans
|
NAAA: Downregulated in GS >7; PTK7: Upregulated in GS >7
|
Prognostic
|
Gleason Score ≤ 7 and Gleason Score >7
|
p <0.05
|
Tissue
|
24741114
|
1428
|
DAB2IP
|
Protein
|
Humans
|
Reduced in lower FFBF (Freedom From Biochemical Faliure)
|
Prognostic
|
Freedom From Biochemical Failure Vs Biochemical Failure
|
p=0.04
|
Tissue
|
24867541
|
1429
|
miR-19a
|
miRNA
|
Humans
|
Upregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1430
|
miR-19b
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1431
|
miR-345
|
miRNA
|
Humans
|
Downregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1432
|
miR-519c-5p
|
miRNA
|
Humans
|
Downregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1433
|
miR-19a
|
miRNA
|
Humans
|
Upregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1434
|
miR-19b
|
miRNA
|
Humans
|
Upregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1435
|
miR-345
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1436
|
miR-519c-5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1437
|
miR_19a+ miR_345+ miR_519c_5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1438
|
miR_19b+miR_345+ miR_519c_5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1439
|
miR_19a + miR_19b + miR_345 + miR_519c_5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1440
|
MUC1
|
Protein
|
Humans
|
Increased with Increased mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.02
|
Tissue
|
24909936
|
1441
|
p53
|
Protein
|
Humans
|
Increased with Increased mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.005
|
Tissue
|
24909936
|
1442
|
AZGP1
|
Protein
|
Humans
|
Increased with Decreased mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.04
|
Tissue
|
24909936
|
1443
|
MUC1 + p53+ AZGP1
|
Protein
|
Humans
|
Increased with Increased mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
NA
|
Tissue
|
24909936
|
1444
|
Methylation status of genes (GSTM2; GSTP1; RARB; ALOX12; APC; PDGFRB; SCGB3A1; CFTR; MT1A; PENK; TERT; CCNA1; RARA; TAL1; ERG; MET; GFI1; MYCL2; SEPT9; COL18A1; KLK10; MFAP4; MMP14; TBX1; EYA4; NEU1; POMC; GADD45A; HTR1B; RASSF1; CDH13; PDGFRA; IRAK3; ASCL2; ESR1; HFE; IGFBP7; RARRES1; CAV1; THY1; BMP4;)
|
Methylation
|
Humans
|
Hypermethylated in Pca
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
24961912
|
1445
|
miR-1
|
miRNA
|
Humans
|
Downregulated in Recurrent PCa
|
Prognostic
|
Recurrence Vs No Recurrence
|
p = 0.036
|
Tissue
|
24967583
|
1446
|
miR-133b
|
miRNA
|
Humans
|
Downregulated in Recurrent PCa
|
Prognostic
|
Recurrence Vs No Recurrence
|
p = 0.012
|
Tissue
|
24967583
|
1447
|
miR-1 + miR-133b
|
miRNA
|
Humans
|
Downregulated in Recurrent PCa
|
Prognostic
|
Recurrence Vs No Recurrence
|
p = 0.012
|
Tissue
|
24967583
|
1457
|
Brachyury
|
Protein
|
Humans
|
Increases with increasing Gleason Score
|
Prognostic
|
Gleason Score GS <7 Vs GS = 7 Vs GS >7
|
p = 0.027
|
Tissue
|
25009296
|
1460
|
Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.002
|
Tissue
|
25057439
|
1461
|
High Mobility Group Box 1 (HMGB1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.001
|
Tissue
|
25057439
|
1462
|
Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in Stage T3-T4
|
Prognostic
|
stage T1-T2 Vs Stage T3-T4
|
p=0.004
|
Tissue
|
25057439
|
1463
|
High Mobility Group Box 1 (HMGB1)
|
Protein
|
Humans
|
Upregulated in Stage T3-T5
|
Prognostic
|
stage T1-T2 Vs Stage T3-T4
|
p=0.009
|
Tissue
|
25057439
|
1464
|
High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in Stage T3-T6
|
Prognostic
|
stage T1-T2 Vs Stage T3-T4
|
p=0.007
|
Tissue
|
25057439
|
1465
|
Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in Distant Metastases
|
Prognostic
|
Distant Metastases Vs No Distant Metastases
|
p=0.013
|
Tissue
|
25057439
|
1466
|
High Mobility Group Box 1 (HMGB1)
|
Protein
|
Humans
|
Upregulated in Distant Metastases
|
Prognostic
|
Distant Metastases Vs No Distant Metastases
|
p=0.019
|
Tissue
|
25057439
|
1467
|
High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in Distant Metastases
|
Prognostic
|
Distant Metastases Vs No Distant Metastases
|
p=0.026
|
Tissue
|
25057439
|
1468
|
High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Increased Coexpression in patients with Decreased overall Survival
|
Prognostic
|
Overall Suvival Vs No Survival
|
p=0.047
|
Tissue
|
25057439
|
1469
|
miR-135a
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer And Adjacent Normal
|
p<0.0001
|
Tissue
|
25065599
|
1470
|
miR-135a
|
miRNA
|
Humans
|
Downregulated in GS ≥ 8
|
Prognostic
|
Glesaon Score ≥ 8 and Gleason Score <8
|
p<0.01
|
Tissue
|
25065599
|
1471
|
miR-135a
|
miRNA
|
Humans
|
Downregulated in Stage pT3a
|
Prognostic
|
Stage pT3a Vs Stage pT2c
|
p<0.05
|
Tissue
|
25065599
|
1472
|
PTEN
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.0011
|
Tissue
|
25075204
|
1473
|
CCND1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.036
|
Tissue
|
25075204
|
1474
|
SMAD4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.0035
|
Tissue
|
25075204
|
1475
|
PTEN + CCND1 +SMAD4 + SSP1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p = 0.00000456
|
Tissue
|
25075204
|
1476
|
pS6
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.021
|
Tissue
|
25075204
|
1477
|
pPRAS40
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.019
|
Tissue
|
25075204
|
1478
|
CCND1 +SMAD4 + SSP1 + pS6 + pPRAS40
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p = 0.000013
|
Tissue
|
25075204
|
1479
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in Malignant Samples (Benign: 0.621 ± 0.06; malignant: 0.438 ± 0.022)
|
Diagnostic
|
Benign Vs Malignant
|
p=0.014
|
Tissue
|
25075250
|
1480
|
miR-219
|
miRNA
|
Humans
|
Downregulated in Malignant Samples (Benign: 0.773 ± 0.082; malignant: 0.467 ± 0.019)
|
Diagnostic
|
Benign Vs Malignant
|
p=0.004
|
Tissue
|
25075250
|
1481
|
miR-21
|
miRNA
|
Humans
|
Downregulated in GS ≥ 8 (Benign: 0.636 ± 0.048; malignant: 0.521 ± 0.027)
|
Prognostic
|
Gleason Score ≥ 8 Vs Gleason Score < 8
|
p=0.004
|
Tissue
|
25075250
|
1482
|
miR-21
|
miRNA
|
Humans
|
Downregulated in Metastatis (No Metastasis: 0.667 ± 0.037; Metastatis: 0.463 ± 0.027)
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate Cancer
|
p<0.0001
|
Tissue
|
25075250
|
1483
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in Metastatis (No Metastasis: 0.514 ± 0.029; Metastatis: 0.354 ± 0.032)
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate Cancer
|
p= 0.0003
|
Tissue
|
25075250
|
1484
|
miR-219
|
miRNA
|
Humans
|
Downregulated in Metastatis (No Metastasis: 0.532 ± 0.028; Metastatis: 0.448 ± 0.029)
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate Cancer
|
p= 0.039
|
Tissue
|
25075250
|
1485
|
miR-21
|
miRNA
|
Humans
|
Downregulated in Patients who suvived (Survival : 0.636 ± 0.039; No Survival: 0.507 ± 0.03)
|
Prognostic
|
Survival Vs No Survival
|
p= 0.009
|
Tissue
|
25075250
|
1486
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in Patients who suvived (Survival : 0.500 ± 0.031; No Survival: 0.406 ± 0.028)
|
Prognostic
|
Survival Vs No Survival
|
p= 0.024
|
Tissue
|
25075250
|
1487
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in Patients With Recurrence (No Recurrence : 0.609 ± 0.036; recurrence: 0.415 ± 0.051)
|
Prognostic
|
PSA Recurrence Vs No Recurrence
|
p= 0.003
|
Tissue
|
25075250
|
1488
|
let-7c
|
miRNA
|
Humans
|
Downregulated in Patients With Recurrence (No Recurrence : 0.703 ± 0.098; recurrence: 0.963 ± 0.06)
|
Prognostic
|
PSA Recurrence Vs No Recurrence
|
p=0.0266
|
Tissue
|
25075250
|
1489
|
Interleukin-1β (IL-1β)
|
Protein
|
Humans
|
Increased in patients with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.02
|
Tissue
|
25075566
|
1490
|
Interferon β (IFNβ)
|
Protein
|
Humans
|
Decreased in patients with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.008
|
Tissue
|
25075566
|
1491
|
Interleukin-1β (IL-1β) + Interferon β (IFNβ)
|
Protein
|
Humans
|
Interleukin-1β (IL-1β): Increased in patients with Biochemical Recurrence; Interferon β (IFNβ): Decreased in patients with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.004
|
Tissue
|
25075566
|
1492
|
mir-23b
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Tissue
|
25115396
|
1493
|
mir-27b
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Tissue
|
25115396
|
1494
|
mir-24-1
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Tissue
|
25115396
|
1495
|
mir-27b
|
miRNA
|
Humans
|
Decreased in patients with shorter progression free interval
|
Prognostic
|
Progression Vs No Progression
|
p=0.0346
|
Tissue
|
25115396
|
1515
|
YWHAZ
|
Protein
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) Vs Gleason Score ≥ 8
|
p<0.001
|
Tissue
|
25156059
|
1516
|
YWHAZ
|
Protein
|
Humans
|
Increased expression in patients with PCa specific death
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
Univariate: p=0.004; Multivariate: p = 0.015
|
Tissue
|
25156059
|
1517
|
YWHAZ
|
Protein
|
Humans
|
Increased expression in patients with Castration Resistant Prostate Cancer (CRPC)
|
Prognostic
|
Castration Resistant Prostate Cancer (CRPC) Vs No CRPC
|
Univariate: p=0.005; Multivariate: p = 0.008
|
Tissue
|
25156059
|
1518
|
YWHAZ
|
Protein
|
Humans
|
Increased expression in patients with PSA Relapse
|
Prognostic
|
High Risk vs. Low Risk (Relapse
|
Univariate: p=0.005; Multivariate: p = 0.019
|
Tissue
|
25156059
|
1522
|
Oligophrenin-1 (OPHN1)
|
mRNA
|
Humans
|
Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold)
|
Diagnostic
|
Prostate Cancer Vs Non Neoplastic Samples
|
NA
|
Tissue
|
25170626
|
1523
|
Oligophrenin-1 (OPHN1)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold)
|
Prognostic
|
Gleason Score 6-7 Vs Gleason Score 8-9-10
|
univariate: p=0.0011; Multivariate: 0.0038
|
Tissue
|
25170626
|
1524
|
Oligophrenin-1 (OPHN1)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold)
|
Prognostic
|
Stage pT2 Vs Stage pT3
|
univariate: p=0.0099; Multivariate: 0.0104
|
Tissue
|
25170626
|
1525
|
Yin Yang 1 (YY1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs PIN
|
p<0.001
|
Tissue
|
25174820
|
1526
|
Death Receptor 5
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs PIN
|
p<0.001
|
Tissue
|
25174820
|
1527
|
Yin Yang 1 (YY1)
|
Protein
|
Humans
|
Downregulated in PCa
|
Prognostic
|
High Grade cancer Vs Low grade Cancer
|
P<0.0001
|
Tissue
|
25174820
|
1528
|
Death Receptor 5
|
Protein
|
Humans
|
Downregulated in PCa
|
Prognostic
|
High Grade cancer Vs Low grade Cancer
|
P<0.0001
|
Tissue
|
25174820
|
1529
|
8-hydroxydeoxyguanosine (8-OHDG)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
25175169
|
1530
|
cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Diagnostic
|
Benign Vs Malignant
|
p=0.015
|
Tissue
|
25175169
|
1531
|
Nuclear-nuclear factor erythroid 2-related factor 2 (n-Nrf-2)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Diagnostic
|
Benign Vs Malignant
|
p=0.016
|
Tissue
|
25175169
|
1532
|
cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Prognostic
|
Biochemical Failure Free Survival Vs No Survival
|
Univariate: p=0.28; Multivariate: p=0.019
|
Tissue
|
25175169
|
1533
|
cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p=0.28; Multivariate: p=0.019
|
Tissue
|
25175169
|
1536
|
E Cadherin
|
Protein
|
Humans
|
Downregulated in patients with early relapse
|
Prognostic
|
Biochemical Relapse Vs No Biochemical Relapse for external beam radiotherapy treated (EBRT)
|
p=0.02
|
Tissue
|
25227682
|
1537
|
Ki-67
|
Protein
|
Humans
|
Upregulated in patients with early relapse
|
Prognostic
|
Early Relapse Vs No Relapse
|
EBRT cohort: p=0.0006; PADT Cohort: p=0.0004
|
Tissue
|
25227682
|
1539
|
Anterior gradient 2 Wild Type (AGR2wt)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Tissue
|
25237833
|
1540
|
Anterior gradient 2 Slice Variant H (AGR2-SV-H)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Tissue
|
25237833
|
1548
|
STEAP1 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in Low Risk PCa (4.45 fold)
|
Diagnostic
|
Low Risk PCa Vs Normal Tissue
|
p = 0.007
|
Tissue
|
25248617
|
1549
|
STEAP1 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in High Risk PCa (8.15 fold)
|
Diagnostic
|
High Risk PCa Vs Normal Tissue
|
p=0.011
|
Tissue
|
25248617
|
1550
|
STEAP1 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in Metastatic PCa (7.45 fold)
|
Diagnostic
|
Metastatic PCa Vs Normal Tissue
|
p=0.011
|
Tissue
|
25248617
|
1551
|
STEAP2 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in Low Risk Localised PCa (5.77 fold)
|
Diagnostic
|
Low Risk Localised PCa Vs Normal Tissue
|
p=0.022
|
Tissue
|
25248617
|
1552
|
STEAP2 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in Locally Advanced PCa (14.10 fold)
|
Diagnostic
|
Localy Advanced PCa Vs Normal Tissue
|
p=0.003
|
Tissue
|
25248617
|
1553
|
miR-221
|
miRNA
|
Humans
|
Downregulated in Recurrent Cases (Recurrent Median: 0.25; Control Median: 0.46)
|
Prognostic
|
Recurrence Vs No Recurrence
|
Regulation: p=0.0002; Univariate: p=0.02; Multivariate: p=0.05
|
Tissue
|
25252191
|
1554
|
miR-21
|
miRNA
|
Humans
|
Downregulated in Recurrent Cases (Recurrent Median: 1.01; Control Median: 1.54)
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.0149
|
Tissue
|
25252191
|
1555
|
miR-141
|
miRNA
|
Humans
|
Downregulated in Recurrent Cases (Recurrent Median: 0.39; Control Median: 0.81)
|
Prognostic
|
Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
25252191
|
1556
|
Chondroitin Sulfate
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p<0.0001
|
Tissue
|
9815775
|
1557
|
Chondroitin Sulfate
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Prognostic
|
Progression Vs No Progression
|
p=0.0001
|
Tissue
|
9815775
|
1558
|
Versican
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.0006
|
Tissue
|
9563891
|
1559
|
Decorin
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.0078
|
Tissue
|
9563891
|
1560
|
Versican
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Prognostic
|
Progression Vs No Progression
|
p=0.0003
|
Tissue
|
9563891
|
1561
|
Linoleic
|
Metabolites
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.04
|
Tissue
|
8922296
|
1562
|
WISP1
|
Protein
|
Humans
|
Increased with decreased BCR survival
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Cohort 1: p = 0.028;Cohort 3: p= 0.042
|
Tissue
|
31069142
|
1563
|
WISP1
|
Protein
|
Humans
|
Upregulated with increasing Stage
|
Prognostic
|
pTNM 2 Vs pTNM 3 Vs pTNM 4
|
p<0.05
|
Tissue
|
31069142
|
1564
|
WISP1
|
mRNA
|
Humans
|
Upregulated in Metastatic PCa
|
Prognostic
|
Primary Vs Metastatis Prostate Cancer
|
p=0.03
|
Tissue
|
31069142
|
1565
|
TMEFF2
|
mRNA
|
Humans
|
Upregulated in PCa (Log 2 Median Centered Intensity)
|
Diagnostic
|
Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer
|
p<0.05
|
Tissue
|
31060542
|
1566
|
TMEFF2
|
mRNA
|
Humans
|
Upregulated in PCa (Log 2 Median Centered Intensity)
|
Prognostic
|
Primary/Localised Vs Metastatic/CRPC Prostate Cancer
|
p<0.05
|
Tissue
|
31060542
|
1567
|
TMEFF2
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p<0.0001
|
Tissue
|
31060542
|
1568
|
BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2;
|
mRNA
|
Humans
|
Upregulated in PCa (Log 2 Median Centered Intensity)
|
Diagnostic
|
Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer
|
p<0.05
|
Tissue
|
31060542
|
1569
|
BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2;
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
31060542
|
1570
|
BUB1B+CDC45+CDK1+CENPI+CLSPN+ERCC6L+EXO1+NCAPG+NUSAP1+RAD51+RRM2
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
31060542
|
1571
|
Osteopontin (OPN)
|
Protein
|
Humans
|
increased with decreased BRFS
|
Prognostic
|
Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival
|
p < 0.036
|
Tissue
|
31059955
|
1572
|
Glucose Transporter 1 (GLUT1)
|
Protein
|
Humans
|
increased with decreased BRFS
|
Prognostic
|
Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival
|
p < 0.001
|
Tissue
|
31059955
|
1573
|
Glucose Transporter 1 (GLUT1)
|
Protein
|
Humans
|
increased with decreased DMFS
|
Prognostic
|
Distant Metastasis Free Survival Vs Distant Metastasis Free Survival
|
p = 0.045
|
Tissue
|
31059955
|
1582
|
Ki-67
|
Protein
|
Humans
|
NA
|
Prognostic
|
Distant Metastatis Vs No Distant Metastatis
|
p<0.0001
|
Tissue
|
25294917
|
1583
|
Cox-2
|
Protein
|
Humans
|
Upregulation
|
Prognostic
|
Distant Metastatis Vs No Distant Metastatis
|
p=0.04
|
Tissue
|
25294917
|
1584
|
p16
|
Protein
|
Humans
|
NA
|
Prognostic
|
Distant Metastatis Vs No Distant Metastatis
|
p=0.0065
|
Tissue
|
25294917
|
1585
|
MDM2
|
Protein
|
Humans
|
NA
|
Prognostic
|
Distant Metastatis Vs No Distant Metastatis
|
p=0.036
|
Tissue
|
25294917
|
1588
|
XLOC_001699; XLOC_005327y; LOC400958; XLOC_008559y; LINC00340; XLOC_000495; RPS18; XLOC_012294; XLOC_l2_008560; XLOC_009911y;
|
LncRNA
|
Humans
|
Upregulated in PCa [Log2 (Tumor/Normal)]: [XLOC_001699 (4.3 fold) ; XLOC_005327y (4.1 fold); LOC400958 (3.9 fold); XLOC_008559y (3.7 fold) ; LINC00340 (3.6 fold) ; XLOC_000495 (3.6 fold) ; RPS18(3.3 fold) ; XLOC_012294 (3.3 fold); XLOC_l2_008560 (3.3 fold); XLOC_009911y (3.2 fold);
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.05
|
Tissue
|
25307116
|
1589
|
SPRY4-IT1
|
LncRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.05
|
Tissue
|
25307116
|
1591
|
uPA/PAI-1
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 0.0479 ± 0.0060; BPH: (0.0332 ± 0.0023)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.0064
|
Tissue
|
25323935
|
1602
|
Vascular endothelial growth factor A (VEGF-A)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.016
|
Tissue
|
26268996
|
1603
|
Vascular endothelial growth factor A (VEGF-A) + Vascular endothelial growth factor Receptor (VEGFR-2)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.006
|
Tissue
|
26268996
|
1605
|
letâ€7c
|
miRNA
|
Humans
|
Downregulated in PCa (log 2 fold change: 0.7140)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1606
|
mir-145
|
miRNA
|
Humans
|
Downregulated in PCa (log 2 fold change: 0.4020)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1607
|
mir-221
|
miRNA
|
Humans
|
Downregulated in PCa (log 2 fold change: 0.5174)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1608
|
mir-21
|
miRNA
|
Humans
|
Upregulated in PCa (log 2 fold change: 0.6068)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1609
|
mir-182
|
miRNA
|
Humans
|
Upregulated in PCa (log 2 fold change: 0.8817)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1610
|
mir-145
|
miRNA
|
Humans
|
Downregulated in Gleason Score Upgradation (Without Upgradation: -0.4831 Vs Upgradation: -1.1202)
|
Prognostic
|
Gleason Score Upgradation Vs No Upgradation
|
p=0.03
|
Tissue
|
31045265
|
1611
|
mir-221
|
miRNA
|
Humans
|
Downregulated in Recurrence (Recurrence: −1.7170 Vs No Recurrence: − 0.9129)
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.04
|
Tissue
|
31045265
|
1624
|
KIF20A
|
mRNA
|
Humans
|
Upregulated in prostate cancer tissues compared with HR: 2.060 Pathways include: Kinesins, Aurora B signaling, Polo-like kinase 1 (PLK1) pathway, M phase pathway, MHC class II antigen presentation Prostate Cancer Vs No Prostate Cancer Diagnostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.8406 (95% CI: 0.6603-0.8256) NA p < 0.0001 1623 NA No NA NA Not validated on independent patient dataset
31031850 2019 CDK1 NA Expression Based mRNA Tissue Humans normal tissues
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1625
|
CCNB1
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.0166
|
Tissue
|
31031850
|
1626
|
BUB1
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1627
|
CENPA
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1628
|
AURKB
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p =0.0002662
|
Tissue
|
31031850
|
1629
|
CCNB2
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.001469
|
Tissue
|
31031850
|
1630
|
BIRC5
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p =0.0001304
|
Tissue
|
31031850
|
1631
|
AURKA
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1632
|
BUB1B
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1633
|
TTK
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1634
|
KIF20A
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1636
|
CDKN3
|
mRNA
|
Humans
|
Upregulated in prostate cancer tissues compared with HR: 2.451 Pathways include: T cell receptor regulation of apoptosis Biochemical recurrence Vs No Biochemical Recurrence Prognostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.6493 NA p =0.0002558 1635 NA No NA NA Not validated on independent patient dataset
31031850 2019 KIF2C NA Expression Based mRNA Tissue Humans normal tissues
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1637
|
NCAPG
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1638
|
CDCA8
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p =0.0001771
|
Tissue
|
31031850
|
1639
|
miR-3162-5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason grades 4+5 and 5 Vs Gleason grade 4
|
p=0.04
|
Tissue
|
31018918
|
1641
|
TGM4; SOSTDC1; MPO; SPRR1A; KLF4; RNU3B1; RNU3B3; RNU3B4; MT-ATP6; MT-ATP8; TMEM170A; LYNX1; IFNL3; PPP1R3G; GPR15; UGT2A3; MED13L; DNAJC10; NPY; XIST; LST1; WNT9A; LRRN3; GPR45; IFIT1; YWHAQ; KIR3DL1; EPPIN; CRLF1; MAL2; MAP3K15; H1FX;
|
mRNA
|
Mice
|
Upregulated in prostate cancer tissues compared with NA Pathway include: Genes were related to 12 pathways: (i) Aryl hydrocarbon receptor (AHR) signaling, (ii) Bone metamorphosis signaling, (iii) Wnt/GSK-3β signaling, (iv) Glucocorticoid receptor signaling, (v) Immune cell signaling, (vi) Gas signaling, (vii) iNOS signaling, (viii) Hypoxia signaling, (ix) Wnt/β-catenin signaling, (x) Cancer metastasis signaling (xi) p38MAPK signaling, and (xii) Oxidative phosphorylation TRAMP mice Vs Non-Transgenic Mice Diagnostic Twenty week old TRAMP mice and non-transgenic littermates tissues were harvested NA NA NA NA p<0.05 1640 Microarrays No NA NA Validated on human patient cohort
30972102 2019 TOX4; RPL38; LSM12; RPL5; HAX1; ALPI; TCTE3; RPL7; MRTO4; HDAC1; UBE2H; KRT26; TNFSF10; DPPA2; PNLDC1; MRPS11; PFDN6; STOML2; VDAC1; RPS8; TDGF1; UBE2E2; GKAP1; RPL10A; RPS15; UMOD; RPL9; RPL30; NPNT; NR1I2; KRTAP16-1; H3F3A; H3F3B; MRPL34; CSE1L; ST6GALNAC1; UBE2Q2; RPS17; RPL35; GMCL1; NIP7; MSL2; EIF4A1; LASP1; LUZP4; EIF1AD; TUBB3; RPL34; RPL17; RPL23; RPL28; KIR3DL2; LMO2; NA; AOC3; H2AFZ; RPL37; TMSB10; AMY2A; AMY2B; PPIA; PPIH; BEGAIN; NT5C3A; RPS28; RPL27; IL24; COPS9; NEK2; SOCS2; UBL5; UBE2D3; VHL; RPL23A; AICDA; LDHA; CNEP1R1; RPL29; SPCS1; RPL41; SP110; PMP22; ARCN1; UQCRB; SLC25A19; UBE2N; SNRPE; ACKR1; RPL21; LEFTY2; RPL31; RPL35A; RPL7A; RPL39; NACA; SP140; MRPL23; VDAC3; VDAC1P5; ATP5L; DIMT1; GMCL1P1; ARFGAP2; RPL22;' NA Expression Based mRNA Tissue Mice normal tissues
|
Diagnostic
|
TRAMP mice Vs Non-Transgenic Mice
|
p<0.05
|
Tissue
|
30972102
|
1642
|
ATP5L; ARFGAP2; DIMT1; GMCL1; MRPL34; RPL22; SP140; VDAC3
|
mRNA
|
Mice
|
Upregulated in Gleason Grade 5
|
Diagnostic
|
TRAMP mice Vs Non-Transgenic Mice
|
p<0.01
|
Tissue
|
30972102
|
1643
|
KLF4; MPO; SOStdc1; SPRR1A; TGM4
|
mRNA
|
Mice
|
Downregulated in TRAMP
|
Diagnostic
|
TRAMP mice Vs Non-Transgenic Mice
|
p<0.01
|
Tissue
|
30972102
|
1644
|
TNFSF; RPL22; EIF4; SLC2A; LMO2/3; KRT; RPS21; RPS19; RPL21; NEK; PPP1R3;
|
mRNA
|
Humans
|
Upregulated in TRAMP
|
Diagnostic
|
prostate cancer vs. benign prostate
|
p<0.05
|
Tissue
|
30972102
|
1645
|
GPR15; GPR45; TME; TGM4; KLF4; LRRN3; WNT; SPRR1A; TMEM;
|
mRNA
|
Humans
|
Upregulated in TRAMP
|
Diagnostic
|
prostate cancer vs. benign prostate
|
p<0.05
|
Tissue
|
30972102
|
1657
|
MMP2 (Matrix Metalloproteinase-2)
|
mRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
30917169
|
1658
|
BASP1 (Brain Abundant Membrane Attached Signal Protein 1)
|
mRNA
|
Humans
|
Downregulated in High Grade PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
30917169
|
1659
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in High Grade PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
30911973
|
1660
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Normal Prostate Vs T2 PCa Vs T3+T4 PCa
|
p<0.001
|
Tissue
|
30911973
|
1661
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Normal Prostate Vs Gleason Score 6 Vs GS 7 VS GS 8 Vs GS 9+GS10
|
p<0.001
|
Tissue
|
30911973
|
1662
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Disease Free Survival Vs No Disease Free Survival
|
p=0.0365
|
Tissue
|
30911973
|
1664
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in GS 6,7,8,9+10
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
30911973
|
1665
|
PLZF (Promyelocytic leukemia zinc finger protein)
|
Protein
|
Humans
|
High expression associated with shorter disease-free survival time
|
Diagnostic
|
Normal Vs Primary and Metastatic PCa
|
NA
|
Tissue
|
25807461
|
1704
|
hsv1-miR-H18
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue, Urine: p<0.001; Serum: p=0.004
|
Tissue+Urine+Serum
|
26126436
|
1705
|
hsv2-miR-H9-5p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue, Urine: p<0.001; Serum: p=0.002
|
Tissue+Urine+Serum
|
26126436
|
1706
|
hsa-miR-615-3p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue: p<0.001;
|
Tissue+Urine+Serum
|
26126436
|
1707
|
hsa-miR-BARTA-4
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue, Serum, Urine)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue: p<0.001;
|
Tissue+Urine+Serum
|
26126436
|
1708
|
hsa-miR-4316
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue, Serum, Urine)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue: p<0.001; Urine: p=0.022
|
Tissue+Urine+Serum
|
26126436
|
1709
|
hsv1-miR-H18
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Tissue+Urine
|
26126436
|
1710
|
hsv2-miR-H9-5p
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Tissue+Urine
|
26126436
|
1711
|
ERG
|
Protein
|
Humans
|
Upregulated in PCa (Tissue, Serum)
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.04
|
Tissue
|
26172920
|
1712
|
SPINK1
|
Protein
|
Humans
|
Upregulated in PCa (Tissue, Urine)
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.004
|
Tissue
|
26172920
|
1713
|
ERG; SPINK1
|
Protein
|
Humans
|
Upregulated in PCa (Tissue, Urine)
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.003
|
Tissue
|
26172920
|
1720
|
FOXM1 (Forkhead Box M1)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.001
|
Tissue
|
30719174
|
1721
|
FOXM1 (Forkhead Box M1)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Low & Intermediate Risk Vs High Risk
|
p<0.001
|
Tissue
|
30719174
|
1722
|
FOXM1 (Forkhead Box M1)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.022; Multivariate: p=0.035
|
Tissue
|
30719174
|
1729
|
SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1;
|
mRNA
|
Humans
|
Upregulated in PCa: (PCa: 39.68 ± 30.00; No PCa: 15.04 ± 7.11)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30286759
|
1730
|
EMX2OS; LINC02137; LINC01116; LINC00839; AL161645.1; AC012123.1; AL354793.1; LINC02385; HOXBâ€AS3; AC005674.1;
|
LncRNA
|
Humans
|
Upregulated in High Risk PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30286759
|
1731
|
hsaâ€mirâ€891a; hsaâ€mirâ€892a; hsaâ€mirâ€1224; hsaâ€mirâ€93; hsaâ€mirâ€23c; hsaâ€mirâ€1251; hsaâ€mirâ€204; hsaâ€mirâ€323b; hsaâ€mirâ€200c; hsaâ€mirâ€96;
|
miRNA
|
Humans
|
Downregulated after surgery (Before Surgery: 31.05 ± 21.01; After Surgery: 23.14 ± 11.1)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30286759
|
1732
|
SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1;
|
mRNA
|
Humans
|
Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;]
|
Prognostic
|
High Risk Vs Low Risk PCa
|
p=0.00822
|
Tissue
|
30286759
|
1733
|
Methylation Status of cg12799885
|
Methylation
|
Humans
|
Differentially Expressed [Log Fold Change: EMX2OS: (-5.98142); LINC02137 (-5.28623); LINC01116 (-3.59594); LINC00839: (- 4.30616); AL161645.1: (-4.9543); AC012123.1: (-4.63826); AL354793.1 (-5.45876); LINC02385: (-5.3465); HOXBâ€AS3 (-5.22943); AC005674.1: (-3.98991);]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1734
|
Methylation Status of DOCK2
|
Methylation
|
Humans
|
Differentially Expressed [Log Fold Change: hsaâ€mirâ€891a (-4.8); hsaâ€mirâ€892a (-5.14); hsaâ€mirâ€1224 (-3.66); hsaâ€mirâ€93 (1.79); hsaâ€mirâ€23c (-2.96); hsaâ€mirâ€1251 (-2.76); hsaâ€mirâ€204 (-1.84); hsaâ€mirâ€323b (-2.31); hsaâ€mirâ€200c (1.58); hsaâ€mirâ€96 (1.98);]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1735
|
Methylation Status of FBXO30
|
Methylation
|
Humans
|
Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1736
|
Methylation Status of GRASP
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1737
|
Methylation Status of HIF3A
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1738
|
Methylation Status of MOB3B
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1739
|
Methylation Status of PFKP
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1740
|
Methylation Status of TPM4
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1741
|
Methylation Status of cg12799885
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.025
|
Tissue
|
30866497
|
1742
|
Methylation Status of DOCK2
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p < 0.001; Multivariate: p=0.004
|
Tissue
|
30866497
|
1743
|
Methylation Status of GRASP
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p < 0.001; Multivariate: p=0.037
|
Tissue
|
30866497
|
1744
|
Methylation Status of HIF3A
|
Methylation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.005 Multivariate: p =0.027
|
Tissue
|
30866497
|
1745
|
Methylation Status of PFKP
|
Methylation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.001 Multivariate: p=0.028
|
Tissue
|
30866497
|
1746
|
Methylation Status of TPM4
|
Methylation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.038;
|
Tissue
|
30866497
|
1747
|
miR-1260
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.00001
|
Tissue
|
30250996
|
1748
|
miR-1274a
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.00001
|
Tissue
|
30250996
|
1753
|
5-hmC (5-hydroxymethylcytosin)+ ERG negative
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.01; Multivariate: p=0.003
|
Tissue
|
30818754
|
1754
|
AZGP1; C0S; H3K18Ac; H3K4Me2; Ki67; p53; PML
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Relapse Vs No Biochemical Relapse
|
AZGP1 p= 0.03; C0S: p=0.01; H3K18Ac: p=0.04; H3K4Me2: p=0.05; Ki67: p=0.02; p53: p=0.002; PML: p=0.03
|
Tissue
|
30288742
|
1755
|
AZGP1; Ki67; PML
|
Protein
|
Humans
|
NA
|
Prognostic
|
Metastatic Relapse Vs No Relapse
|
AZGP1: p=0.002; Ki67: p=0.04; PML:p=0.04
|
Tissue
|
30288742
|
1756
|
AZGP1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Specific Death Vs No Death
|
p=0.002
|
Tissue
|
30288742
|
1757
|
AZGP1+Ki67
|
Protein
|
Humans
|
NA
|
Prognostic
|
Metastatic Relapse Vs No Relapse
|
Discovery: Univariate: p=0.03; Multivariate: p=0.04
|
Tissue
|
30288742
|
1758
|
AZGP1+Ki67
|
Protein
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Specific Death Vs No Death
|
Discovery: Univariate: p=0.005; Multivariate: p=0.03;Validation: Univariate: p=0.05
|
Tissue
|
30288742
|
1822
|
BUB1
|
mRNA
|
Humans
|
Methylated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1823
|
TPX2
|
mRNA
|
Humans
|
Methylated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1824
|
NCAPG
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1825
|
UBE2C
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1826
|
MELK
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1827
|
CCNA2
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1828
|
CCNB1
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1829
|
CDK1
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1830
|
E2F2
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1831
|
DLGAP5
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1832
|
TMEM206
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1833
|
CDKN3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1834
|
SHMT2
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1835
|
SRD5A2
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1836
|
CSRP1
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1837
|
PGM5
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1838
|
NFIB
|
mRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1839
|
HEATR5B (HEAT repeat containing 5B); DDC (Dopa decarboxylase, transcript variant 6); TAS1R3 (Taste 1 receptor member 3); XIAP (X-linked inhibitor of apoptosis, transcript variant 2);
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30890858
|
1840
|
GABPB1-AS1 (GABPB1 antisense RNA 1); DDC (Dopa decarboxylase, transcript variant 6); HEATR5B (HEAT repeat containing 5B); CARD11 (Caspase recruitment domain family member 11, transcript variant 2);
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30890858
|
1841
|
GABPB1-AS1 (GABPB1 antisense RNA 1); KRT5 (Keratin 5); NCS1 (Neuronal calcium sensor 1, transcript variant 2); COL17A1 ( Collagen type XVII alpha 1 chain); ANXA1 (Annexin A1); LGALS3BP (Galectin 3 binding protein);
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30890858
|
1842
|
MT1IP (Metallothionein 1I, pseudogene (MT1IP), transcript variant 1); TRPT1 (tRNA phosphotransferase 1 (TRPT1), transcript variant 6); CHFR (Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase (CHFR), transcript variant 2); ZNF830 (Zinc finger protein 830); REXO1L2P (RNA exonuclease one homolog (S. cerevisiae)-like 2); SLC25A21 (SLC25A21 antisense RNA 1);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T1C Vs T2
|
p<0.05
|
Tissue
|
30890858
|
1843
|
FXR2 (Fragile X mental retardation, autosomal homolog 2); GADD45GIP1 (Growth arrest and DNA-damage-inducible, gamma interacting protein 1); STX4 (Syntaxin 4, transcript variant 1); CALCOCO2 (Calcium binding and coiled-coil domain 2, transcript variant 1); BEST4 (Bestrophin 4); URI1 (Prefoldin-like chaperone, transcript variant 3); DCP2 (Decapping mRNA 2, transcript variant 3);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2 Vs T2a
|
p<0.05
|
Tissue
|
30890858
|
1844
|
RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); SIRPA (Signal-regulatory protein alpha (SIRPA), transcript variant 3); COMP (Cartilage oligomeric matrix protein); SOD3 (Superoxide dismutase 3, extracellular); DIDO1 (Death inducer-obliterator 1, transcript variant 3); PRELP (Proline/arginine-rich end leucine-rich repeat protein, transcript variant 1);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2a Vs T2b
|
p<0.05
|
Tissue
|
30890858
|
1845
|
BGN (Homo sapiens biglycan); RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); USP21 (Ubiquitin-specific peptidase 21, transcript variant 3); NR1D1 (Nuclear receptor subfamily 1 group D, member 1); ANGPTL2 (Angiopoietin-like 2);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2b Vs T2c
|
p<0.05
|
Tissue
|
30890858
|
1846
|
SMAP2 (Small ArfGAP2 (SMAP2), transcript variant 2); TMSA (Prothymosin, alpha (PTMA), transcript variant 1); YY1AP1 (YY1 associated protein 1 (YY1AP1), transcript variant 6); DOCK9 (Dedicator of cytokinesis 9 (DOCK9), transcript variant 2); KITLG (KIT ligand (KITLG), transcript variant b);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2c Vs T3a
|
p<0.05
|
Tissue
|
30890858
|
1847
|
FAM133DP (Family with sequence similarity 133 member D pseudogene); SAMM50 (Sorting and assembly machinery component 50 homolog, protein coding); OR4F13P (Olfactory receptor family 4 subfamily F member 13 pseudogene);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T3a Vs T3b
|
p<0.05
|
Tissue
|
30890858
|
1848
|
IKZF3 (IKAROS family zinc finger 3 (Aiolos), transcript variant 12); USP13 (Ubiquitin-specific peptidase 13 (isopeptidase T-3)); CLASP1 (Cytoplasmic linker associated protein 1, transcript variant 3); CEP112 (Centrosomal protein 112kDa, transcript variant 3); TSEN15 (tRNA splicing endonuclease subunit, transcript variant 1); FLVCR2 (Feline leukemia virus subgroup C cellular receptor family, member 2,transcript variant 2); GOLGA8B (Golgin A8 family, member B, transcript variant 1); ZNF438 (Zinc finger protein 438, transcript variant 1); SCARNA22 (Small Cajal body-specific RNA 22); LPPR1 (Lipid phosphate phosphatase-related protein type 1, transcript variant 2); PTGFR (Prostaglandin F receptor (FP), transcript variant 1); NREP (Neuronal regeneration related protein, transcript variant 1);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2c Vs T3/4
|
p<0.05
|
Tissue
|
30890858
|
1852
|
miR-425-5p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.001
|
Tissue
|
30720162
|
1854
|
miR-424
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.043
|
Tissue
|
30345533
|
1855
|
miR-572
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p= 0.031
|
Tissue
|
30345533
|
1856
|
miR-572+ miR-424
|
miRNA
|
Humans
|
Upregulated in PC3 and DU145
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p= 0.031
|
Tissue
|
30345533
|
1857
|
miR-572+ miR-424+ miR-1 + miR133b
|
miRNA
|
Humans
|
Downregulated in Recurrent PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p= 0.031
|
Tissue
|
30345533
|
1860
|
Promoter methylation of: miR-193b+ miR-34b/c
|
Methylation
|
Humans
|
Upregulated in Recurrent PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Tissue
|
30373654
|
1861
|
Methlyation Status of APC, GSTP1 RARβ2
|
Methylation
|
Humans
|
Upregulated in PCa (Non PCa: 1504.7 Vs PCa: 1657.1)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Tissue
|
30373654
|
1865
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
1866
|
Methlyation Status of GSTP1
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
1867
|
Methlyation Status of RARβ2
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
1868
|
Methlyation Status of miR-34b/c
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
1869
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Low & Intermediate Risk Vs High Risk
|
p<0.01
|
Tissue
|
30373654
|
1870
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Low & Intermediate Risk Vs High Risk
|
p<0.05
|
Tissue
|
30373654
|
1871
|
Promoter methylation of: miR-193b+ miR-34b/c
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Prostate Cancer Specific Survival Vs No Survival
|
p=0.017
|
Tissue
|
30373654
|
1872
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in High Risk
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.044
|
Tissue
|
30373654
|
1873
|
Promoter methylation of: GSTP1
|
Methylation
|
Humans
|
Methylated in High Risk
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Tissue
|
30373654
|
1874
|
Methlyation Status of miR-34b/c
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Tissue
|
30373654
|
1876
|
PD-L2 (Programmed death ligand 2)
|
mRNA
|
Humans
|
Methylated in PCa
|
Prognostic
|
Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival
|
p=0.01
|
Tissue
|
30321406
|
1877
|
PD-L2 (Programmed death ligand 2)
|
mRNA
|
Humans
|
Methylated in PCa
|
Prognostic
|
Distant Metastatic Free Survival Vs No DMFS Survival
|
p=0.01
|
Tissue
|
30321406
|
1878
|
PD-L2 (Programmed death ligand 2)
|
mRNA
|
Humans
|
Upregulated in PCa: []; Downregulated in PCa: []
|
Prognostic
|
Prostate Cancer Specific Survival Vs No PCSS Survival
|
p<0.001
|
Tissue
|
30321406
|
1894
|
ASAP1
|
DNA (Copy Number variations)
|
Humans
|
NA
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1895
|
HDAC9
|
DNA (Copy Number variations)
|
Humans
|
NA
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1896
|
CHD1
|
DNA (Copy Number variations)
|
Humans
|
NA
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1897
|
RB1
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1898
|
PTEN
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1899
|
MYC
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1900
|
ASAP1
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1901
|
HDAC9
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1902
|
CHD1
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1903
|
RB1
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1904
|
PTEN
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1905
|
MYC
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1906
|
AFP; AKR1C1; AKR1C3; AKR1C4; C1orf229; C5orf28; C5orf34; CCNE1; DNMT1; E2F3; ENSA; FBXO4; G6PD; KPNA2; LETM2; LGSN; MRPS30; OPLAH; OR4K15; OR4L1; PAIP1; SKP1; SPEF2; WDR70; ZNF124; ZNF280A; ZNF324B; ZNF669; ZNF695;
|
mRNA
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Primary Prostate Cancer Vs Metastatic Prostate Cancer
|
p<0.05
|
Tissue
|
30401717
|
1907
|
ANO7; NSA2; BOK; PDE8B; CECR6; PER3; CNNM1; PPP1R7; CNTNAP3; SCAMP1; COX15; SEMA4G; DMGDH; SLC7A8; DUSP1; TMEM18; EPHA7; TRIM8; FAM20C; TSLP; FOXC1; WDR41; ZNF658; GABRG3; GLB1L3; GLOD4; KCNMB1; LOC100128239; LOXL4; MTERFD2; NCAM1; NDN;
|
mRNA
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Primary Prostate Cancer Vs Metastatic Prostate Cancer
|
p<0.05
|
Tissue
|
30401717
|
1908
|
ADAM12; AURKA; AURKB; C7orf49; CDCA8; CENPF; CIT; DNMT3B; DYRK2; FANCD2; FGD1; GDAP1; GPI; GTSE1; HNRNPUL1; IPO9; KIF23; LIG1; NCAPH; NHSL1; PEG10; SKP2; TMEM65; TOP2A; TPX2; UBE2T;
|
mRNA
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Primary Prostate Cancer Vs Metastatic Prostate Cancer
|
p<0.05
|
Tissue
|
30401717
|
1909
|
ALDH1A3; APH1B; ATAD1; CTBS; CTSO; DHRS7; ESR1; FOXC1; MEIS2; NR4A1; PDE8B; RPS27L; SEC62; SPCS3; ZMAT1;
|
mRNA
|
Humans
|
Upregulated in Metastatic PCa
|
Prognostic
|
Primary Prostate Cancer Vs Metastatic Prostate Cancer
|
p<0.05
|
Tissue
|
30401717
|
1910
|
HSP27; prohibitin; GSTP1; fibrinogen β chain; ALDH6A1; A1AT; HSP60;
|
Protein
|
Humans
|
Downregulated in Metastatic PCa
|
Diagnostic
|
Metastatic Prostate Cancer Vs No Prostate Cancer
|
NA
|
Tissue
|
30396985
|
1911
|
HSP27
|
Protein
|
Humans
|
Upregulated in Metastatic PCa
|
Prognostic
|
Survival Vs No Survival
|
p=0.007
|
Tissue
|
30396985
|
1912
|
Prohibitin
|
Protein
|
Humans
|
Upregulated in Metastatic PCa
|
Prognostic
|
Survival Vs No Survival
|
p<0.001
|
Tissue
|
30396985
|
1913
|
ALDH6A1
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Survival Vs No Survival
|
p<0.001
|
Tissue
|
30396985
|
1914
|
Prohibitin+ HSP27+ALDH6A1
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Survival Vs No Survival
|
NA
|
Tissue
|
30396985
|
1915
|
Prohibitin+ HSP27
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);] Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Survival Vs No Survival
|
NA
|
Tissue
|
30396985
|
1916
|
Prohibitin+ALDH6A1
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Survival Vs No Survival
|
NA
|
Tissue
|
30396985
|
1917
|
CAV1; TP53; MAGEA11; CALM1; EGFR; UBE2I; CALR; SMAD3; FHL2; HDAC1; APP; MYC; JUN; ESR1; GNB2L1; HIPK3; SMAD2; APPBP2; CDC2; BRCA1; RB1; SMAD1;PXN; XRCC6; IL6ST; STAT3; DLG1; AES; TRAF6; FLNA; TRIM29; PCAF; REPS2; AKT1; PRKCA; RAF1; HLA-B; TRAF2; SMARCA4; MAPK1; CHGB; RANBP9; CCND1; GSK3B; HSPA1A; BCL2; VCL; RAI17; TGFBR1; SELENBP1;
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
22654636
|
1918
|
CAV1; MAGEA11; CALM1; CALR; TP53; FHL2; EGFR; APP; JUN; SMAD3; SMAD2; ESR1; RB1; HIPK3; BRCA1; SMAD1; GNB2L1; XRCC6; UBE2I; HDAC1; CDC2; AES; STAT3; IL6ST; APPBP2; PCAF; REPS2; FLNA; RAF1; MYC; MAPK1; TRAF6; CCND1; SMARCA4; HLA-B; TRAF2; RANBP9; PIAS4; GSK3B; TRIM29; FOS; IDE; SRC; PXN; SLC25A4; SP1; NR5A1 YWHAG; AKT1; CCNE1;
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Prostate Cancer Vs Lymph Node Metastasis
|
NA
|
Tissue
|
22654636
|
1943
|
Methylation status of A0X1
|
Methylation
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1944
|
Methylation status of CYBA
|
Methylation
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1945
|
Methylation status of EDG3
|
Methylation
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1946
|
Methylation status of ELF4
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1947
|
Methylation status of EPB41L3
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1948
|
Methylation status of FLJ12056
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1949
|
Methylation status of FLJ90650
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1950
|
Methylation status of FLT4
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1951
|
Methylation status of GAS6
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1952
|
Methylation status of GRASP
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1953
|
Methylation status of GSTP1
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1954
|
Methylation status of HAAO
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1955
|
Methylation status of HIF3A
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1956
|
Methylation status of HOXC11
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1957
|
Methylation status of LEP
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1958
|
Methylation status of MGC39606
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1959
|
Methylation status of MOBKL2B
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1960
|
Methylation status of RAB34
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1961
|
Methylation status of RARb
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1962
|
Methylation status of RHCG
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1963
|
Methylation status of RND2
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1964
|
Methylation status of SLC34A2
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1965
|
Methylation status of SPATA6
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1966
|
Methylation status of TPM4
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1967
|
Methylation status of ZNF154
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1968
|
Methylation status of ACTL6B
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1969
|
Methylation status of AEBP1
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0021
|
Tissue
|
22589488
|
1970
|
Methylation status of AMID
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1971
|
Methylation status of CD8A
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1972
|
Methylation status of CRIP1
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0037
|
Tissue
|
22589488
|
1973
|
Methylation status of FLJ30934
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1974
|
Methylation status of FLNC
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1975
|
Methylation status of FMOD
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1976
|
Methylation status of FOXE3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1977
|
Methylation status of GAS7
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1978
|
Methylation status of GDPD5
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1979
|
Methylation status of HS3ST2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1980
|
Methylation status of LOC349136
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1981
|
Methylation status of NEUROG1
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1982
|
Methylation status of PLTP
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1983
|
Methylation status of PTGER2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1984
|
Methylation status of RASGRF2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1985
|
Methylation status of RUNX3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1986
|
Methylation status of SIX6
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1987
|
Methylation status of SLC9A3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1988
|
Methylation status of SPSB4
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0008
|
Tissue
|
22589488
|
1989
|
Methylation status of SRD5A2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1990
|
Methylation status of SUSD3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0014
|
Tissue
|
22589488
|
1991
|
Methylation status of SYT10
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1992
|
Methylation status of TMEM74
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0005
|
Tissue
|
22589488
|
1993
|
Methylation status of CHST7
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0050
|
Tissue
|
22589488
|
1994
|
Methylation status of LMX1B
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0021
|
Tissue
|
22589488
|
1995
|
Methylation status of PHLDA 3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0772
|
Tissue
|
22589488
|
1996
|
Methylation status of RAFTLIN
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0050
|
Tissue
|
22589488
|
1997
|
Methylation status of RASGRF2
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0015
|
Tissue
|
22589488
|
1998
|
Methylation status of TNFRSF10D
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0008
|
Tissue
|
22589488
|
1999
|
Methylation status of ZNF135
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0061
|
Tissue
|
22589488
|
2000
|
Methylation status of ALPL
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0182
|
Tissue
|
22589488
|
2001
|
Methylation status of AMPH
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0021
|
Tissue
|
22589488
|
2002
|
Methylation status of BCDIN3
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2003
|
Methylation status of BCL11B
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2004
|
Methylation status of BRD4
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0038
|
Tissue
|
22589488
|
2005
|
Methylation status of C18orf34
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2006
|
Methylation status of DCAMKL1
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2007
|
Methylation status of FGF5
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2008
|
Methylation status of FLJ42486
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2009
|
Methylation status of JAM2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2010
|
Methylation status of LHX9
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2011
|
Methylation status of LOC283537
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2012
|
Methylation status of LRAT
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0034
|
Tissue
|
22589488
|
2013
|
Methylation status of PDE4B
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2014
|
Methylation status of POU3F3
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2015
|
Methylation status of PTGS2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0153
|
Tissue
|
22589488
|
2016
|
Methylation status of RASGRF2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0002
|
Tissue
|
22589488
|
2017
|
Methylation status of SLC27A6
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0017
|
Tissue
|
22589488
|
2018
|
Methylation status of SLC03A1
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2019
|
Methylation status of SPSB4
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2020
|
Methylation status of STAT3
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0017
|
Tissue
|
22589488
|
2021
|
Methylation status of SYN2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2022
|
Methylation status of TACR3
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0086
|
Tissue
|
22589488
|
2023
|
Methylation status of TIRAP
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0003
|
Tissue
|
22589488
|
2024
|
Methylation status of WNT11
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0011
|
Tissue
|
22589488
|